Erlotinib (OSI-774)

Name: Erlotinib (OSI-774)
Brand: Selleck Chemicals
SKU: S7786
Rating: 5 (443 reviews)

For research use only.

Catalog No.S7786 Synonyms: CP358774, NSC 718781, Tarceva

443 publications

CAS No. 183321-74-6

Erlotinib (OSI-774, CP358774, NSC 718781, Tarceva) is an EGFR inhibitor with IC50 of 2 nM, >1000-fold more sensitive for EGFR than human c-Src or v-Abl. Erlotinib induces autophagy.

Selleck's Erlotinib (OSI-774) has been cited by 443 publications

Nat Cell Biol, 2021, 23(4):377-390

PubMed: 33795873 ( click the link to review the publication )

Nat Med, 2019, 25(1):111-118

PubMed: 30478424 ( click the link to review the publication )

Cell, 2019, 178(4):807-819

PubMed: 31398338 ( click the link to review the publication )

Cancer Cell, 2019, 35(3):504-518

PubMed: 30827889 ( click the link to review the publication )

Cancer Cell, 2019, 10.1016/j.ccell.2019.09.001

PubMed: 31588020 ( click the link to review the publication )

Nat Immunol, 2019, 20(7):835-851

PubMed: 31160797 ( click the link to review the publication )

Nat Med, 2018, 24(11):1752-1761

PubMed: 30349086 ( click the link to review the publication )

Nat Med, 2018, 24(7):968-977

PubMed: 29808010 ( click the link to review the publication )

Nat Med, 2018, 24(4):512-517

PubMed: 29505033 ( click the link to review the publication )

Nat Methods, 2018, 15(8):631-639

PubMed: 30038414 ( click the link to review the publication )

Nat Med, 2017, 23(10):1167-1175

PubMed: 28920960 ( click the link to review the publication )

Nat Genet, 2017, 49(12):1693-1704

PubMed: 29106415 ( click the link to review the publication )

Gastroenterology, 2017, 153(4):1082-1095

PubMed: 28625833 ( click the link to review the publication )

Cancer Cell, 2016, 29(4):563-573

PubMed: 27070703 ( click the link to review the publication )

Cancer Discov, 2015, 5(11):1155-63

PubMed: 26286086 ( click the link to review the publication )

Cancer Cell, 2015, 27(3):397-408

PubMed: 25759024 ( click the link to review the publication )

Cancer Cell, 2015, 27(4):533-46

PubMed: 25873175 ( click the link to review the publication )

Cancer Discov, 2013, 3(12):1404-15

PubMed: 24065731 ( click the link to review the publication )

Cell Metab, 2013, 17(6):1000-8

PubMed: 23707073 ( click the link to review the publication )

Cell, 2012, 151(5):937-50

PubMed: 23178117 ( click the link to review the publication )

Nat Genet, 2012, 44(8):852-60

PubMed: 22751098 ( click the link to review the publication )

Sci Adv, 2021, 7(10)eabe8671

PubMed: 33658202 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2021, 118(19)e2019580118

PubMed: 33941693 ( click the link to review the publication )

J Cell Biol, 2021, 220(2)e202004229

PubMed: 33443570 ( click the link to review the publication )
Theranostics, 2021, 11(2):824-840

PubMed: 33391507 ( click the link to review the publication )

PLoS Biol, 2021, 19(6):e3000797

PubMed: 34061819 ( click the link to review the publication )

Cancer Lett, 2021, 507:40-54

PubMed: 33741422 ( click the link to review the publication )

Cancers (Basel), 2021, 13(6)1198

PubMed: 33801941 ( click the link to review the publication )

PLoS Pathog, 2021, 17(1):e1009216

PubMed: 33481911 ( click the link to review the publication )

Cells, 2021, 10(4)716

PubMed: 33804833 ( click the link to review the publication )

Front Cell Dev Biol, 2021, 9:634371

PubMed: 33777943 ( click the link to review the publication )

J Cell Mol Med, 2021, 10.1111/jcmm.16555

PubMed: 33955688 ( click the link to review the publication )

J Transl Med, 2021, 19(1):91

PubMed: 33639987 ( click the link to review the publication )

Sci Rep, 2021, 11(1):7259

PubMed: 33790333 ( click the link to review the publication )

Drug Metab Dispos, 2021, 49(1):53-61

PubMed: 33148688 ( click the link to review the publication )

Environ Toxicol, 2021, 10.1002/tox.23125

PubMed: 33734566 ( click the link to review the publication )

Anticancer Res, 2021, 41(3):1261-1269

PubMed: 33788717 ( click the link to review the publication )

Exp Ther Med, 2021, 21(1):9

PubMed: 33235618 ( click the link to review the publication )

Oncol Rep, 2021, 45(1):217-229

PubMed: 33200228 ( click the link to review the publication )

Nat Nanotechnol, 2021, 10.1038/s41565-021-00872-w

PubMed: 33686255 ( click the link to review the publication )

Oncol Lett, 2021, 21(1):44

PubMed: 33262836 ( click the link to review the publication )

Mol Ther Oncolytics, 2021, 20:364-372

PubMed: 33614917 ( click the link to review the publication )

Acta Neuropathol, 2020, 10.1007/s00401-020-02226-7

PubMed: 33009951 ( click the link to review the publication )

Nat Commun, 2020, 10;11(1):2935

PubMed: 32523045 ( click the link to review the publication )

Nat Commun, 2020, 11(1):3157

PubMed: 32572029 ( click the link to review the publication )

EMBO J, 2020, 2;39(5):e101679

PubMed: 32009252 ( click the link to review the publication )

EMBO Mol Med, 2020, e11099

PubMed: 32558295 ( click the link to review the publication )

EMBO Mol Med, 2020, 12(8):e11987

PubMed: 32672423 ( click the link to review the publication )
Cancer Res, 2020, 80(22):4998-5010

PubMed: 33023947 ( click the link to review the publication )

Cell Rep, 2020, 31(11):107764

PubMed: 32553168 ( click the link to review the publication )

Elife, 2020, 2;9:e54954

PubMed: 32484436 ( click the link to review the publication )

Mucosal Immunol, 2020, 4

PubMed: 32132671 ( click the link to review the publication )

Oncogene, 2020, 39(20):3997-4013

PubMed: 32242147 ( click the link to review the publication )

Oncogene, 2020, 10.1038/s41388-020-01497-4

PubMed: 33037411 ( click the link to review the publication )

Cancer Lett, 2020, 476:23-33

PubMed: 31958486 ( click the link to review the publication )

Sci Signal, 2020, 28;13(629)

PubMed: 32345725 ( click the link to review the publication )

Cancers (Basel), 2020, 12(11)E3172

PubMed: 33126775 ( click the link to review the publication )

Cancers (Basel), 2020, 10;12(1) pii: E173

PubMed: 31936715 ( click the link to review the publication )

Cancers (Basel), 2020, 27;12(5)pii: E1087

PubMed: 32349331 ( click the link to review the publication )

Cancers (Basel), 2020, 13;12(2) pii: E436

PubMed: 32069833 ( click the link to review the publication )

Cancers (Basel), 2020, 12(2)

PubMed: 32045997 ( click the link to review the publication )

Cancers (Basel), 2020, 12(1)

PubMed: 31968611 ( click the link to review the publication )

Cells, 2020, 17;9(4) pii: E1003

PubMed: 32316635 ( click the link to review the publication )

Cancer Discov, 2020, CD-19-1262

PubMed: 32513774 ( click the link to review the publication )

Mol Cancer Ther, 2020, 5;molcanther.510.2019

PubMed: 32371581 ( click the link to review the publication )

Mol Cancer Ther, 2020, 19;molcanther10362019

PubMed: 32430488 ( click the link to review the publication )

Mol Cancer Ther, 2020, 5 pii: molcanther

PubMed: 32371586 ( click the link to review the publication )

Mol Cancer Ther, 2020, molcanther.1160.2019

PubMed: 33323457 ( click the link to review the publication )

Neurobiol Dis, 2020, 9;104961

PubMed: 32531343 ( click the link to review the publication )

Front Cell Dev Biol, 2020,

PubMed: 32850868 ( click the link to review the publication )

J Cancer, 2020, 11(19):5746-5757

PubMed: 32913468 ( click the link to review the publication )

Transl Res, 2020, S1931-5244(20)30257-7

PubMed: 33197651 ( click the link to review the publication )
Transl Lung Cancer Res, 2020, 9(5):1904-1914

PubMed: 33209611 ( click the link to review the publication )

Cancer Sci, 2020, 111(10):3793-3801

PubMed: 32687646 ( click the link to review the publication )

J Cell Physiol, 2020, 10.1002/jcp.29463

PubMed: 31960422 ( click the link to review the publication )

Eur J Pharm Biopharm, 2020, S0939-6411(20)30305-2

PubMed: 33068736 ( click the link to review the publication )

Mol Cancer Res, 2020, 10.1158/1541-7786.MCR-20-0420

PubMed: 33028660 ( click the link to review the publication )

Front Oncol, 2020, 12;10:696

PubMed: 32528877 ( click the link to review the publication )

Front Oncol, 2020, 10:585292

PubMed: 33194732 ( click the link to review the publication )

Front Oncol, 2020, 10:1593

PubMed: 33014812 ( click the link to review the publication )

Biochem Pharmacol, 2020, 10.1016/j.bcp.2020.113914

PubMed: 32173363 ( click the link to review the publication )

Int J Mol Sci, 2020,

PubMed: 32823915 ( click the link to review the publication )

Int J Mol Sci, 2020, 21(23)E9307

PubMed: 33291316 ( click the link to review the publication )

Sci Rep, 2020, 10(1):17768

PubMed: 33082482 ( click the link to review the publication )

Sci Rep, 2020, 17;10(1):2735

PubMed: 32066763 ( click the link to review the publication )

Sci Rep, 2020, 10(1):3842

PubMed: 32123209 ( click the link to review the publication )

Sci Rep, 2020, 10(1):4748

PubMed: 32179851 ( click the link to review the publication )

J Biol Chem, 2020, jbc.RA120.014960

PubMed: 33273014 ( click the link to review the publication )

Cancer Manag Res, 2020, 12:4453-4460

PubMed: 32606939 ( click the link to review the publication )

Cancer Res Treat, 2020, 10.4143/crt.2020.585

PubMed: 33070556 ( click the link to review the publication )

Oncol Rep, 2020, 44(6):2581-2594

PubMed: 33125153 ( click the link to review the publication )

Oncol Rep, 2020, 45(1):217-229

PubMed: 33200228 ( click the link to review the publication )

J Pharm Biomed Anal, 2020, 195:113864

PubMed: 33387839 ( click the link to review the publication )

Environ Toxicol, 2020, 10.1002/tox.22942

PubMed: 32485087 ( click the link to review the publication )

Onco Targets Ther, 2020, 13:10983-10994

PubMed: 33149613 ( click the link to review the publication )

Thorac Cancer, 2020, 11

PubMed: 32525282 ( click the link to review the publication )
Chin Med, 2020, 15:66

PubMed: 32612672 ( click the link to review the publication )

Hum Cell, 2020, 10.1007/s13577-020-00420-z

PubMed: 32870449 ( click the link to review the publication )

J Cell Commun Signal, 2020, 10.1007

PubMed: 32157550 ( click the link to review the publication )

Cancer Lett, 2020, 477:19-30

PubMed: 32120023 ( click the link to review the publication )

J Am Soc Nephrol, 2020, ASN.2019111215

PubMed: 32616537 ( click the link to review the publication )

Neurooncol Adv, 2020, 2(1):vdaa067

PubMed: 32642717 ( click the link to review the publication )

Radiat Oncol, 2020, 15(1):58

PubMed: 32143669 ( click the link to review the publication )

Redox Biol, 2020, 36:101652

PubMed: 32750669 ( click the link to review the publication )

Nat Commun, 2020, 11(1):3521

PubMed: 32665556 ( click the link to review the publication )

J Pharmacol Toxicol Methods, 2020, 106895

PubMed: 32629158 ( click the link to review the publication )

Cancer Manag Res, 2020, 12:4283-4297

PubMed: 32606925 ( click the link to review the publication )

Cancer Cell, 2020, 38(6):872-890.e6

PubMed: 33217342 ( click the link to review the publication )

Chin Med J (Engl), 2020, 5;133(11):1304-1311

PubMed: 32452893 ( click the link to review the publication )

J Thorac Oncol, 2020, 15(5):752-765

PubMed: 31972351 ( click the link to review the publication )

Biochem Pharmacol, 2020, 114154

PubMed: 32681833 ( click the link to review the publication )

Nat Commun, 2019, 10(1):2532

PubMed: 31182717 ( click the link to review the publication )

Nano Lett, 2019, 19(10):7526-7533

PubMed: 31487192 ( click the link to review the publication )

Autophagy, 2019, 10.1080/15548627.2019.1659654

PubMed: 31448672 ( click the link to review the publication )

Clin Cancer Res, 2019, 10.1158/1078-0432

PubMed: 31776128 ( click the link to review the publication )

Small, 2019, 15(33):e1900309

PubMed: 31245925 ( click the link to review the publication )

Cancer Res, 2019, 79(11):2947-2961

PubMed: 30987999 ( click the link to review the publication )

Cell Syst, 2019, 10.1016/j.cels.2019.10.002

PubMed: 31668800 ( click the link to review the publication )

Clin Cancer Res, 2019, 25(11):3341-3351

PubMed: 30796031 ( click the link to review the publication )

Mol Syst Biol, 2019, 15(3):e8323

PubMed: 30858180 ( click the link to review the publication )
Cancer Res, 2019, 79(19):5048-5059

PubMed: 31416839 ( click the link to review the publication )

Cell Rep, 2019, 28(8):2012-2022

PubMed: 31433979 ( click the link to review the publication )

Cell Rep, 2019, 28(2):512-525.e6

PubMed: 31291585 ( click the link to review the publication )

Int J Cancer, 2019, 10.1002/ijc.32487

PubMed: 31162839 ( click the link to review the publication )

Oncogene, 2019, 38(5):656-670

PubMed: 30171258 ( click the link to review the publication )

Cancer Lett, 2019, 466:23-34

PubMed: 31521695 ( click the link to review the publication )

Cancer Lett, 2019, 454:78-89

PubMed: 30980868 ( click the link to review the publication )

J Exp Clin Cancer Res, 2019, 38(1):84

PubMed: 30777099 ( click the link to review the publication )

J Exp Clin Cancer Res, 2019, 38(1):154

PubMed: 30971297 ( click the link to review the publication )

J Exp Clin Cancer Res, 2019, 38(1):83

PubMed: 30770740 ( click the link to review the publication )

J Exp Clin Cancer Res, 2019, 38(1):211

PubMed: 31118055 ( click the link to review the publication )

Cancers (Basel), 2019, 11(1)

PubMed: 30609749 ( click the link to review the publication )

Cancers (Basel), 2019, 11(6)

PubMed: 31181806 ( click the link to review the publication )

Breast Cancer Res, 2019, 21(1):77

PubMed: 31262335 ( click the link to review the publication )

Anal Chem, 2019, 91(15):10026-10032

PubMed: 31282657 ( click the link to review the publication )

Cell Death Dis, 2019, 10(4):282

PubMed: 30910997 ( click the link to review the publication )

Cell Chem Biol, 2019, 26(3):400-410

PubMed: 30595532 ( click the link to review the publication )

Cancer Discov, 2019, 9(6):756-777

PubMed: 30862724 ( click the link to review the publication )

J Cancer, 2019, 10(9):2063-2073

PubMed: 31205567 ( click the link to review the publication )

Am J Cancer Res, 2019, 9(8):1708-1721

PubMed: 31497352 ( click the link to review the publication )

Oncogenesis, 2019, 8(12-:70

PubMed: 31772161 ( click the link to review the publication )

Artif Cells Nanomed Biotechnol, 2019, 47(1):3231-3238

PubMed: 31373232 ( click the link to review the publication )

Front Oncol, 2019, 9:586

PubMed: 31428570 ( click the link to review the publication )

Front Oncol, 2019, 9:461

PubMed: 31214503 ( click the link to review the publication )
Front Oncol, 2019, 9:1070

PubMed: 31681603 ( click the link to review the publication )

Biochem Pharmacol, 2019, 169:113640

PubMed: 31536726 ( click the link to review the publication )

Int J Mol Sci, 2019, 20(19)

PubMed: 31546690 ( click the link to review the publication )

Int J Mol Sci, 2019, 20(18)

PubMed: 31514305 ( click the link to review the publication )

Sci Rep, 2019,

PubMed: 31882684 ( click the link to review the publication )

Sci Rep, 2019, 9(1):845

PubMed: 30696915 ( click the link to review the publication )

Sci Rep, 2019, 9(1):5309

PubMed: 30926929 ( click the link to review the publication )

J Biol Chem, 2019, 294(27):10530-10543

PubMed: 31126985 ( click the link to review the publication )

Cytotherapy, 2019, 21(6):603-611

PubMed: 31010733 ( click the link to review the publication )

Mol Pharmacol, 2019, 95(5):528-536

PubMed: 30858165 ( click the link to review the publication )

Cancer Cell Int, 2019, 19:10

PubMed: 30636931 ( click the link to review the publication )

Gene, 2019, 687:143-150

PubMed: 30359740 ( click the link to review the publication )

Respir Res, 2019, 20(1-:270

PubMed: 31791326 ( click the link to review the publication )

Int J Mol Sci, 2019, 20(10)

PubMed: 31121829 ( click the link to review the publication )

Int J Oncol, 2019, 54(2):527-536

PubMed: 30535494 ( click the link to review the publication )

J Ethnopharmacol, 2019, 239:111928

PubMed: 31077779 ( click the link to review the publication )

Cancer Biol Ther, 2019, 10.1080/15384047.2019.1665952

PubMed: 31559898 ( click the link to review the publication )

Transl Oncol, 2019, 12(3):432-440

PubMed: 30562682 ( click the link to review the publication )

Oncol Rep, 2019, 41(1):447-454

PubMed: 30365151 ( click the link to review the publication )

Eur J Pharmacol, 2019, 850:97-108

PubMed: 30753867 ( click the link to review the publication )

Biosci Rep, 2019, 39(8)

PubMed: 31316001 ( click the link to review the publication )

PLoS One, 2019, 14(9):e0214901

PubMed: 31539380 ( click the link to review the publication )

Biochem Biophys Res Commun, 2019, 513(3):546-552

PubMed: 30981504 ( click the link to review the publication )

Oncol Lett, 2019, 17(3):2729-2736

PubMed: 30854046 ( click the link to review the publication )
Anticancer Res, 2019, 39(7):3785-3793

PubMed: 31262905 ( click the link to review the publication )

FEBS Open Bio, 2019, 9(10):1689-1704

PubMed: 31314158 ( click the link to review the publication )

Clin Respir J, 2019, 13(1):23-33

PubMed: 30480362 ( click the link to review the publication )

J Thorac Oncol, 2019, 14(9):1556-1566

PubMed: 31108249 ( click the link to review the publication )

JCI Insight, 2019, 4(4)

PubMed: 30830869 ( click the link to review the publication )

Am J Cancer Res, 2019, 9(12):2719-2729

PubMed: 31911857 ( click the link to review the publication )

Endocr Connect, 2019, 8(6):680-690

PubMed: 31035254 ( click the link to review the publication )

JCI Insight, 2019, 4(21)

PubMed: 31600169 ( click the link to review the publication )

Sci Rep, 2019, 9(1):5692

PubMed: 30952931 ( click the link to review the publication )

J Clin Invest, 2018, 128(6):2500-2518

PubMed: 29613856 ( click the link to review the publication )

Nat Commun, 2018, 9(1):4655

PubMed: 30405134 ( click the link to review the publication )

Nat Commun, 2018, 13;9(1):2720

PubMed: 30006524 ( click the link to review the publication )

J Exp Med, 2018, 215(1):115-140

PubMed: 29191914 ( click the link to review the publication )

J Thorac Oncol, 2018, 13(7):926-937

PubMed: 29596910 ( click the link to review the publication )

EMBO Mol Med, 2018, 10(9)

PubMed: 30108112 ( click the link to review the publication )

Clin Cancer Res, 2018, 24(11):2594-2604

PubMed: 29298799 ( click the link to review the publication )

Clin Cancer Res, 2018, 24(13):3126-3136

PubMed: 29618618 ( click the link to review the publication )

Clin Cancer Res, 2018, 10.1158/1078-0432.CCR-18-0792

PubMed: 29967251 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2018, 115(26):E6030-E6038

PubMed: 29875142 ( click the link to review the publication )

Cancer Immunol Res, 2018, 10.1158/2326-6066

PubMed: 29382670 ( click the link to review the publication )

PLoS Biol, 2018, 16(12):e2006660

PubMed: 30543635 ( click the link to review the publication )

PLoS Biol, 2018,

PubMed: 30261040 ( click the link to review the publication )

Cancer Res, 2018, 78(16):4642-4657

PubMed: 29760048 ( click the link to review the publication )

Clin Cancer Res, 2018, 24(23):6066-6077

PubMed: 30061362 ( click the link to review the publication )
Cancer Res, 2018, 78(24):6866-6880

PubMed: 30322862 ( click the link to review the publication )

Int J Cancer, 2018, 143(8):1994-2007

PubMed: 29756386 ( click the link to review the publication )

Sci Signal, 2018, 11(549)

PubMed: 30254057 ( click the link to review the publication )

Pigment Cell Melanoma Res, 2018, 31(2):253-266

PubMed: 28972303 ( click the link to review the publication )

Cell Death Dis, 2018, 9(3):262

PubMed: 29449529 ( click the link to review the publication )

Cell Death Dis, 2018,

PubMed: 29880898 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(10):2217-2225

PubMed: 30045926 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(4):806-813

PubMed: 29167314 ( click the link to review the publication )

Endocr Relat Cancer, 2018, 25(4):471-480

PubMed: 29440231 ( click the link to review the publication )

Mol Cancer Res, 2018, 16(11):1773-1784

PubMed: 29967110 ( click the link to review the publication )

Mol Cancer Res, 2018, 16(7):1185-1195

PubMed: 29724813 ( click the link to review the publication )

Lung Cancer, 2018, 126:72-79

PubMed: 30527195 ( click the link to review the publication )

Mol Pharm, 2018, 15(5):1892-1900

PubMed: 29595984 ( click the link to review the publication )

J Immunol, 2018, 200(8):2809-2818

PubMed: 29531172 ( click the link to review the publication )

J Cell Physiol, 2018, 233(9):6975-6983

PubMed: 29336487 ( click the link to review the publication )

Mol Cancer Res, 2018, 16(5):777-790

PubMed: 29431617 ( click the link to review the publication )

J Virol, 2018,

PubMed: 29386292 ( click the link to review the publication )

J Cell Mol Med, 2018, 22(6):3073-3085

PubMed: 29575527 ( click the link to review the publication )

Toxicol Sci, 2018, 166(2):394-408

PubMed: 30496568 ( click the link to review the publication )

Sci Rep, 2018, 8(1):18043

PubMed: 30575780 ( click the link to review the publication )

J Biol Chem, 2018, 293(35):13401-13414

PubMed: 29997256 ( click the link to review the publication )

J Proteome Res, 2018, 17(1):63-75

PubMed: 29164889 ( click the link to review the publication )

Front Pharmacol, 2018, 9:1214

PubMed: 30483119 ( click the link to review the publication )

Cancer Manag Res, 2018, 10:565-581

PubMed: 29606890 ( click the link to review the publication )
Cancer Commun (Lond), 2018, 38(1):19

PubMed: 29764505 ( click the link to review the publication )

Int J Oncol, 2018,

PubMed: 30226590 ( click the link to review the publication )

BMC Cancer, 2018,

PubMed: 29506489 ( click the link to review the publication )

Cancer Med, 2018, 7(4):1394-1403

PubMed: 29493886 ( click the link to review the publication )

Cancer Med, 2018,

PubMed: 29239135 ( click the link to review the publication )

Molecules, 2018, 23(7)

PubMed: 30037018 ( click the link to review the publication )

Oncol Rep, 2018, 40(1):29-38

PubMed: 29749533 ( click the link to review the publication )

J Pharm Biomed Anal, 2018, 150:112-120

PubMed: 29220734 ( click the link to review the publication )

Biochem Biophys Res Commun, 2018, 495(1):733-739

PubMed: 29137977 ( click the link to review the publication )

Anticancer Res, 2018, 38(11):6195-6200

PubMed: 30396937 ( click the link to review the publication )

Urology, 2018, 112:225.e1-225.e7

PubMed: 29154981 ( click the link to review the publication )

Acta Haematol, 2018, 140(1):30-39

PubMed: 30071517 ( click the link to review the publication )

J Craniomaxillofac Surg, 2018, 46(3):492-497

PubMed: 29311018 ( click the link to review the publication )

Oncotarget, 2018, 9(100):37352-37366

PubMed: 30647837 ( click the link to review the publication )

Oncotarget, 2018, 9(60):31572-31589

PubMed: 30167080 ( click the link to review the publication )

Oncotarget, 2018, 9(51):29680-29697

PubMed: 30038713 ( click the link to review the publication )

JCI Insight, 2018, 3(24)

PubMed: 30568033 ( click the link to review the publication )

Oncotarget, 2018, 9(101):37520-37533

PubMed: 30680067 ( click the link to review the publication )

F1000Res, 2018, 7:1906

PubMed: 30881689 ( click the link to review the publication )

Mol Ther Nucleic Acids, 2018, 11:455-467

PubMed: 29858080 ( click the link to review the publication )

Oncol Lett, 2018, 15(5):6107-6114

PubMed: 29731842 ( click the link to review the publication )

Oncoscience, 2018, 5(1-2):21-38

PubMed: 29556515 ( click the link to review the publication )

Gut, 2017, 66(1):124-136

PubMed: 27402485 ( click the link to review the publication )

Sci Transl Med, 2017, 14;9(394):eaah6144

PubMed: 28615362 ( click the link to review the publication )
Nat Commun, 2017, 8(1):410

PubMed: 28871105 ( click the link to review the publication )

Nat Commun, 2017, 8(1):823

PubMed: 29018192 ( click the link to review the publication )

Clin Cancer Res, 2017, 23(19):5923-5935

PubMed: 28679766 ( click the link to review the publication )

Genes Dev, 2017, 31(2):184-196

PubMed: 28167502 ( click the link to review the publication )

Cancer Res, 2017, 77(8):2018-2028

PubMed: 28202526 ( click the link to review the publication )

Genome Med, 2017, 9(1):40

PubMed: 28446242 ( click the link to review the publication )

Biomaterials, 2017, 148:69-80

PubMed: 28968536 ( click the link to review the publication )

Elife, 2017, 6e27388

PubMed: 28980940 ( click the link to review the publication )

Oncogene, 2017, 36(48):6691-6700

PubMed: 28745317 ( click the link to review the publication )

Cell Death Dis, 2017, 8(8):e2980

PubMed: 28796259 ( click the link to review the publication )

Cell Death Dis, 2017, 8(5):e2773

PubMed: 28492539 ( click the link to review the publication )

Arch Toxicol, 2017, 91(8):2921-2938

PubMed: 28032146 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(10):2234-2245

PubMed: 28729401 ( click the link to review the publication )

Mol Cancer Ther, 2017,

PubMed: 27913578 ( click the link to review the publication )

Mol Oncol, 2017, 11(6):628-639

PubMed: 28306189 ( click the link to review the publication )

Mol Oncol, 2017, 11(8):1065-1077

PubMed: 28486761 ( click the link to review the publication )

J Biomed Nanotechnol, 2017, 13(4):458-68

PubMed: 29388752 ( click the link to review the publication )

Cancer Sci, 2017,

PubMed: 27783866 ( click the link to review the publication )

Lung Cancer, 2017, 106:115-124

PubMed: 28285685 ( click the link to review the publication )

Lung Cancer, 2017, 113:72-78

PubMed: 29110853 ( click the link to review the publication )

J Am Heart Assoc, 2017, 6(10)

PubMed: 29051215 ( click the link to review the publication )

Sci Rep, 2017,

PubMed: 28572590 ( click the link to review the publication )

Sci Rep, 2017, 7(1):781

PubMed: 28396596 ( click the link to review the publication )

Sci Rep, 2017, 7(1):1669

PubMed: 28490807 ( click the link to review the publication )
Sci Rep, 2017, 7:44206

PubMed: 28287179 ( click the link to review the publication )

Clin Lung Cancer, 2017,

PubMed: 28038979 ( click the link to review the publication )

J Proteome Res, 2017, 16(2):1077-1086

PubMed: 28152594 ( click the link to review the publication )

Mol Cell Biol, 2017, 37(10)e00649-16

PubMed: 28265001 ( click the link to review the publication )

Biomed Pharmacother, 2017, 96:619-625

PubMed: 29035827 ( click the link to review the publication )

Phytomedicine, 2017,

PubMed: 29157829 ( click the link to review the publication )

Int J Oncol, 2017, 50(6):2049-2058

PubMed: 28440469 ( click the link to review the publication )

Cell Biosci, 2017, 7:43

PubMed: 28852468 ( click the link to review the publication )

BMC Cancer, 2017,

PubMed: 28806950 ( click the link to review the publication )

Cancer Res Treat, 2017, 49(4):915-926

PubMed: 28052650 ( click the link to review the publication )

Oncol Rep, 2017, 38(4):2205-2210

PubMed: 28791365 ( click the link to review the publication )

Pancreas, 2017, 46(4):575-581

PubMed: 28196025 ( click the link to review the publication )

J Appl Toxicol, 2017, 37(3):382-390

PubMed: 27480533 ( click the link to review the publication )

Biosci Rep, 2017, 37(3)

PubMed: 28507201 ( click the link to review the publication )

PLoS One, 2017, 12(9):e0184155

PubMed: 28898253 ( click the link to review the publication )

PLoS ONE, 2017,

PubMed: 29253018 ( click the link to review the publication )

Biochem Biophys Res Commun, 2017, 486(4):1027-1033

PubMed: 28366635 ( click the link to review the publication )

SLAS Discov, 2017, 22(7):915-922

PubMed: 28346107 ( click the link to review the publication )

Biol Pharm Bull, 2017, 40(8):1306-1313

PubMed: 28515374 ( click the link to review the publication )

Oncotarget, 2017, 8(35):58417-58429

PubMed: 28938567 ( click the link to review the publication )

Gels, 2017, 3(3)

PubMed: 30920523 ( click the link to review the publication )

Oncotarget, 2017, 8(58):98771-98781

PubMed: 29228726 ( click the link to review the publication )

Tumour Biol, 2017, 39(7):1010428317709639

PubMed: 28714370 ( click the link to review the publication )

Oncotarget, 2017, 8(14):22414-22432

PubMed: 26461472 ( click the link to review the publication )
Oncotarget, 2017, 8(40):68221-68229

PubMed: 28978110 ( click the link to review the publication )

JCO Precis Oncol, 2017, 1:PO.16.00019

PubMed: 32913967 ( click the link to review the publication )

Elife, 2017, 6

PubMed: 28145866 ( click the link to review the publication )

Oncotarget, 2017, 9(9):8206-8222

PubMed: 29492189 ( click the link to review the publication )

Oncotarget, 2017, 8(29):47305-47316

PubMed: 28521301 ( click the link to review the publication )

Oncotarget, 2017,

PubMed: 28978083 ( click the link to review the publication )

Oncotarget, 2017,

PubMed: 28423495 ( click the link to review the publication )

Oncotarget, 2017, 9(2):1641-1655

PubMed: 29416720 ( click the link to review the publication )

Genome Biol, 2016, 17:80

PubMed: 27139883 ( click the link to review the publication )

Nat Commun, 2016, 7:11815

PubMed: 27283993 ( click the link to review the publication )

Nat Commun, 2016, 7:11551

PubMed: 27187615 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2016, 113(21):E2935-44

PubMed: 27162365 ( click the link to review the publication )

Cancer Lett, 2016, 376(1):188-96

PubMed: 26996299 ( click the link to review the publication )

J Pathol, 2016, 239(3):320-34

PubMed: 27102572 ( click the link to review the publication )

PLoS Pathog, 2016,

PubMed: 27711202 ( click the link to review the publication )

PLoS Pathog, 2016, 12(5):e1005622

PubMed: 27152417 ( click the link to review the publication )

Cell Death Dis, 2016,

PubMed: 27685624 ( click the link to review the publication )

Mol Cancer Ther, 2016,

PubMed: 27207775 ( click the link to review the publication )

Neoplasia, 2016, 18(7):425-35

PubMed: 27435925 ( click the link to review the publication )

Neoplasia, 2016, 18(2):111-20

PubMed: 26936397 ( click the link to review the publication )

Cancer Sci, 2016, 107(8):1134-40

PubMed: 27240419 ( click the link to review the publication )

Biochim Biophys Acta, 2016, 1859(11):1449-1458

PubMed: 27412911 ( click the link to review the publication )

Stem Cells Int, 2016, 2016:9601493

PubMed: 26788073 ( click the link to review the publication )

BMC Genomics, 2016, 17(1):723

PubMed: 27613601 ( click the link to review the publication )
Int J Oncol, 2016, 48(6):2558-66

PubMed: 27035631 ( click the link to review the publication )

Int J Oncol, 2016, 49(1):243-52

PubMed: 27177201 ( click the link to review the publication )

Exp Cell Res, 2016, 344(2):194-200

PubMed: 27180268 ( click the link to review the publication )

Eur J Pharmacol, 2016, 789:458-467

PubMed: 27514773 ( click the link to review the publication )

PLoS ONE, 2016,

PubMed: 26962861 ( click the link to review the publication )

PLoS One, 2016, 11(5):e0155230

PubMed: 27153109 ( click the link to review the publication )

BMC Vet Res, 2016, 12:82

PubMed: 27245053 ( click the link to review the publication )

Oncotarget, 2016, 7(30):47998-48010

PubMed: 27384992 ( click the link to review the publication )

Oncotarget, 2016, 7(13):15492-506

PubMed: 26909860 ( click the link to review the publication )

Oncotarget, 2016, 7(32):51922-51933

PubMed: 27409162 ( click the link to review the publication )

Oncotarget, 2016, 7(37):59809-59819

PubMed: 27494858 ( click the link to review the publication )

Cancer Immunol Res, 2016,

PubMed: 27680026 ( click the link to review the publication )

Oncotarget, 2016, 7(4):3847-56

PubMed: 26716903 ( click the link to review the publication )

Oncotarget, 2016,

PubMed: 27590506 ( click the link to review the publication )

Oncotarget, 2016, 7(18-:25983-6002

PubMed: 27036020 ( click the link to review the publication )

Mol Cell, 2015, 57(3):521-36

PubMed: 25658204 ( click the link to review the publication )

Clin Cancer Res, 2015, 21(20):4686-97

PubMed: 26124204 ( click the link to review the publication )

Proc Natl Acad Sci USA, 2015, 112(6):1839-44

PubMed: 25605917 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2015, 112(30):9406-11

PubMed: 26170313 ( click the link to review the publication )

Cancer Res, 2015, 10.1158/0008-5472.CAN-14-2005

PubMed: 25744720 ( click the link to review the publication )

Cell Death Differ, 2015, 22(5):801-14

PubMed: 25361079 ( click the link to review the publication )

Elife, 2015,

PubMed: 25686219 ( click the link to review the publication )

Int J Cancer, 2015, 10.1002/ijc.29483

PubMed: 25688715 ( click the link to review the publication )

Oncogene, 2015,

PubMed: 25659577 ( click the link to review the publication )
FASEB J, 2015, 29(9):3702-12

PubMed: 25985800 ( click the link to review the publication )

Mol Cancer Ther, 2015, 10.1158/1535-7163.MCT-13-0951

PubMed: 25589492 ( click the link to review the publication )

Cell Commun Signal, 2015, 13:26

PubMed: 25975820 ( click the link to review the publication )

Radiother Oncol, 2015, 116(3):431-7

PubMed: 26320552 ( click the link to review the publication )

Biochem Pharmacol, 2015, 98(4):639-48

PubMed: 26484875 ( click the link to review the publication )

Sci Rep, 2015,

PubMed: 26538233 ( click the link to review the publication )

Sci Rep, 2015,

PubMed: 25705018 ( click the link to review the publication )

J Biol Chem, 2015,

PubMed: 26152725 ( click the link to review the publication )

J Biol Chem, 2015, 290(28):17495-504

PubMed: 26023239 ( click the link to review the publication )

Ann Thorac Surg, 2015, 100(2):414-21

PubMed: 26141774 ( click the link to review the publication )

Biochem J, 2015, 465(2):271-9

PubMed: 25351958 ( click the link to review the publication )

J Chromatogr A, 2015, 1400:117-23

PubMed: 25981288 ( click the link to review the publication )

J Chromatogr A, 2015, 10.1016/j.chroma.2015.04.055

PubMed: ( click the link to review the publication )

Toxicol Appl Pharmacol, 2015, 10.1016/j.taap.2015.05.001

PubMed: 25981168 ( click the link to review the publication )

Am J Physiol Heart Circ Physiol, 2015, 309(9):H1516-27

PubMed: 26371162 ( click the link to review the publication )

Acta Pharmacol Sin, 2015, 10.1038/aps.2015.4

PubMed: 25864651 ( click the link to review the publication )

Prostate, 2015, 10.1002/pros.22945

PubMed: 25560638 ( click the link to review the publication )

Drug Des Devel Ther, 2015, 9:3183-90

PubMed: 26124641 ( click the link to review the publication )

Cancer Chemoth Pharm, 2015, 10.1007/s00280-015-2751-6

PubMed: 25907508 ( click the link to review the publication )

PLoS One, 2015, 10(5):e0127348

PubMed: 25973895 ( click the link to review the publication )

PLoS One, 2015, 10(10):e0140782

PubMed: 26474061 ( click the link to review the publication )

PLoS One, 2015, 10(4):e0123901

PubMed: 25875914 ( click the link to review the publication )

Biochem Biophys Res Commun, 2015, 463(4):612-7

PubMed: 26043686 ( click the link to review the publication )

J Biotechnol, 2015, 10.1016/j.jbiotec.2015.01.012

PubMed: 25615947 ( click the link to review the publication )
Anal Biochem, 2015, 10.1016/j.ab.2015.01.016

PubMed: 25659657 ( click the link to review the publication )

Biomarkers, 2015,

PubMed: 26329528 ( click the link to review the publication )

Pathol Oncol Res, 2015, 10.1007/s12253-015-9916-9

PubMed: 25749811 ( click the link to review the publication )

Oncol Lett, 2015,

PubMed: 26622654 ( click the link to review the publication )

Biochem J, 2015, 471(2):267-79

PubMed: 26285655 ( click the link to review the publication )

Oncotarget, 2015,

PubMed: 26036637 ( click the link to review the publication )

Oncotarget, 2015,

PubMed: 25686822 ( click the link to review the publication )

Oncotarget, 2015,

PubMed: 26325669 ( click the link to review the publication )

BMC Res Notes, 2015, 8:203

PubMed: 26032726 ( click the link to review the publication )

Oncotarget, 2015,

PubMed: 25909220 ( click the link to review the publication )

PLoS One, 2015, 10(2):e0118210

PubMed: 25706985 ( click the link to review the publication )

Oncotarget, 2015, 6(7):5118-33

PubMed: 25742786 ( click the link to review the publication )

Oncotarget, 2015,

PubMed: 25576915 ( click the link to review the publication )

Tumour Biol, 2015, 36(7):5485-95

PubMed: 26036758 ( click the link to review the publication )

J Virol, 2015, 90(4):1918-30

PubMed: 26656684 ( click the link to review the publication )

Cancer Prev Res (Phila), 2015, 8(9):765-76

PubMed: 26100522 ( click the link to review the publication )

Oncotarget, 2015,

PubMed: 26378037 ( click the link to review the publication )

Oncotarget, 2015,

PubMed: 25965827 ( click the link to review the publication )

Oncotarget, 2015,

PubMed: 26486084 ( click the link to review the publication )

Nat Commun, 2014, 3.84166666666667

PubMed: 25366117 ( click the link to review the publication )

J Natl Cancer Inst, 2014, 106(9)

PubMed: 25214559 ( click the link to review the publication )

J Thorac Oncol, 2014, 9(6):775-83

PubMed: 24828661 ( click the link to review the publication )

Clin Cancer Res, 2014, 20(13):3613-22

PubMed: 24803578 ( click the link to review the publication )

Clin Cancer Res, 2014, 20(15):4047-58

PubMed: 24895459 ( click the link to review the publication )
Clin Cancer Res, 2014, 20(18):4806-15

PubMed: 25052479 ( click the link to review the publication )

Clin Cancer Res, 2014, 20(13):3613-22

PubMed: 24803578 ( click the link to review the publication )

Cancer Res, 2014, 74(1):253-62

PubMed: 24165158 ( click the link to review the publication )

Elife, 2014, 3:e02523

PubMed: 24844246 ( click the link to review the publication )

Oncogene, 2014, 33(35):4418-23

PubMed: 24469055 ( click the link to review the publication )

Br J Pharmacol, 2014, 171(24):5757-73

PubMed: 25117211 ( click the link to review the publication )

Antioxid Redox Sign, 2014, 10.1089/ars.2013.5304

PubMed: 24684506 ( click the link to review the publication )

Cell Death Dis, 2014, 5:e1445

PubMed: 25299770 ( click the link to review the publication )

Mol Oncol, 2014, 10.1016/j.molonc.2014.05.005

PubMed: 24908424 ( click the link to review the publication )

Lung Cancer, 2014, 85(2):152-60

PubMed: 24954871 ( click the link to review the publication )

Antimicrob Agents Chemother, 2014, 10.1128/AAC.02393-14

PubMed: 24663025 ( click the link to review the publication )

J Transl Med, 2014, 12(1):265

PubMed: 25240937 ( click the link to review the publication )

Am J Cancer Res, 2014, 6(6):649-663

PubMed: ( click the link to review the publication )

J Pharmacol Exp Ther, 2014, 351(2):352-8

PubMed: 25187431 ( click the link to review the publication )

Drug Metab Dispos, 2014, 42(11):1851-7

PubMed: 25165131 ( click the link to review the publication )

J Mol Endocrinol, 2014, 52(2):223-34

PubMed: 24463098 ( click the link to review the publication )

Am J Transl Res, 2014, 6(6):649-63

PubMed: 25628777 ( click the link to review the publication )

Oncol Res, 2014, 21(3):137-44

PubMed: 24512728 ( click the link to review the publication )

BMC Microbiol, 2014,

PubMed: 25471819 ( click the link to review the publication )

PLoS One, 2014, 9(12):e114000

PubMed: 25486409 ( click the link to review the publication )

Biomed Res Int, 2014,

PubMed: 24895573 ( click the link to review the publication )

Histochem Cell Biol, 2014, 10.1007/s00418-014-1223-0

PubMed: 24824474 ( click the link to review the publication )

Guangxi Medical University, 2014, Suning Huang

PubMed: ( click the link to review the publication )

Biores Open Access, 2014, 3(4):176-82

PubMed: 25126481 ( click the link to review the publication )
Nat Chem Biol, 2013, 9(5):307-12

PubMed: 23502424 ( click the link to review the publication )

Cell Rep, 2013, 4(4):764-75

PubMed: 23972990 ( click the link to review the publication )

Int J Cancer, 2013, 133(2):505-13

PubMed: 23319394 ( click the link to review the publication )

Sci Signal, 2013,

PubMed: 23532334 ( click the link to review the publication )

BRIT J CANCER, 2013, 109(8):2155-66

PubMed: 24045666 ( click the link to review the publication )

Mol Cancer Ther, 2013, 12(10):2213-25

PubMed: 23918833 ( click the link to review the publication )

Lung Cancer, 2013, 81(3):354-61

PubMed: 23769318 ( click the link to review the publication )

Invest Ophthalmol Vis Sci, 2013, 54(1):864-70

PubMed: 23299479 ( click the link to review the publication )

Prostate, 2013, 73(13):1453-61

PubMed: 23765757 ( click the link to review the publication )

PLoS One, 2013, 8(1):e54509

PubMed: 23349913 ( click the link to review the publication )

PLoS One, 2013, 8(12):e81393

PubMed: 24339922 ( click the link to review the publication )

PLoS One, 2013, 8(12):e82236

PubMed: 24349229 ( click the link to review the publication )

PLoS One, 2013, 8(5):e62104

PubMed: 23690929 ( click the link to review the publication )

Laser in Surg Med, 2013, 45(7):460-8

PubMed: 24037824 ( click the link to review the publication )

Oncotarget, 2013,

PubMed: 23896512 ( click the link to review the publication )

Head Neck, 2013, 35(1):86-93

PubMed: 22495823 ( click the link to review the publication )

Tuberc Respir Dis, 2013, 75(1):9-17

PubMed: 23946753 ( click the link to review the publication )

Tuberc Respir Dis, 2013, 75(3):95-103

PubMed: 24101933 ( click the link to review the publication )

J Clin Invest, 2012, 122(9):3197-210

PubMed: 22886302 ( click the link to review the publication )

Int J Cancer, 2012, 131(12):2961-9

PubMed: 22514082 ( click the link to review the publication )

Int J Cancer, 2012, 131(2):334-43

PubMed: 21858806 ( click the link to review the publication )

Cancer, 2012, 118(21):5198-209

PubMed: 22510844 ( click the link to review the publication )

Cancer Sci, 2012, 103(1):7-16

PubMed: 21951556 ( click the link to review the publication )

Int J Mol Sci, 2012, 13(9):12000-16

PubMed: 23109896 ( click the link to review the publication )
PLoS One, 2012, 7(9):e42441

PubMed: 22957020 ( click the link to review the publication )

PLoS One, 2012, 7(10):e48532

PubMed: 23119048 ( click the link to review the publication )

Oncogene, 2011, 30(22):2547-57

PubMed: 21278786 ( click the link to review the publication )

Mol Cancer Ther, 2011, 10(10):1846-56

PubMed: 21768330 ( click the link to review the publication )

J Immunother, 2011, 34(4):372-81

PubMed: 21499124 ( click the link to review the publication )

Transl Oncol, 2011, 4(2):92-100

PubMed: 21461172 ( click the link to review the publication )

Int J Proteomics, 2011, 2011:215496

PubMed: 22091388 ( click the link to review the publication )

Carcinogenesis, 2010, 31(4):577-86

PubMed: 20097731 ( click the link to review the publication )

Carcinogenesis, 2010, 31(11):1948-55

PubMed: 20837598 ( click the link to review the publication )

Case Western Reserve University, 2010, Zhang Z

PubMed: ( click the link to review the publication )

Eur J Pharm Sci, , 10.1016/j.ejps.2016.04.025

PubMed: 27112992 ( click the link to review the publication )

Purity & Quality Control

Choose Selective EGFR Inhibitors

Biological Activity

Description

Erlotinib (OSI-774, CP358774, NSC 718781, Tarceva) is an EGFR inhibitor with IC50 of 2 nM, >1000-fold more sensitive for EGFR than human c-Src or v-Abl. Erlotinib induces autophagy.

Targets

EGFR ^[1]
(Cell-free assay)

2 nM

In vitro

Erlotinib HCl potently inhibits EGFR activation in intact cells including HNS human head and neck tumor cells (IC50 20nM), DiFi human colon cancer cells and MDA MB-468 human breast cancer cells. Erlotinib HCl (1 μM) induces apoptosis in DiFi human colon cancer cells. ^[1] Erlotinib inhibits growth of a panel of NSCLC cell lines including A549, H322, H3255, H358 H661, H1650, H1975, H1299, H596 with IC50 ranging from 29 nM to >20 μM. ^[2] Erlotinib HCl(2 μM) significantly inhibits growth of AsPC-1 and BxPC-3 pancreatic cells. ^[3] The effects of Erlotinib HCl in combination with gemcitabine are considered additive in KRAS-mutated pancreatic cancer cells. Ten micromolar of Erlotinib HCl inhibits EGFR phospho-rylation at the Y845 (Src-dependent phosphorylation) and Y1068 (auto-phosphorylation) sites. ^[4] Combination with Erlotinib HCl could down-modulate rapamycin-stimulated Akt activity and produces a synergistic effect on cell growth inhibition. ^[5]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Activity Description	PMID
human SKBR3 cells	MXnGeY5kfGmxbjDhd5NigQ>?			MWTJcohq[mm2aX;uJI9nKEiHUkKgbY4hcHWvYX6gV2tDWjNiY3XscJMh[nliSGTSSkBie3OjeTygTWM2OD1zLki5JO69VS5?	MkT4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTl6MUW0NVIoRjF7OEG1OFEzRC:jPh?=
human A431 cells	M4PncmZ2dmO2aX;uJIF{e2G7			MVfJcohq[mm2aX;uJI9nKEWJRmKgbY4hcHWvYX6gRVQ{OSClZXzsd{BjgSCKVGLGJIF{e2G7LDDJR\|UxRTBwNEKg{txONg>?	NWjxOYRuRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUm4NVU1OTJpPkG5PFE2PDF{PD;hQi=>
Huh7.5	MnGwRY51cX[rcnHsJIF{e2G7		MUWzNEBucW6\|	NVrNfFV2SW62aY\pdoFtKGGldHn2bZR6KGGpYXnud5QhUGWyYYTpeIl{KENidnnyeZMhUjZxSl\IJIlv\mWldHXkJIlvKGi3bXHuJGh2cDdwNTDj[YxteyCjc4Pld5Nm\CCjczDpcohq[mm2aX;uJI9nKEiFVjDy[ZBtcWOjdHnvckBxemW2cnXheIVlKG[xcjCzNEBucW6\|IH\vcIxwf2WmIHL5JIlv\mWldHnvckBu\WG\|dYLl[EBi\nSncjC3NkBpenNiYomgZYxidWG{IHLseYUh\HmnIHLhd4VlKG[udX;y[ZNk\W6lZTDhd5NigQ>?	MV[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjl{NUKwPEc,OjZ7MkWyNFg9N2F-
Huh7.5	MkWyRY51cX[rcnHsJIF{e2G7		Ml7qO\|IhcHK\|	NXPQOZZ[SW62aY\pdoFtKGGldHn2bZR6KGGpYXnud5QhUGWyYYTpeIl{KENidnnyeZMhUjZxSl\IJIlv\mWldHXkJIlvKGi3bXHuJGh2cDdwNTDj[YxteyCjc4Pld5Nm\CCjczDpcohq[mm2aX;uJI9nKH[rcnHsJJJmeGyrY3H0bY9vKG2nYYP1doVlKGGodHXyJFczKGi{czDifUBtfWOrZnXyZZNmKHKncH;yeIVzKGenbnWgZZN{[XluIFXDOVAhRSByLkWg{txONg>?	M4KxTFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3OEKyO\|M6Lz5{NUiyNlc{QTxxYU6=
Huh7.5	NF7FdmlCdnSrdnnyZYwh[XO\|YYm=		MWi3NkBpenN?	NID3WG5CdnSrdnnyZYwh[WO2aY\peJkh[WejaX7zeEBJ\XCjdHn0bZMhSyC4aYL1d{BLPi:MRlig[Yxm[3S{b4DvdoF1\WRiaX6gbJVu[W5iSIXoO{42KGOnbHzzJIF{e2W\|c3XkJIF{KGmwaHnibZRqd25ib3[gbY51emGlZXzseYxieiCrbn\lZ5Rqfmm2eTDkdpVoKHS{ZXH0[YQh\X[ncomgNlQhcHK\|IH\vdkA4OiCqcoOgcYVie3W{ZXSgO\|IhcHK\|IIDvd5Qh\WynY4Tyc5BwemG2aX;uJIJ6KGy3Y3nm[ZJie2VicnXwc5J1\XJiZ3Xu[UBie3OjeTygSWM2OCB;IECuOUDPxE1w	MV28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTh{MkezPUc,OjV6MkK3N\|k9N2F-
Huh7.5	M3\3SGFvfGm4aYLhcEBie3OjeR?=		M3;ZW\|czKGi{cx?=	MVHBcpRqfmm{YXygZYN1cX[rdImgZYdicW6\|dDDI[ZBifGm2aYOgR{B3cXK3czDKOk9LTkhiaX7m[YN1\WRiaX6gbJVu[W5iSIXoO{42KGOnbHzzJIF{e2W\|c3XkJIF{KGmwaHnibZRqd25ib3[g[Zh1emGlZXzseYxieiCrbn\lZ5Rqfmm2eTDkdpVoKHS{ZXH0[YQh\X[ncomgNlQhcHK\|IH\vdkA4OiCqcoOgcYVie3W{ZXSgZYZ1\XJiN{KgbJJ{KGK7IHz1Z4ln\XKjc3WgdoVxd3K2ZYKg[4Vv\SCjc4PhfUwhTUN3MDC9JFAvPSEQvF2u	NFf2TXc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUiyNlc{QSd-MkW4NlI4Ozl:L3G+
NCI-H292	M2XabGFvfGmycn;sbYZmemG2aY\lJIF{e2G7		NHr1bnc4OiCqcoO=	NIPWeoJCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIF7DTU1JOjl{IHPlcIx{KGW6cILld5Nqdmdid3ns[EB1gXCnIFXHSnIh[W[2ZYKgO\|IhcHK\|IHL5JIx2dWmwZYPj[Y5k\SCjc4PhfUwhTUN3MDC9JFAvODNzIN88UU4>	MoLwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ2NUW5NVkoRjJ4NEW1PVE6RC:jPh?=
A431	MmTJS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		MlTHO\|IhcHK\|	M2Lx[2dzd3e2aDDpcohq[mm2aX;uJI9nKGi3bXHuJGE1OzFiY3XscJMhd3[ncnX4dJJme3OrbnegSWdHWiCjZoTldkA4OiCqcoOgZpkhVVSWIHHzd4F6NCCJSUWwJF0hOC52NzFOwG0v	Ml3xQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTd7OEO3OFUoRjF5OUizO\|Q2RC:jPh?=
A431	MlXRS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		M2jJZVczKGi{cx?=	NX2xeox3T3Kxd4ToJIlvcGmkaYTpc44hd2ZiaIXtZY4hSTR\|MTDj[YxteyCjZoTldkA4OiCqcoOgZpkhVVSWIHHzd4F6NCCJSUWwJF0hOC57MUWg{txONg>?	NVTETFdCRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUm5Olk1PjVpPkG5PVY6PDZ3PD;hQi=>
BA/F3	NXvkdFRrT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		NGXncng6PiCqcoO=	M{TxcWdzd3e2aDDpcohq[mm2aX;uJI9nKG2xdYPlJGJCN0Z\|IHPlcIx{KGW6cILld5NqdmdiRVfGVkBF\WxzIH31eIFvfCCjZoTldkA6PiCqcoOgZpkh[2WubDD0bZRmei2pbH:gZZN{[XluIFfJOVAhRSByLkWg{txONg>?	MX[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zODJ{MkezN{c,OjB{MkK3N\|M9N2F-
BA/F3	Ml;OS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		NXXFbnlXQTZiaILz	NYLNdmJbT3Kxd4ToJIlvcGmkaYTpc44hd2ZibX;1d4UhSkFxRkOgZ4VtdHNiZYjwdoV{e2mwZzDFS2ZTKESnbEOgcZV1[W62IHHmeIVzKDl4IHjyd{BjgSClZXzsJJRqfGW{LXfsc{Bie3OjeTygS2k2OCB;IECuOUDPxE1w	MXi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zODJ{MkezN{c,OjB{MkK3N\|M9N2F-
BA/F3	M1;pdGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		MYq5OkBpenN?	NVfCPGpVT3Kxd4ToJIlvcGmkaYTpc44hd2ZibX;1d4UhSkFxRkOgZ4VtdHNiZYjwdoV{e2mwZzDFS2ZTKESnbEWgcZV1[W62IHHmeIVzKDl4IHjyd{BjgSClZXzsJJRqfGW{LXfsc{Bie3OjeTygS2k2OCB;IECuOUDPxE1w	M{XHN\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyMkKyO\|M{Lz5{MEKyNlc{OzxxYU6=
BA/F3	NXq4WW11T3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		MXG5OkBpenN?	MkLIS5Jwf3SqIHnubIljcXSrb36gc4YhdW:3c3WgRmEwTjNiY3XscJMh\XiycnXzd4lv\yCHR1\SJGw5PTiUIH31eIFvfCCjZoTldkA6PiCqcoOgZpkh[2WubDD0bZRmei2pbH:gZZN{[XluIFfJOVAhRSByLkWg{txONg>?	NYHjW\|FkRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkCyNlI4OzNpPkKwNlIzPzN\|PD;hQi=>
WM266.4	NYLoT45wT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		NVPiSnhlOjRiaILz	NFLaNXZIem:5dHigbY5pcWKrdHnvckBqdiCqdX3hckBYVTJ4Nj60JINmdGy\|IHHmeIVzKDJ2IHjyd{BjgSCPVGSgdoVlfWO2aX;uJIF{e2G7LDDHTVUxKD1iOD6xNkDPxE1w	MUi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjl6NUm2Nkc,OjJ7OEW5OlI9N2F-
A549	NF:ycINCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		MVWyOEBpenN?	MVnBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEF3NEmgZ4VtdHNiYX\0[ZIhOjRiaILzJIJ6KE2WVDDhd5NigSxiR1m1NEA:KDBwMEOg{txONg>?	NXjYRXVyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOzPVE{PjRpPkKzN\|kyOzZ2PD;hQi=>
MCF7	NEf0V2VCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		NGrMcIMzPCCqcoO=	MWLBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKE2FRkegZ4VtdHNiYX\0[ZIhOjRiaILzJIJ6KE2WVDDhd5NigSxiR1m1NEA:KDBwMEig{txONg>?	NYHhNlk{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOzPVE{PjRpPkKzN\|kyOzZ2PD;hQi=>
WM266.4	MkO2RY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		NX;TUmdoOjRiaILz	MXTBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKFePMk[2MlQh[2WubIOgZZN{\XO\|ZXSgZZMh[2WubDD2bYFjcWyrdImgZYZ1\XJiMkSgbJJ{KGK7IF3UWEBie3OjeTygS2k2OCB;IEiuNVQh\|ryPLh?=	MXi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzJ\|OEi0NUc,Ojd{M{i4OFE9N2F-
NIH3T3	NF;sXIZHfW6ldHnvckBie3OjeR?=			NFnvSYlKdmirYnn0bY9vKG:oIFXHSkB{fGmvdXzheIVlKGi3bXHuJIVz[kJzIHH1eI9xcG:\|cHjvdplt[XSrb36gbY4hVkmKM2SzJINmdGy\|LDDJR\|UxKD1iMD6wNVk{KM7:TT6=	MlXwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTZ2OECyPFQoRjF4NEiwNlg1RC:jPh?=
T24 NIH	MoTwSpVv[3Srb36gZZN{[Xl?			NWDUXmhjUW6qaXLpeIlwdiCxZjDsbYdidmRic4TpcZVt[XSnZDDldoJDOiCjdYTvdIhwe3Cqb4L5cIF1cW:wIHnuJHQzPCCQSVigZ4VtdHNuIFnDOVAhRSByLkK5PUDPxE1w	NHHGSFY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zNkS4NFI5PCd-MU[0PFAzQDR:L3G+
Jurkat	M4q3Tmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		NULKWGZnOjRiaILz	MUjHdo94fGhiaX7obYJqfGmxbjDv[kBpfW2jbjDKeZJs[XRiY3XscJMh[W[2ZYKgNlQhcHK\|LDDJR\|UxKD1iMjFOwG0v	M3X0cFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF5MUe4O\|IzLz5zN{G3PFczOjxxYU6=
erythroleukemia cells	M1zofWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		Mlf5NlQhcHK\|	MXzHdo94fGhiaX7obYJqfGmxbjDv[kBLSUt{IG[2NVdHKG23dHHueEBmgHC{ZYPzbY5oKGi3bXHuJIVzgXSqcn;s[ZVs\W2rYTDj[YxteyCjZoTldkAzPCCqcoOsJGlEPTBiPTCyJO69VS5?	NYHqN2I1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUexO\|g4OjJpPkG3NVc5PzJ{PD;hQi=>
erythroleukemia cells	MX;Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		NIPXbZMzPCCqcoO=	M2PvfGdzd3e2aDDpcohq[mm2aX;uJI9nKG2xdYPlJIVzgXSqcn;s[ZVs\W2rYTDj[YxteyCjZoTldkAzPCCqcoOsJGlEPTBiPTCyJO69VS5?	NVXCZmlWRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUexO\|g4OjJpPkG3NVc5PzJ{PD;hQi=>
COS7	MUTGeY5kfGmxbjDhd5NigQ>?			NV34NXhqUW6qaXLpeIlwdiCxZjDoeY1idiCMQVuyJHY3OTeIIH31eIFvfCCneIDy[ZN{\WRiaX6gR29UPyClZXzsd{whUUN3MDC9JFQh\|ryPLh?=	MoLBQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTdzN{i3NlIoRjF5MUe4O\|IzRC:jPh?=
hematopoietic progenitor cells	NFq3[I5Iem:5dHigbY5pcWKrdHnvckBie3OjeR?=			M2LZN2dzd3e2aDDpcohq[mm2aX;uJI9nKEqDS{KgWlYyP0ZibYX0ZY51KGW6cILld5NqdmdiaHXtZZRweG:rZYTpZ{Bxem:pZX7peI9zKGOnbHzzJIl{d2yjdHXkJIZzd21icH;sfYN6fGinbXnhJJZmemFicHH0bYVvfCCkeTDjc4xwdnliZn;ycYlv\yCjc4PhfUwhUUN3MDC9JFUh\|ryPLh?=	NXL0SWZxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUexO\|g4OjJpPkG3NVc5PzJ{PD;hQi=>
BA/F3	M{XidGN6fG:2b4jpZ4l1gSCjc4PhfS=>			NIHMRWtEgXSxdH;4bYNqfHliYXfhbY5{fCCvb4Xz[UBDSS:IMzDj[YxteyCneIDy[ZN{cW6pIFXHSnIhVDh3OGKgcZV1[W62LDDJR\|UxKD1iMD6wNVI2KM7:TT6=	MXe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQTJ\|OUKyPUc,OTl{M{myNlk9N2F-
A431	M3;pW2N6fG:2b4jpZ4l1gSCjc4PhfS=>		M4XUfVczKGi{cx?=	M37yNGN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGE1OzFiY3XscJMh[W[2ZYKgO\|IhcHK\|IHL5JHNTSiCjc4PhfUwhUUN3MDC9JFAvODl4IN88UU4>	MnfVQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTl6OEi3OlEoRjF7OEi4O\|YyRC:jPh?=
MCF7	NHjPZnNCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		MYq0PEBpenN?	NVKxdI86SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDNR2Y4KGOnbHzzJIFnfGW{IES4JIhzeyCkeTDNWHQh[XO\|YYmsJGlEPTBiPTCwMlAzKM7:TT6=	Ml7pQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTl7MUS4N\|UoRjF7OUG0PFM2RC:jPh?=
Sf9	NWCyTlA4TnWwY4Tpc44h[XO\|YYm=			NGKwbY9KdmirYnn0bY9vKG:oIHPsc45m\CCHR1\SJIF2fG:yaH;zdIhwenmuYYTpc44h\XiycnXzd4VlKGmwIHLhZ5Vtd3[rcoXzMYlv\mWldHXkJHNnQSClZXzsd{BjgSC\|b3zp[E1xcGG\|ZTDFUGlUSSxiSVO1NEA:KDBwMEOg{txONg>?	MUK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQTlzNEizOUc,OTl7MUS4N\|U9N2F-
Sf9	NEfv[XJHfW6ldHnvckBie3OjeR?=			MUXJcohq[mm2aX;uJI9nKGi3bXHuJINtd26nZDDISXIzKGG3dH;wbI9{eGixconsZZRqd25iZYjwdoV{e2WmIHnuJIJi[3Wub4\pdpV{NWmwZnXjeIVlKFOoOTDj[YxteyCkeTDzc4xq\C2yaHHz[UBGVEmVQTygTWM2OCB;IECuNVYh\|ryPLh?=	MoT0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTl7MUS4N\|UoRjF7OUG0PFM2RC:jPh?=
MCF7	NVXqc4ZxSW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		NFrvTFY1QCCqcoO=	MV;BcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKE2FRkegZ4VtdHNiYX\0[ZIhPDhiaILzJIJ6KE2WVDDhd5NigSxiSVO1NEA:KDBwMEGg{txONg>?	MXy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQTlzNEizO{c,OTl7MUS4N\|c9N2F-
Sf9	MXfGeY5kfGmxbjDhd5NigQ>?			MVrJcohq[mm2aX;uJI9nKGOub37l[EBGT0[UIHH1eI9xcG:\|cHjvdplt[XSrb36g[ZhxemW\|c3XkJIlvKGKjY4Xsc5ZqenW\|LXnu[oVkfGWmIGPmPUBk\WyuczDifUB{d2yrZD3wbIF{\SCHTFnTRUwhUUN3MDC9JFAvODJizszNMi=>	MWS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQTlzNEizO{c,OTl7MUS4N\|c9N2F-
Sf9	MVvGeY5kfGmxbjDhd5NigQ>?			M{XpXGlvcGmkaYTpc44hd2ZiaIXtZY4h[2yxbnXkJGhGWjJiYYX0c5Bpd3OyaH;yfYxifGmxbjDlfJBz\XO\|ZXSgbY4h[mGldXzveolzfXNvaX7m[YN1\WRiU3[5JINmdGy\|IHL5JJNwdGmmLYDoZZNmKEWOSWPBMEBKSzVyIE2gNE4yOiEQvF2u	NVizSGwxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUm5NVQ5OzdpPkG5PVE1QDN5PD;hQi=>
MCF7	MWHBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		M4DjN\|Q5KGi{cx?=	MUnBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKE2FRkegZ4VtdHNiYX\0[ZIhPDhiaILzJIJ6KE2WVDDhd5NigSxiSVO1NEA:KDBwMEKg{txONg>?	NXLlWYlyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkCwNFUyOTZpPkKwNFA2OTF4PD;hQi=>
NCI-H2122	M2K5WWFvfGmycn;sbYZmemG2aY\lJIF{e2G7			MnLCRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCQQ1mtTFIyOjJiY3XscJMtKEmFNUCgQUAyKM7:TT6=	NUP2emtwRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkCxOFM4PzhpPkKwNVQ{Pzd6PD;hQi=>
SK-BR-3	NGTBZllCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=			NVX2cmo3SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDTT{1DWi1\|IHPlcIx{KGGodHXyJIhzeyCkeTDBWHAh[2:wdHXueEBie3OjeTygTWM2OCB;IEGuOVYh\|ryPLh?=	NXT0fIk6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkCxOFM4PzhpPkKwNVQ{Pzd6PD;hQi=>
SCC15	MlHNRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?			MlH5RY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCVQ1OxOUBk\WyuczygTWM2OCB;IEGuPVQh\|ryPLh?=	NHKzcG09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MEG0N\|c4QCd-MkCxOFM4Pzh:L3G+
SCC25	NYPJbWZ7SW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=			M33ocWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iU1PDNlUh[2WubIOsJGlEPTBiPTCzMlM1KM7:TT6=	NXyxT4s3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkCxOFM4PzhpPkKwNVQ{Pzd6PD;hQi=>
NCI-H358	NXHv[mIzSW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=			MYLBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKE6FST3IN\|U5KGOnbHzzJIFnfGW{IHjyd{BjgSCDVGCgZ49vfGWwdDDhd5NigSxiSVO1NEA:KDZizszNMi=>	M3HUbVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyMUSzO\|c5Lz5{MEG0N\|c4QDxxYU6=
HCC827	NVK4NmRiSW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=			M3PlZWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iSFPDPFI4KGOnbHzzJIFnfGW{IHjyd{BjgSCDVGCgZ49vfGWwdDDhd5NigSxiSVO1NEA:KDdwNTFOwG0v	MXm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zODF2M{e3PEc,OjBzNEO3O\|g9N2F-
BxPC3	Mk\yRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?			NFyxfFJCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFL4VGM{KGOnbHzzJIFnfGW{IHjyd{BjgSCDVGCgZ49vfGWwdDDhd5NigSxiSVO1NEA:KDdwNjFOwG0v	NFG3emw9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MEG0N\|c4QCd-MkCxOFM4Pzh:L3G+
H460	M17sNmFvfGmycn;sbYZmemG2aY\lJIF{e2G7			MnTLRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCKNE[wJINmdGy\|IHHmeIVzKGi{czDifUBCXFBiY3;ueIVvfCCjc4PhfUwhUUN3MDC9JFgvOiEQvF2u	MUG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zODF2M{e3PEc,OjBzNEO3O\|g9N2F-
CAL27	MX7BcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?			M3z0dWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iQ1HMNlch[2WubIOsJGlEPTBiPTCxNE4yPSEQvF2u	NHPxSm09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MEG0N\|c4QCd-MkCxOFM4Pzh:L3G+
SKHEP1	MoPPRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?			MUjBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKFONSFXQNUBk\WyuczDh[pRmeiCqcoOgZpkhSVSSIHPvcpRmdnRiYYPzZZktKEmFNUCgQUAyOC5\|NzFOwG0v	NEnFfFg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MEG0N\|c4QCd-MkCxOFM4Pzh:L3G+
MDA-MB-468	MnzYRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?			NHTpWlFCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIF3ERU1OSi12NkigZ4VtdHNuIFnDOVAhRSBzMT60JO69VS5?	NW\4N3lORGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkCxOFM4PzhpPkKwNVQ{Pzd6PD;hQi=>
LNCAP	MWfBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?			MmDtRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCOTlPBVEBk\WyuczygTWM2OCB;IEG4MlM2KM7:TT6=	MUG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zODF2M{e3PEc,OjBzNEO3O\|g9N2F-
A431	MmfRSpVv[3Srb36gZZN{[Xl?			NXjleG5EUW6qaXLpeIlwdiCxZjDFS2ZTKGmwdILhZ4VtdHWuYYKgdIhwe3Cqb4L5cIF1cW:wIHnuJIh2dWGwIFG0N\|Eh[2WubIOgZpkhTUyLU1GsJGlEPTBiPTCwMlA{PCEQvF2u	NWK0TXhWRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkCzOFY3PTVpPkKwN\|Q3PjV3PD;hQi=>
N87	M4LKfWZ2dmO2aX;uJIF{e2G7			MoPlTY5pcWKrdHnvckBw\iCHcnLCNkBqdnS{YXPlcIx2dGG{IIDoc5NxcG:{eXzheIlwdiCrbjDoeY1idiCQOEegZ4VtdHNiYomgSWxKW0FuIFnDOVAhRSB3LkKg{txONg>?	NFzVPFI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MEO0OlY2PSd-MkCzOFY3PTV:L3G+
A431	MX;GeY5kfGmxbjDhd5NigQ>?		M1TJZVExKG2rboO=	M3XSNmlvcGmkaYTpc44hd2ZiRVfGVkBxcG:\|cHjvdplt[XSrb36gbY4hcHWvYX6gRVQ{OSClZXzsd{Bi\nSncjCxNEBucW6\|IHL5JGZNUVODLDDJR\|UxKD1iMT6yJO69VS5?	MYC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zODRyM{ewNEc,OjB2MEO3NFA9N2F-
NCI-H661	NYTtT5JbS3m2b4TvfIlkcXS7IHHzd4F6		MVq0JJRwKDViZHH5dy=>	M2j1VGN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJG5EUS2KNk[xJINmdGy\|IHHmeIVzKDRidH:gOUBl[Xm\|IHL5JG1VXCCjc4PhfUwhUUN3MDC9JFEzNjdzIN88UU4>	NIDIfWY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MES2OlU2PSd-MkC0OlY2PTV:L3G+
DU145	NYS1dHF5S3m2b4TvfIlkcXS7IHHzd4F6		M1\DW\|QhfG9iNTDkZZl{	MWXDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDEWVE1PSClZXzsd{Bi\nSncjC0JJRwKDViZHH5d{BjgSCPVGSgZZN{[XluIFnDOVAhRSBzOT60JO69VS5?	Mm\4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjB2Nk[1OVUoRjJyNE[2OVU2RC:jPh?=
A549	M3LNeWN6fG:2b4jpZ4l1gSCjc4PhfS=>		M1ziRlQhfG9iNTDkZZl{	NF3XcmREgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBCPTR7IHPlcIx{KGGodHXyJFQhfG9iNTDkZZl{KGK7IF3UWEBie3OjeTygTWM2OCB;IEOzMlA{KM7:TT6=	Mlz2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjB2Nk[1OVUoRjJyNE[2OVU2RC:jPh?=
PC3	NF7IO4REgXSxdH;4bYNqfHliYYPzZZk>		MoX0OEB1dyB3IHThfZM>	NETTWm1EgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBRSzNiY3XscJMh[W[2ZYKgOEB1dyB3IHThfZMh[nliTWTUJIF{e2G7LDDJR\|UxKD1iM{[uO\|Yh\|ryPLh?=	MmPsQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjB2Nk[1OVUoRjJyNE[2OVU2RC:jPh?=
A431	M4Xm[mZ2dmO2aX;uJIF{e2G7			MX;Jcohq[mm2aX;uJI9nKEWJRmKg[ZhxemW\|c3XkJIlvKGi3bXHuJGE1OzFiY3XscJMtKEmFNUCgQUAyNjJizszNMi=>	MofuQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjB3NUiwO\|IoRjJyNUW4NFczRC:jPh?=
MCF7	NHTNSopCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		Mn7YOFghcHK\|	MmfqRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCPQ1[3JINmdGy\|IHHmeIVzKDR6IHjyd{BjgSCPVGSgZZN{[XluIFnDOVAhRSByLkCyJO69VS5?	M361VFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyNUm0PFU6Lz5{MEW5OFg2QTxxYU6=
Sf9	M{PJU2Z2dmO2aX;uJIF{e2G7		M3HMPVEhcHJ?	NYPz[2lxUW6qaXLpeIlwdiCxZjDoeY1idiC{ZXPvcYJqdmGwdDDIbZM3gC22YXfn[YQhTUeIUjDheZRweGixc4Doc5J6dGG2aX;uJIV5eHKnc4Pl[EBqdiCVZkmgZ4VtdHNiYX\0[ZIhOSCqcjDifUBGVEmVQTygTWM2OCB;IECuNFMh\|ryPLh?=	NGO5UYg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MEW5OFg2QSd-MkC1PVQ5PTl:L3G+
Sf9	NW\ObnJXTnWwY4Tpc44h[XO\|YYm=		MXOxJIhz	NIrFb5BKdmirYnn0bY9vKG:oIHj1cYFvKHKnY3;tZolv[W62IFjpd\|Z5NXSjZ3fl[EBJTVJ{IHH1eI9xcG:\|cHjvdplt[XSrb36g[ZhxemW\|c3XkJIlvKFOoOTDj[YxteyCjZoTldkAyKGi{IHL5JGVNUVODLDDJR\|UxKD1iMD6xOkDPxE1w	MV:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zODV7NEi1PUc,OjB3OUS4OVk9N2F-
MCF7	M3zVcmN6fG:2b4jpZ4l1gSCjc4PhfS=>		Ml;POFghcHK\|	NIXnRnNEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBOS0Z5IHPlcIx{KGGodHXyJFQ5KGi{czDifUBOXFRiYYPzZZktKEmFNUCgQUAxNjB{IN88UU4>	NXez[4NqRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkC2Nlc2QTdpPkKwOlI4PTl5PD;hQi=>
Sf9	MW\GeY5kfGmxbjDhd5NigQ>?			Mn;ETY5pcWKrdHnvckBw\iCqaYP0bYRqdmVvdHHn[4VlKHKnY3;tZolv[W62IFXHSnIh[XW2b4Doc5NxcG:{eXzheIlwdiCneIDy[ZN{\WRiaX6gV4Y6KGOnbHzzJIJ6KHOxbHnkMZBp[XOnIFXMTXNCNCCLQ{WwJF0hOC5yMzFOwG0v	M3z2RVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyNkK3OVk4Lz5{ME[yO\|U6PzxxYU6=
MIAPaCa	NWXMNXB1TnWwY4Tpc44h[XO\|YYm=			MVvJcohq[mm2aX;uJI9nKEWJRmKgdIhwe3Cqb4L5cIF1cW:wIHnuJIh2dWGwIF3JRXBiS2FiY3XscJMh[nliRVzJV2EtKEmFNUCgQUAxNjB3MTFOwG0v	NEPRN2k9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MEixO\|UzOyd-MkC4NVc2OjN:L3G+
MIAPaCa	NF\lOoZHfW6ldHnvckBie3OjeR?=			NH2y[o9KdmirYnn0bY9vKG:oIFXSRoIzKHCqb4PwbI9zgWyjdHnvckBqdiCqdX3hckBOUUGSYVPhJINmdGy\|IHL5JGVNUVODLDDJR\|UxKD1iNj63N{DPxE1w	Mk\6QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjB6MUe1NlMoRjJyOEG3OVI{RC:jPh?=
Sf9	Mo\sSpVv[3Srb36gZZN{[Xl?		M3PvdVEhcHJ?	M{TIT2lvcGmkaYTpc44hd2ZicnXjc41jcW6jboSgSWdHWiCneIDy[ZN{\WRiaX6gZoFkfWyxdnnyeZMhcW6oZXP0[YQhW2Z7IHPlcIx{KGGodHXyJFEhcHJiYomgSGVNTkmDL4TpcYUuemW\|b3z2[YQh\my3b4LpcYV1enliYYPzZZktKEmFNUCgQUAxNjB\|IN88UU4>	NEn3UFM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUe2N\|E1QCd-MkG3OlMyPDh:L3G+
A549	NInhPWFCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		Mo\WOFghcHK\|	NG\FbmxCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFG1OFkh[2WubIOg[ZhxemW\|c3nu[{BGT0[UIHHzd4V{e2WmIHHzJIlvcGmkaYTpc44hd2ZiYnHzZYwh[2WubDDndo94fGhiYX\0[ZIhPDhiaILzJIJ6KE2WVDDhd5NigSxiSVO1NEA:KDBwMkeg{txONg>?	MYq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTd4M{G0PEc,OjF5NkOxOFg9N2F-
MCF7	NU\2RoxSS3m2b4TvfIlkcXS7IHHzd4F6		NGjvWYM1QCCqcoO=	MWHDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDNR2Y4KGOnbHzzJIFnfGW{IES4JIhzeyCkeTDNWHQh[XO\|YYmsJGlEPTBiPTCwMlAzKM7:TT6=	MUS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOThyMkK5NEc,OjF6MEKyPVA9N2F-
Sf9	M3vabmZ2dmO2aX;uJIF{e2G7		NEPYVFQyKGi{	NE\F[GZKdmirYnn0bY9vKG:oIFjpd{11[WepZXSgSWdHWiCneIDy[ZN{\WRiaX6gbY5{\WO2IGPmPUBk\WyuczDh[pRmeiBzIHjyJIJ6KHSrbXWtdoV{d2y4ZXSg[ox2d3KrbXX0dolkKGGwYXz5d4l{NCCLQ{WwJF0hOC5yMzFOwG0v	MoK3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF6MU[1NVcoRjJzOEG2OVE4RC:jPh?=
HepG2	NGXF[YVCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		NFzMT4c1QCCqcoO=	NWS3WFlZSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDI[ZBIOiClZXzsd{Bi\nSncjC0PEBpenNiYomgUXRVKGG\|c3H5MEBKSzVyIE2gNE4xQCEQvF2u	M4jCfFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzOEG2OVE4Lz5{MUixOlUyPzxxYU6=
A16-F10	NXrHWVRzSW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		NX;H[I84PDhiaILz	M4PzTGFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iQUG2MWYyOCClZXzsd{Bi\nSncjC0PEBpenNiYomgUXRVKGG\|c3H5MEBKSzVyIE2gNE4xOiEQvF2u	MWK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjFzMkW0NUc,OjJzMUK1OFE9N2F-
Sf9	M3TBPWZ2dmO2aX;uJIF{e2G7		MX:xNEBucW6\|	Mo\wTY5pcWKrdHnvckBw\iCHR1\SJIV5eHKnc4Pl[EBqdiCkYXP1cI93cXK3czDpcoZm[3SnZDDT[lkh[2WubIOgZZN{\XO\|ZXSgZZMhcW6qaXLpeIlwdiCxZjDheZRweGixc4Doc5J6dGG2aX;uJJBz\WmwY4XiZZRm\CCob4KgNVAhdWmwczDt[YF{fXKnZDDh[pRmeiBzIHjyJIJ6KESHTF\JRU9VcW2nLWLld49tfmWmIF\seY9zd22ndIL5MEBKSzVyIE2gNE4xOyEQvF2u	NWq2NZl7RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkKxNVI2PDFpPkKyNVEzPTRzPD;hQi=>
HepG2	MXvBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		M4\PTFQ5KGi{cx?=	MULBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEincFeyJINmdGy\|IHHmeIVzKDR6IHjyd{BjgSCPVGSgZZN{[XluIFnDOVAhRSByLkGyJO69VS5?	NHjsZZE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkGxNlU1OSd-MkKxNVI2PDF:L3G+
DIFI	M{Tre2N6fG:2b4jpZ4l1gSCjc4PhfS=>		M4jZNFQh\GG7cx?=	MUPDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDETWZKKGOnbHzzJIFnfGW{IESg[IF6eyCkeTDwdo9xcWSrdX2gbY9lcWSnIIP0ZYlvcW6pLXLhd4VlKG[udX;yc41mfHKrYzDhcoFtgXOrczygTWM2OCB;IECuNVQh\|ryPLh?=	Mn65QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJzNkm2NFEoRjJ{MU[5OlAyRC:jPh?=
CAL27	M{fOemN6fG:2b4jpZ4l1gSCjc4PhfS=>		MXW0JIRigXN?	NWDUR4d{S3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hS0GOMkegZ4VtdHNiYX\0[ZIhPCCmYYnzJIJ6KHC{b4Dp[Il2dSCrb3Tp[IUhe3SjaX7pcocu[mG\|ZXSg[ox2d3KxbXX0dolkKGGwYXz5d4l{NCCLQ{WwJF0hOC5{M{mg{txONg>?	NIe2boc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkG2PVYxOSd-MkKxOlk3ODF:L3G+
GXF251L	NHXze3FEgXSxdH;4bYNqfHliYYPzZZk>		M3fNOVQh\GG7cx?=	NVS3UJN2S3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hT1iIMkWxUEBk\WyuczDh[pRmeiB2IHThfZMh[nlicILvdIllcXWvIHnv[Ill\SC\|dHHpcolv\y2kYYPl[EBndHWxcn;t[ZRzcWNiYX7hcJl{cXNuIFnDOVAhRSByLkO2PUDPxE1w	NF\4boU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkG2PVYxOSd-MkKxOlk3ODF:L3G+
LXFA 629L	MVPDfZRwfG:6aXPpeJkh[XO\|YYm=		NFq1W3M1KGSjeYO=	MV\DfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDMXGZCKDZ{OVygZ4VtdHNiYX\0[ZIhPCCmYYnzJIJ6KHC{b4Dp[Il2dSCrb3Tp[IUhe3SjaX7pcocu[mG\|ZXSg[ox2d3KxbXX0dolkKGGwYXz5d4l{NCCLQ{WwJF0hOC54NjFOwG0v	MlO4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJzNkm2NFEoRjJ{MU[5OlAyRC:jPh?=
DU145	MVHDfZRwfG:6aXPpeJkh[XO\|YYm=		MX[0JIRigXN?	MYLDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDEWVE1PSClZXzsd{Bi\nSncjC0JIRigXNiYomgdJJweGmmaYXtJIlw\GmmZTDzeIFqdmmwZz3iZZNm\CCobIXvdo9u\XS{aXOgZY5idHm\|aYOsJGlEPTBiPTCwMlk3PiEQvF2u	MUK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjF4OU[wNUc,OjJzNkm2NFE9N2F-
LXFA 289L	MnvER5l1d3SxeHnjbZR6KGG\|c3H5		NFfLcm01KGSjeYO=	M{fQVmN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGxZTkFiMki5UEBk\WyuczDh[pRmeiB2IHThfZMh[nlicILvdIllcXWvIHnv[Ill\SC\|dHHpcolv\y2kYYPl[EBndHWxcn;t[ZRzcWNiYX7hcJl{cXNuIFnDOVAhRSBzLke4JO69VS5?	Ml\FQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJzNkm2NFEoRjJ{MU[5OlAyRC:jPh?=
LNCAP	MmTiR5l1d3SxeHnjbZR6KGG\|c3H5		M3GyT\|Qh\GG7cx?=	MojlR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gUG5ESVBiY3XscJMh[W[2ZYKgOEBl[Xm\|IHL5JJBzd3CrZHn1cUBqd2SrZHWgd5RicW6rbnetZoF{\WRiZnz1c5JwdWW2cnnjJIFv[Wy7c3nzMEBKSzVyIE2gOk43OyEQvF2u	M2L4SlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{MU[5OlAyLz5{MkG2PVYxOTxxYU6=
OVXF 899L	NE\wfGFEgXSxdH;4bYNqfHliYYPzZZk>		NHjjelA1KGSjeYO=	NIqzcmxEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBQXliIIEi5PWwh[2WubIOgZYZ1\XJiNDDkZZl{KGK7IIDyc5Bq\Gm3bTDpc4Rq\GVic4ThbY5qdmdvYnHz[YQh\my3b4LvcYV1emmlIHHuZYx6e2m\|LDDJR\|UxKD1iOD63O{DPxE1w	MoHnQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJzNkm2NFEoRjJ{MU[5OlAyRC:jPh?=
PAXF 546L	NHy2[G5EgXSxdH;4bYNqfHliYYPzZZk>		NF\ZVVg1KGSjeYO=	M1G5cmN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJHBCYEZiNUS2UEBk\WyuczDh[pRmeiB2IHThfZMh[nlicILvdIllcXWvIHnv[Ill\SC\|dHHpcolv\y2kYYPl[EBndHWxcn;t[ZRzcWNiYX7hcJl{cXNuIFnDOVAhRSBzMDFOwG0v	M{TxUFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{MU[5OlAyLz5{MkG2PVYxOTxxYU6=
RXF 486L	NVL1OI81S3m2b4TvfIlkcXS7IHHzd4F6		MVu0JIRigXN?	NIWySlREgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBTYEZiNEi2UEBk\WyuczDh[pRmeiB2IHThfZMh[nlicILvdIllcXWvIHnv[Ill\SC\|dHHpcolv\y2kYYPl[EBndHWxcn;t[ZRzcWNiYX7hcJl{cXNuIFnDOVAhRSBzMDFOwG0v	NFrEO2Y9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkG2PVYxOSd-MkKxOlk3ODF:L3G+
BXF T24	NYnnO\|NtS3m2b4TvfIlkcXS7IHHzd4F6		M4PYNVQh\GG7cx?=	M1fCZ2N6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGJZTiCWMkSgZ4VtdHNiYX\0[ZIhPCCmYYnzJIJ6KHC{b4Dp[Il2dSCrb3Tp[IUhe3SjaX7pcocu[mG\|ZXSg[ox2d3KxbXX0dolkKGGwYXz5d4l{NCCLQ{WwJF0hOTNwOTFOwG0v	NWmyWpExRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkKxOlk3ODFpPkKyNVY6PjBzPD;hQi=>
CXF 269L	MXnDfZRwfG:6aXPpeJkh[XO\|YYm=		MnHUOEBl[Xm\|	MkTDR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gR3hHKDJ4OVygZ4VtdHNiYX\0[ZIhPCCmYYnzJIJ6KHC{b4Dp[Il2dSCrb3Tp[IUhe3SjaX7pcocu[mG\|ZXSg[ox2d3KxbXX0dolkKGGwYXz5d4l{NCCLQ{WwJF0hOTZizszNMi=>	MVu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjF4OU[wNUc,OjJzNkm2NFE9N2F-
PC3M	NWPlSJRLS3m2b4TvfIlkcXS7IHHzd4F6		MYC0JIRigXN?	M2jUeWN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJHBEO01iY3XscJMh[W[2ZYKgOEBl[Xm\|IHL5JJBzd3CrZHn1cUBqd2SrZHWgd5RicW6rbnetZoF{\WRiZnz1c5JwdWW2cnnjJIFv[Wy7c3nzMEBKSzVyIE2gNVcvOiEQvF2u	NF3pZVI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkG2PVYxOSd-MkKxOlk3ODF:L3G+
LXFL 529L	NVPxXIxYS3m2b4TvfIlkcXS7IHHzd4F6		MkjuOEBl[Xm\|	NVrFeI9HS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hVFiITDC1NllNKGOnbHzzJIFnfGW{IESg[IF6eyCkeTDwdo9xcWSrdX2gbY9lcWSnIIP0ZYlvcW6pLXLhd4VlKG[udX;yc41mfHKrYzDhcoFtgXOrczygTWM2OCB;IEG3MlQh\|ryPLh?=	NHrzeYI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkG2PVYxOSd-MkKxOlk3ODF:L3G+
MEXF 276L	M2\pRmN6fG:2b4jpZ4l1gSCjc4PhfS=>		M1XBSFQh\GG7cx?=	M4jKVmN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJG1GYEZiMke2UEBk\WyuczDh[pRmeiB2IHThfZMh[nlicILvdIllcXWvIHnv[Ill\SC\|dHHpcolv\y2kYYPl[EBndHWxcn;t[ZRzcWNiYX7hcJl{cXNuIFnDOVAhRSBzOD62JO69VS5?	MoG4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJzNkm2NFEoRjJ{MU[5OlAyRC:jPh?=
Saos2	MkXYR5l1d3SxeHnjbZR6KGG\|c3H5		NWDTUlJrPCCmYYnz	NGewZWxEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBU[W:\|MjDj[YxteyCjZoTldkA1KGSjeYOgZpkheHKxcHnkbZVuKGmxZHnk[UB{fGGrbnnu[{1j[XOnZDDmcJVwem:vZYTybYMh[W6jbInzbZMtKEmFNUCgQUAzOSEQvF2u	M2\5d\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{MU[5OlAyLz5{MkG2PVYxOTxxYU6=
UXF 1138L	NH\sZodEgXSxdH;4bYNqfHliYYPzZZk>		MXi0JIRigXN?	NUfu[WxPS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hXViIIEGxN\|hNKGOnbHzzJIFnfGW{IESg[IF6eyCkeTDwdo9xcWSrdX2gbY9lcWSnIIP0ZYlvcW6pLXLhd4VlKG[udX;yc41mfHKrYzDhcoFtgXOrczygTWM2OCB;IEK0MlUh\|ryPLh?=	NWrkXmpwRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkKxOlk3ODFpPkKyNVY6PjBzPD;hQi=>
MAXF 401NL	NEGyR3JEgXSxdH;4bYNqfHliYYPzZZk>		MXG0JIRigXN?	NHfJOZhEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBOSViIIESwNW5NKGOnbHzzJIFnfGW{IESg[IF6eyCkeTDwdo9xcWSrdX2gbY9lcWSnIIP0ZYlvcW6pLXLhd4VlKG[udX;yc41mfHKrYzDhcoFtgXOrczygTWM2OCB;IEK1JO69VS5?	M4LweVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{MU[5OlAyLz5{MkG2PVYxOTxxYU6=
MEXF 1341L	NX;uW3IzS3m2b4TvfIlkcXS7IHHzd4F6		NGPHWm81KGSjeYO=	M3vqW2N6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJG1GYEZiMUO0NWwh[2WubIOgZYZ1\XJiNDDkZZl{KGK7IIDyc5Bq\Gm3bTDpc4Rq\GVic4ThbY5qdmdvYnHz[YQh\my3b4LvcYV1emmlIHHuZYx6e2m\|LDDJR\|UxKD1iM{CuNUDPxE1w	NGK5N2E9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkG2PVYxOSd-MkKxOlk3ODF:L3G+
PXF 1752L	MkHER5l1d3SxeHnjbZR6KGG\|c3H5		MXS0JIRigXN?	NX[4coZZS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hWFiIIEG3OVJNKGOnbHzzJIFnfGW{IESg[IF6eyCkeTDwdo9xcWSrdX2gbY9lcWSnIIP0ZYlvcW6pLXLhd4VlKG[udX;yc41mfHKrYzDhcoFtgXOrczygTWM2OCB;IEOxMlYh\|ryPLh?=	MoHJQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJzNkm2NFEoRjJ{MU[5OlAyRC:jPh?=
MDA231	NHLRTYFEgXSxdH;4bYNqfHliYYPzZZk>		MlLZOEBl[Xm\|	M3y5[2N6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJG1FSTJ\|MTDj[YxteyCjZoTldkA1KGSjeYOgZpkheHKxcHnkbZVuKGmxZHnk[UB{fGGrbnnu[{1j[XOnZDDmcJVwem:vZYTybYMh[W6jbInzbZMtKEmFNUCgQUA{PC53IN88UU4>	NWTm[YJ5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkKxOlk3ODFpPkKyNVY6PjBzPD;hQi=>
LXFL 1121L	NFrZO5REgXSxdH;4bYNqfHliYYPzZZk>		MorIOEBl[Xm\|	NWnsbGRQS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hVFiITDCxNVIyVCClZXzsd{Bi\nSncjC0JIRigXNiYomgdJJweGmmaYXtJIlw\GmmZTDzeIFqdmmwZz3iZZNm\CCobIXvdo9u\XS{aXOgZY5idHm\|aYOsJGlEPTBiPTCzOE43KM7:TT6=	NVLqSo9tRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkKxOlk3ODFpPkKyNVY6PjBzPD;hQi=>
PXF 698L	MVvDfZRwfG:6aXPpeJkh[XO\|YYm=		MW[0JIRigXN?	NF64N2VEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBRYEZiNkm4UEBk\WyuczDh[pRmeiB2IHThfZMh[nlicILvdIllcXWvIHnv[Ill\SC\|dHHpcolv\y2kYYPl[EBndHWxcn;t[ZRzcWNiYX7hcJl{cXNuIFnDOVAhRSB\|Nj60JO69VS5?	NHTn[Xo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkG2PVYxOSd-MkKxOlk3ODF:L3G+
RXF 393NL	M3vZXGN6fG:2b4jpZ4l1gSCjc4PhfS=>		NHmzV2g1KGSjeYO=	M1jDV2N6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJHJZTiB\|OUPOUEBk\WyuczDh[pRmeiB2IHThfZMh[nlicILvdIllcXWvIHnv[Ill\SC\|dHHpcolv\y2kYYPl[EBndHWxcn;t[ZRzcWNiYX7hcJl{cXNuIFnDOVAhRSB2NT62JO69VS5?	M4PnXVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{MU[5OlAyLz5{MkG2PVYxOTxxYU6=
LIXF 575L	MlzUR5l1d3SxeHnjbZR6KGG\|c3H5		NITTdWg1KGSjeYO=	M{fDR2N6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGxKYEZiNUe1UEBk\WyuczDh[pRmeiB2IHThfZMh[nlicILvdIllcXWvIHnv[Ill\SC\|dHHpcolv\y2kYYPl[EBndHWxcn;t[ZRzcWNiYX7hcJl{cXNuIFnDOVAhRSB2Nz6yJO69VS5?	NE\KbXA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkG2PVYxOSd-MkKxOlk3ODF:L3G+
A431	MWPGeY5kfGmxbjDhd5NigQ>?		MVS2NEBucW6\|	MX;Jcohq[mm2aX;uJI9nKEWJRmKgeJlzd3OrbnWgb4lv[XOnIHHjeIl3cXS7IHnuJGVITi2\|dHnteYxifGWmIHj1cYFvKEF2M{GgZ4VtdHNiYX\0[ZIhPjBibXnud{BjgSCHTFnTRUwhUUN3MDC9JFEvOiEQvF2u	NILTW3E9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkKwOFc1OSd-MkKyNFQ4PDF:L3G+
MCF7	MnvRRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		MWC0PEBpenN?	NWC5UYtzSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDNR2Y4KGOnbHzzJIFnfGW{IES4JIhzeyCkeTDNWHQh[XO\|YYmsJGlEPTBiPTCwMlAzKM7:TT6=	NWDUTXA6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkKyO\|c2QDhpPkKyNlc4PTh6PD;hQi=>
Sf9	NUXFSlNITnWwY4Tpc44h[XO\|YYm=		NIfwR3MyKGi{	NWLRZZFyUW6qaXLpeIlwdiCxZjDheZRweGixc4Doc5J6dGG2aX;uJI9nKHKnY3;tZolv[W62IFjpd{11[WepZXSgSWdHWiCneIDy[ZN{\WRiaX6gZoFkfWyxdnnyeZMhcW6oZXP0[YQhW2Z7IHPlcIx{KGGodHXyJFEhcHJiYomgSGVNTkmDL4TpcYUuemW\|b3z2[YQh\my3b4LpcYV1enliYYPzZZktKEmFNUCgQUAxNjB\|IN88UU4>	NXTi[GxwRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkKyO\|c2QDhpPkKyNlc4PTh6PD;hQi=>
Sf9	NYj3dVNTTnWwY4Tpc44h[XO\|YYm=		MU[xJIhz	NV;pO3dkUW6qaXLpeIlwdiCxZjDobZN1cWSrbnWteIFo\2WmIHj1cYFvKHKnY3;tZolv[W62IHP5eI9xdGG\|bXnjJIRwdWGrbjDv[kBGT0[UIHX4dJJme3OnZDDpckBj[WO3bH;2bZJ2eyCrbn\lZ5Rm\CCrboPlZ5QhW2Z7IHPlcIx{KGGodHXyJFEhcHJiYomgSGVNTkmDL4TpcYUuemW\|b3z2[YQh\my3b4LvcYV1emmlIHHuZYx6e2m\|LDDJR\|UxKD1iMD6wN{DPxE1w	NVP4ZXNJRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkKzOlEzPzJpPkKyN\|YyOjd{PD;hQi=>
MCF7	NVvtc\|JrSW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		M4\LNFQ5KGi{cx?=	MXHBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKE2FRkegZ4VtdHNiYX\0[ZIhPDhiaILzJIJ6KE2WVDDhd5NigSxiSVO1NEA:KDBwMEeg{txONg>?	Ml7TQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ\|NkGyO\|IoRjJ{M{[xNlczRC:jPh?=
B16F10	MkLYRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		NGWzNYs1QCCqcoO=	M365R2FvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgcY92e2ViQkG2SlExKGOnbHzzJIFnfGW{IES4JIhzeyCkeTDNWHQh[XO\|YYmsJGlEPTBiPTCwMlEh\|ryPLh?=	NIP1e4Y9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkO2NVI4Oid-MkKzOlEzPzJ:L3G+
HCT116	NYf3fZNiSW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		Mk\1OFghcHK\|	M2q1d2FvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iSFPUNVE3KGOnbHzzJIFnfGW{IES4JIhzeyCkeTDNWHQh[XO\|YYmsJGlEPTBiPTCwMlE1KM7:TT6=	MV68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjN4MUK3Nkc,OjJ\|NkGyO\|I9N2F-
Sf9	NGnHSYNHfW6ldHnvckBie3OjeR?=		Mnm3NUBpeg>?	NWr5dJpLUW6qaXLpeIlwdiCxZjDobZN1cWSrbnWteIFo\2WmIHj1cYFvKHKnY3;tZolv[W62IHP5eI9xdGG\|bXnjJIRwdWGrbjDv[kBJTVJ{IHX4dJJme3OnZDDpckBj[WO3bH;2bZJ2eyCrbn\lZ5Rm\CCrboPlZ5QhW2Z7IHPlcIx{KGGodHXyJFEhcHJiYomgSGVNTkmDL4TpcYUuemW\|b3z2[YQh\my3b4LvcYV1emmlIHHuZYx6e2m\|LDDJR\|UxKD1iMD6xOEDPxE1w	NI[ycIo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkO2NVI4Oid-MkKzOlEzPzJ:L3G+
A431	MUDDfZRwfG:6aXPpeJkh[XO\|YYm=		NVzXXHFPPDhiaILz	M1XKVGN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGE1OzFiY3XscJMhd3[ncjDlfJBz\XO\|aX7nJGVITlJiYX\0[ZIhPDhiaILzJIJ6KE2WVDDhd5NigSxiSVO1NEA:KDBwMEW1JO69VS5?	MVO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjRzNE[xNkc,OjJ2MUS2NVI9N2F-
HEK293 Flp-In	MmrYSpVv[3Srb36gZZN{[Xl?		M2jDTVUhdWmwcx?=	NGDnZZhKdmirYnn0bY9vKG:oIHj1cYFvKGyrdnXyJG9CXFB{QkGg[ZhxemW\|c3XkJIlvKEiHS{K5N{BHdHBvSX6gZ4VtdHNiYYPz[ZN{\WRiYYOgdoVlfWO2aX;uJIlvKFt\|SG3FN3MhfXC2YXvlJIlv[3WkYYTl[EBnd3JiNTDtbY5{KGK7IIPjbY51cWyuYYTpc44h[2:3boTpcoctKEmFNUCgQUAxNjV3IN88UU4>	MkP0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ3NEGwOlgoRjJ{NUSxNFY5RC:jPh?=
HEK293 Flp-In	NEfoW\|dHfW6ldHnvckBie3OjeR?=			MVTJcohq[mm2aX;uJI9nKGi3bXHuJIxqfmW{IF;BWHAySjFiZYjwdoV{e2WmIHnuJGhGUzJ7MzDGcJAuUW5iY3XscJMh[XO\|ZYPz[YQh[XNicnXkeYN1cW:wIHnuJGUyPy2kZYThS{B2eHSja3WgZpkhe2OrboTpcIxifGmxbjDjc5VvfGmwZzygTWM2OCB;IEKxJO69VS5?	MVe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjV2MUC2PEc,OjJ3NEGwOlg9N2F-
HEK293 Flp-In	NFvjZ4hHfW6ldHnvckBie3OjeR?=		NVn2[FI1PSCvaX7z	NV[4ZlVVUW6qaXLpeIlwdiCxZjDoeY1idiCuaY\ldkBQSVSSMVKzJIV5eHKnc4Pl[EBqdiCKRVuyPVMhTmyyLVnuJINmdGy\|IHHzd4V{e2WmIHHzJJJm\HWldHnvckBqdiCdM1jdSVE4NWKndHHHJJVxfGGtZTDpcoN2[mG2ZXSg[o9zKDVibXnud{BjgSC\|Y3nueIltdGG2aX;uJINwfW62aX7nMEBKSzVyIE2gOFQh\|ryPLh?=	NIK2N3I9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkW0NVA3QCd-MkK1OFExPjh:L3G+
A431	NXrSN\|IzTnWwY4Tpc44h[XO\|YYm=		MnL6OlAhdWmwcx?=	MlPTTY5pcWKrdHnvckBw\iCHR1\SJIlvKGi3bXHuJGE1OzFiY3XscJMheHKndILlZZRm\CCob4KgOlAhdWmwczDt[YF{fXKnZDDh[pRmeiBzIHjyJIJ6KEWOSWPBMEBKSzVyIE2gNU4zKM7:TT6=	NVLSZnB6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK3N\|kxQTBpPkKyO\|M6ODlyPD;hQi=>
SF539	MmTCSpVv[3Srb36gZZN{[Xl?		Mn\0OlAhdWmwcx?=	M{jjbmlvcGmkaYTpc44hd2ZiUFTHSnJj\XSjIHnuJIh2dWGwIGPGOVM6KGOnbHzzJJBz\XS{ZXH0[YQh\m:{IE[wJI1qdnNibXXhd5Vz\WRiYX\0[ZIhOSCqcjDifUBGVEmVQTygTWM2OCB;IEGyMlIh\|ryPLh?=	NGnaSHo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkezPVA6OCd-MkK3N\|kxQTB:L3G+
PC9	MojoSpVv[3Srb36gZZN{[Xl?		MnzwNlQhcHK\|	NXHIOlhVUW6qaXLpeIlwdiCxZjDFS2ZTKHCqb4PwbI9zgWyjdHnvckBqdiCqdX3hckBRSzliY3XscJMh[W[2ZYKgNlQhcHK\|IHL5JIJ6KFenc4Tldo4h[myxdDDhcoFtgXOrczygTWM2OCB;IEGuN\|Yh\|ryPLh?=	NUTmT2NsRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK5PFAzOThpPkKyPVgxOjF6PD;hQi=>
WM266.4	MXrBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		NF\BOoszPCCqcoO=	M1P4cWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iV12yOlYvPCClZXzsd{Bi\nSncjCyOEBpenNiYomgUXRVKGG\|c3H5MEBKSzVyIE2gPE4xQSEQvF2u	M4nVe\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{OUi1PVU4Lz5{Mkm4OVk2PzxxYU6=
MCF7	MnTURY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		MnnjNlQhcHK\|	Ml63RY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCPQ1[3JINmdGy\|IHHmeIVzKDJ2IHjyd{BjgSCPVGSgZZN{[XluIFnDOVAhRSB6Lkm3JO69VS5?	NFj5N4s9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{Mkm4OVk2Pyd-MkK5PFU6PTd:L3G+
Sf9	NHKwUmRHfW6ldHnvckBie3OjeR?=			NFX2SVJKdmirYnn0bY9vKG:oIFXHSnIh[3m2b4DsZZNucWNiZH;tZYlvKCijbXnuc{Bi[2mmczC2OFUhfG9iMUG4OkkhMHWwa37ve44hd3KrZ3nuLUBmgHC{ZYPz[YQhcW5iU3[5JINmdGy\|IHHzd4V{e2WmIHHzJJJm\HWldHnvckBqdiCnbor5cYUh[XW2b4Doc5NxcG:{eXzheIlwdiCkeTDESWxHUUFidHnt[UBz\XOxbI\l[EBndHWxcn;t[ZRzgSxiSVO1NEA:KDBwMEOg{txONg>?	NVnZeZRWRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOyOFU2PzBpPkKzNlQ2PTdyPD;hQi=>
HepG2	M2XF[WFvfGmycn;sbYZmemG2aY\lJIF{e2G7		MmPzOFghcHK\|	MnjFRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCKZYDHNkBk\WyuczDh[pRmeiB2ODDodpMh[nliTWTUJIF{e2G7LDDJR\|UxKD1iMD6xNkDPxE1w	NYTpbWlCRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOyOFU2PzBpPkKzNlQ2PTdyPD;hQi=>
A16-F10	M3yxXWFvfGmycn;sbYZmemG2aY\lJIF{e2G7		Mnf0OFghcHK\|	MXzBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEFzNj3GNVAh[2WubIOgZYZ1\XJiNEigbJJ{KGK7IF3UWEBie3OjeTygTWM2OCB;IECuNkDPxE1w	MmrvQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN{NEW1O\|AoRjJ\|MkS1OVcxRC:jPh?=
MCF7	MXfBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		NGjoXFI1QCCqcoO=	M1XqNmFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iTVPGO{Bk\WyuczDh[pRmeiB2ODDodpMh[nliTWTUJIF{e2G7LDDJR\|UxKD1iMD6wNkDPxE1w	MXO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzJ2NUiwNkc,OjN{NEW4NFI9N2F-
B16/F10	MnfWRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		M{[2flQ5KGi{cx?=	NXPHemVGSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBud3W\|ZTDCNVYwTjFyIHPlcIx{KGGodHXyJFQ5KGi{czDifUBOXFRiYYPzZZktKEmFNUCgQUAxNjB3IN88UU4>	MVm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzJ2NUiwNkc,OjN{NEW4NFI9N2F-
Sf9	MXfGeY5kfGmxbjDhd5NigQ>?			NYH0N\|ZnUW6qaXLpeIlwdiCxZjDoeY1idiCKRWKyJIN6fG:ybHHzcYlkKGSxbXHpckAp[W2rbn:gZYNq\HNiNke2JJRwKDF{NEWpJIV5eHKnc4Pl[EBqdiCVZkmgZ4VtdHNiYomgSGVNTkmDIITpcYUhemW\|b3z2[YQh\my3b4LvcYV1enluIFnDOVAhRSByLkG2JO69VS5?	MWS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzJ2NUiwNkc,OjN{NEW4NFI9N2F-
A431	NFT3SI5HfW6ldHnvckBie3OjeR?=		NXXUR3ViPjBibXnudy=>	M4XUUmlvcGmkaYTpc44hd2ZiRVfGMYlv\HWlZXSgSWdHWiCyaH;zdIhwenmuYYTpc44hcW5iaIXtZY4hSTR\|MTDj[YxteyCxdnXy[ZhxemW\|c3nu[{BGT0[UIIDy[ZRz\WG2ZXSg[o9zKDZyIH3pcpMheHKrb4KgeI8hTUeIIHHk[Il1cW:wIH3lZZN2emWmIHHmeIVzKDFyIH3pcpMh[nlicHjvd5Bpd3S7cn;zbY5mKEWOSWPBJIN6fG:kbH;0JIFv[Wy7c3nzMEBKSzVyIE2gNU4zKM7:TT6=	NV7VUldmRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOzO\|UxQTBpPkKzN\|c2ODlyPD;hQi=>
SF539	NVPLXXVCTnWwY4Tpc44h[XO\|YYm=		M2PJNVYxKG2rboO=	NU\Qeph6UW6qaXLpeIlwdiCxZjDQSGdHNUKELXnu[JVk\WRiUFTHSnIh[mW2YTDwbI9{eGixconsZZRqd25iaX6gbJVu[W5iU1[1N\|kh[2WubIOgc5ZmemW6cILld5NqdmdiUFTHSnIh[mW2YTDwdoV1emWjdHXkJIZweiB4MDDtbY5{KHC{aX;yJJRwKFCGR1[tRmIh[WSmaYTpc44hdWWjc4Xy[YQh[W[2ZYKgNVAhdWmwczDifUBxcG:\|cHjveJlzd3OrbnWgSWxKW0FiY4n0c4Jtd3RiYX7hcJl{cXNuIFnDOVAhRSBzMj6yJO69VS5?	M3\vN\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|M{e1NFkxLz5{M{O3OVA6ODxxYU6=
A431	M{fINGZ2dmO2aX;uJIF{e2G7		M37sT\|YxKG2rboO=	MVLJcohq[mm2aX;uJI9nKEWJRmKgbY4hcHWvYX6gRVQ{OSClZXzsd{Bie3Onc4Pl[EBieyCrbnjpZol1cW:wIH;mJGVITi2rbnT1Z4VlKHS7cn;zbY5mKHCqb4PwbI9zgWyjdHnvckBqdmO3YnH0[YQh\m:{IE[wJI1qdnNicILpc5IhfG9iRVfGMYFkfGm4YYTpc44hdWWjc4Xy[YQhOTBibXnud{BjgSCHTFnTRUwhUUN3MDC9JFEvOiEQvF2u	NYPKVJFrRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO0N\|QyOzlpPkKzOFM1OTN7PD;hQi=>
SF539	M1LMXmZ2dmO2aX;uJIF{e2G7		M4jDclYxKG2rboO=	NE[1VYZKdmirYnn0bY9vKG:oIGDES2ZT[mW2YTDpckBpfW2jbjDTSlU{QSClZXzsd{Bie3Onc4Pl[EBieyCrbnjpZol1cW:wIH;mJHBFT0[ULVLCMYlv\HWlZXSgeJlzd3OrbnWgdIhwe3Cqb4L5cIF1cW:wIHnuZ5Vj[XSnZDDmc5IhPjBibXnud{BxemmxcjD0c{BGT0ZvYXP0bZZifGmxbjDt[YF{fXKnZDCxNEBucW6\|IHL5JGVNUVODLDDJR\|UxKD1iMUKuNkDPxE1w	NWXibXY5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO0N\|QyOzlpPkKzOFM1OTN7PD;hQi=>
PC9	NX32bGN7TnWwY4Tpc44h[XO\|YYm=		NX60XnpYOiCqcoO=	NIfsUmtKdmirYnn0bY9vKG:oIFXHSnIh\XixbjCxPUBl\WyndHnvckBi[3SrdnH0bY5oKG23dHHueEBxcG:\|cHjvdplt[XSrb36gbY4hcHWvYX6gVGM6KGOnbHzzJIFnfGW{IEKgbJJ{KGK7IH\seY9z\XOlZX7j[UBie3OjeTygTWM2OCB;IECuNFA2QSEQvF2u	MkOyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN7M{C5PVQoRjJ\|OUOwPVk1RC:jPh?=
LoVo	MX3GeY5kfGmxbjDhd5NigQ>?		NVvofpRDOiCqcoO=	MWnJcohq[mm2aX;uJI9nKHerbHSgeJlx\SCHR1\SJJBpd3OyaH;yfYxifGmxbjDpckBpfW2jbjDMc3ZwKGOnbHzzJIFnfGW{IEKgbJJ{KGK7IH\seY9z\XOlZX7j[UBie3OjeTygTWM2OCB;IECuNFc4KM7:TT6=	MYC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzl\|MEm5OEc,OjN7M{C5PVQ9N2F-
NCI-H1975	NWCxVWU4TnWwY4Tpc44h[XO\|YYm=		MViyJIhzew>?	NX7ycmNxUW6qaXLpeIlwdiCxZjDFS2ZTKEx6NUjSM3Q6PzCPIHTveYJt\SCvdYThcpQheGixc4Doc5J6dGG2aX;uJIlvKGi3bXHuJG5EUS2KMUm3OUBk\WyuczDh[pRmeiB{IHjyd{BjgSCobIXvdoV{[2WwY3WgZZN{[XluIFnDOVAhRSB5Lk[g{txONg>?	MV28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzl\|MEm5OEc,OjN7M{C5PVQ9N2F-
Sf9	MVzGeY5kfGmxbjDhd5NigQ>?		NUPUVndXOTBibXnudy=>	MVPJcohq[mm2aX;uJI9nKHKnY3;tZolv[W62IFXHSnIhc2mwYYPlJIN6fG:ybHHzcYlkKGSxbXHpckApfW6tbn;3ckBwemmpaX6pJIV5eHKnc4Pl[EBqdiCkYXP1cI93cXK3czDlfJBz\XO\|aX;uJJZm[3Sxcj3pcoZm[3SnZDDpcpNm[3Ric3[5JINmdGy\|IHHzd4V{e2WmIHHzJIxmfmWuIH;mJIF2fG:yaH;zdIhwenmuYYTpc44h[W[2ZYKgNVAhdWmwczDifUBFTUyISVGveIlu\S2{ZYPvcJZm\CCobIXvdo9u\XS{eTygTWM2OCB;IECuNFMh\|ryPLh?=	MUm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzl4Mk[2NEc,OjN7NkK2OlA9N2F-
HepG2	MYDBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		NH7GT\|k1QCCqcoO=	MknyRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCKZYDHNkBk\WyuczDh[pRmeiB2ODDodpMh[nliTWTUJIF{e2G7LDDJR\|UxKD1iMD6xNkDPxE1w	NXrhfYVmRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO5OlI3PjBpPkKzPVYzPjZyPD;hQi=>
A549	MV;BcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		M4WxW\|Q5KGi{cx?=	M2mxbmFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iQUW0PUBk\WyuczDh[pRmeiB2ODDodpMh[nliTWTUJIF{e2G7LDDJR\|UxKD1iMD6xN{DPxE1w	NHv0[\|Y9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{m2NlY3OCd-MkO5OlI3PjB:L3G+
Sf9	MXPGeY5kfGmxbjDhd5NigQ>?		MVGxNEBucW6\|	NFXB[VdKdmirYnn0bY9vKG:oIILlZ49u[mmwYX70JGVITlJiY4n0c5Bt[XOvaXOg[I9u[WmwIDi2OFUhfG9iMUG4OkkhMHWwa37ve44hd3KrZ3nuLUBifXSxcHjvd5Bpd3K7bHH0bY9vKGW6cILld5Nm\CCrbjDiZYN2dG:4aYL1d{Bqdm[nY4Tl[EBqdnOnY4SgV4Y6KGOnbHzzJJBz\WmwY4XiZZRm\CCob4KgNVAhdWmwczDmc4xtd3enZDDifUBCXFBvTXfDcFIh[WSmaYTpc44hdWWjc4Xy[YQh[W[2ZYKgNUBpeiCkeTDmcJVwem:vZYTybYMh[W6jbInzbZMtKEmFNUCgQUAxNjB\|MjFOwG0v	MXO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDF2NEi1OEc,OjRzNES4OVQ9N2F-
HepG2	MVzDfZRwfG:6aXPpeJkh[XO\|YYm=		NFm1Rnk1QCCqcoO=	MnPhR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gTIVxTzJiY3XscJMh[XO\|ZYPz[YQh[XNiZ4Lve5RpKGmwaHnibZRqd25iYX\0[ZIhPDhiaILzJIJ6KE2WVDDhd5NigSxiSVO1NEA:KDBwMUKg{txONg>?	NV\XdVRpRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSxOFQ5PTRpPkK0NVQ1QDV2PD;hQi=>
A549	NVjlSYZFS3m2b4TvfIlkcXS7IHHzd4F6		NULRcVBpPDhiaILz	M3rT[mN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGE2PDliY3XscJMh[XO\|ZYPz[YQh[XNiZ4Lve5RpKGmwaHnibZRqd25iYX\0[ZIhPDhiaILzJIJ6KE2WVDDhd5NigSxiSVO1NEA:KDBwMUOg{txONg>?	MWi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDF2NEi1OEc,OjRzNES4OVQ9N2F-
A431	NIniO5lCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		M2nC[VczKGi{cx?=	NUTFb4g5SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDBOFMyKGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDTVmIh[XO\|YYmsJGlEPTBiPTCwMlQxQSEQvF2u	MkTDQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjRzOEO3OFIoRjJ2MUizO\|QzRC:jPh?=
NCI-H1975	M3SxVWFvfGmycn;sbYZmemG2aY\lJIF{e2G7		NEnEcIs4OiCqcoO=	NX\OUIFpSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDOR2kuUDF7N{WgZ4VtdHNiZYjwdoV{e2mwZzDFS2ZTKFR5OUDNJI12fGGwdDDh[pRmeiB5MjDodpMh[nliU2LCJIF{e2G7LDDJR\|UxKD1iNj65JO69VS5?	NGrPVpc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEG4N\|c1Oid-MkSxPFM4PDJ:L3G+
KB	NVPJd4dKTnWwY4Tpc44h[XO\|YYm=		NEPGOFIyKGi{	NYnJeXY1UW6qaXLpeIlwdiCxZjDFS2Yue3SrbYXsZZRm\CCjdYTvdIhwe3Cqb4L5cIF1cW:wIH;mJGVITlJiaX6gbJVu[W5iS1KgZ4VtdHNiaX7jeYJifGWmIH\vdkAyKGi{IIDybY9zKHSxIFXHSkBkcGGubHXu[4UhdWWjc4Xy[YQh[W[2ZYKgOkBucW6\|IHL5JGVNUVODLDDJR\|UxKD1iMD6wNVkh\|ryPLh?=	NV7VVWxCRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS0NVEyOjNpPkK0OFEyOTJ\|PD;hQi=>
A431	NXfHNYdHS3m2b4TvfIlkcXS7IHHzd4F6		M2j3XFczKGi{cx?=	MlHNR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gRVQ{OSClZXzsd{BmgHC{ZYPzbY5oKEWJRmKgZYZ1\XJiN{KgbJJ{KGK7IF3UWEBie3OjeTygTWM2OCB;IECuO\|Uh\|ryPLh?=	M4PQV\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NEGxNVI{Lz5{NESxNVEzOzxxYU6=
Calu3	MXnDfZRwfG:6aXPpeJkh[XO\|YYm=		NFXuVoU4OiCqcoO=	NYjyVZdRS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hS2GudUOgZ4VtdHNiZYjwdoV{e2mwZzDISXIzKGGodHXyJFczKGi{czDifUBOXFRiYYPzZZktKEmFNUCgQUAxNjl\|IN88UU4>	M4r5OlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NEGxNVI{Lz5{NESxNVEzOzxxYU6=
NCI-H1975	M1rvZ2N6fG:2b4jpZ4l1gSCjc4PhfS=>		NYDIXpRnPzJiaILz	Mmm1R5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gUmNKNUhzOUe1JINmdGy\|IHX4dJJme3OrbnegSWdHWiCOOEW4Vk9VPzlyTTDteZRidnRiYX\0[ZIhPzJiaILzJIJ6KE2WVDDhd5NigSxiSVO1NEA:KDVwNUGg{txONg>?	NFH2epk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NESxNVEzOyd-MkS0NVEyOjN:L3G+
A431	NE[0UolCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		MXW3NkBpenN?	Mn6wRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCDNEOxJINmdGy\|IHHzd4V{e2WmIHHzJIdzd3e2aDDpcohq[mm2aX;uJIFnfGW{IEeyJIhzeyCkeTDTVmIh[XO\|YYmsJGlEPTBiPTCwMlU3KM7:TT6=	MUK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDV4NUm2PUc,OjR3NkW5Olk9N2F-
NCI-H1975	MmixRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		M2npWFczKGi{cx?=	MYjBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHfl[ol1cW6rYj3y[ZNqe3SjboSgbJVu[W5iTlPJMWgyQTd3IHPlcIx{KGG\|c3Xzd4VlKGG\|IHfyc5d1cCCrbnjpZol1cW:wIHHmeIVzKDd{IHjyd{BjgSCVUlKgZZN{[XluIFnDOVAhRSB5LkC2JO69VS5?	M17q[lxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NU[1PVY6Lz5{NEW2OVk3QTxxYU6=
Sf9	MmL3SpVv[3Srb36gZZN{[Xl?		MWSxJIhz	MlziTY5pcWKrdHnvckBw\iCjdYTvdIhwe3Cqb4L5cIF1cW:wIH;mJJJm[2:vYnnuZY51KEWJRmKgZ5l1d3CuYYPtbYMh\G:vYXnuJEg3PDVidH:gNVE5PiliKIXub45wf25ib4Lp[4lvMSCneIDy[ZN{\WRiaX6gV4Y6KGOnbHzzJIFnfGW{IEGgbJIh[nliRFXMSmlCN3SrbXWtdoV{d2y4ZXSg[ox2d3KxbXX0dolkKGGwYXz5d4l{NCCLQ{WwJF0hOC5yM{Kg{txONg>?	NVHHNos1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS2NFc6QThpPkK0OlA4QTl6PD;hQi=>
HepG2	NIjmb3BCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		MXq0PEBpenN?	MlTiRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCKZYDHNkBk\WyuczDh[pRmeiB2ODDodpMh[nliTWTUJIF{e2G7LDDJR\|UxKD1iMD6xNkDPxE1w	NXfmfXV5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS2NFc6QThpPkK0OlA4QTl6PD;hQi=>
A549	NIHMSHVCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		M{fVUVQ5KGi{cx?=	MonYRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCDNUS5JINmdGy\|IHHmeIVzKDR6IHjyd{BjgSCPVGSgZZN{[XluIFnDOVAhRSByLkGzJO69VS5?	NGraOG09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NE[wO\|k6QCd-MkS2NFc6QTh:L3G+
Sf9	MUfGeY5kfGmxbjDhd5NigQ>?		NX\K[5B{OSCqch?=	M{S0W2lvcGmkaYTpc44hd2ZiYYX0c5Bpd3OyaH;yfYxifGmxbjDv[kBGT0[UIHP5eI9xdGG\|bXnjJIRwdWGrbjCoZY1qdm9iYXPp[JMhPjR3IITvJFEyQDZrIDj1cotvd3ewIH;ybYdqdiliZYjwdoV{e2WmIHnuJHNnQSClZXzsd{Bi\nSncjCxJIhzKGK7IITpcYUuemW\|b3z2[YQh\my3b4LvcYV1enluIFnDOVAhRSByLkCzNkDPxE1w	MX68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDZ\|MESxNkc,OjR4M{C0NVI9N2F-
HepG2	MlW2RY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		NXu1XYxsPDhiaILz	NWnuNWlOSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDI[ZBIOiClZXzsd{Bi\nSncjC0PEBpenNiYomgUXRVKGG\|c3H5MEBKSzVyIE2gNE4yOiEQvF2u	NHz0dGY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NE[zNFQyOid-MkS2N\|A1OTJ:L3G+
A549	M2fZUWFvfGmycn;sbYZmemG2aY\lJIF{e2G7		NXzCVo86PDhiaILz	MUDBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEF3NEmgZ4VtdHNiYX\0[ZIhPDhiaILzJIJ6KE2WVDDhd5NigSxiSVO1NEA:KDBwMUOg{txONg>?	MYO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDZ\|MESxNkc,OjR4M{C0NVI9N2F-
Sf9	MWLGeY5kfGmxbjDhd5NigQ>?		NFvKUpcyKGi{	Mm[yTY5pcWKrdHnvckBw\iCjdYTvdIhwe3Cqb4L5cIF1cW:wIH;mJIh2dWGwIFjFVlIh[3m2b4DsZZNucWNiZH;tZYlvKCijbXnuc{Bi[2mmczC2O\|YhfG9iMUK0OUkhMHWwa37ve44hd3KrZ3nuLUBmgHC{ZYPz[YQhcW5iU3[5JINmdGy\|IHHmeIVzKDFiaIKgZpkhfGmvZT3y[ZNwdH[nZDDmcJVwem:vZYTyfUwhUUN3MDC9JFAvOTZizszNMi=>	M{fuZVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NkOwOFEzLz5{NE[zNFQyOjxxYU6=
A431	NH7ZVGNHfW6ldHnvckBie3OjeR?=			M1e0e2lvcGmkaYTpc44hd2ZiRVfGVkBqdiCqdX3hckBCPDNzIHPlcIx{KGK7IIDoc5NxcG:2eYLvd4lv\SCHTFnTRUBie3OjeTygTWM2OCB;IECuNFAyOiEQvF2u	NHXCUnE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEi5NFY2Oid-MkS4PVA3PTJ:L3G+
MCF7	NHj6OJREgXSxdH;4bYNqfHliYYPzZZk>			NEDFPJJEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBGWi2yb4PpeIl3\SCPQ1[3JINmdGy\|LDDJR\|UxKD1iMD6wNFEzKM7:TT6=	M3HBOFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OEmwOlUzLz5{NEi5NFY2OjxxYU6=
U251	MXTGeY5kfGmxbjDhd5NigQ>?			NVX2Vm1kUW6qaXLpeIlwdiCxZjDWSWdHWjJiaX6gbJVu[W5iVUK1NUBk\WyuczDifUBxcG:\|cHjveJlzd3OrbnWgSWxKW0FiYYPzZZktKEmFNUCgQUAxNjF{NEeg{txONg>?	NF3yOGc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEi5NFY2Oid-MkS4PVA3PTJ:L3G+
MDA-MB-468	MnrOR5l1d3SxeHnjbZR6KGG\|c3H5			MnPiR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6geJJqeGynIH7l[4F1cX[nIF3ERU1OSi12NkigZ4VtdHNuIFnDOVAhRSByLkKzOVIh\|ryPLh?=	MlHQQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR6OUC2OVIoRjJ2OEmwOlUzRC:jPh?=
MDA-MB-231	MX;DfZRwfG:6aXPpeJkh[XO\|YYm=			M{K4bWN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJJRzcXCuZTDu[YdifGm4ZTDNSGEuVUJvMkOxJINmdGy\|LDDJR\|UxKD1iMD60N\|g2KM7:TT6=	NXnGSXBURGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS4PVA3PTJpPkK0PFkxPjV{PD;hQi=>
MDA-MB-435	MWPDfZRwfG:6aXPpeJkh[XO\|YYm=			MVzDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDNSGEuVUJvNEO1JINmdGy\|LDDJR\|UxKD1iMD62NlIyKM7:TT6=	MnTSQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR6OUC2OVIoRjJ2OEmwOlUzRC:jPh?=
HCC827	NGnGc2NEgXSxdH;4bYNqfHliYYPzZZk>		NXqzTpBVPDhiaILz	NVWyT4VRS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hUEOFOEK3JINmdGy\|IHHmeIVzKDR6IHjyd{BjgSCPVGSgZZN{[XluIFnDOVAhRSByLkCwNkDPxE1w	NH74cXE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEmwNFg{OCd-MkS5NFA5OzB:L3G+
NCI-H1993	Mk\kR5l1d3SxeHnjbZR6KGG\|c3H5		Ml31OFghcHK\|	NH61TYdEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBPS0lvSEG5PVMh[2WubIOgZYZ1\XJiNEigbJJ{KGK7IF3UWEBie3OjeTygTWM2OCB;IEKuNFQ{KM7:TT6=	NUHiPHF7RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS5NFA5OzBpPkK0PVAxQDNyPD;hQi=>
A549	MX7DfZRwfG:6aXPpeJkh[XO\|YYm=		NFjXblE1QCCqcoO=	NHLWZm9EgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBCPTR7IHPlcIx{KGGodHXyJFQ5KGi{czDifUBOXFRiYYPzZZktKEmFNUCgQUA4NjB7OTFOwG0v	MWC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDlyMEizNEc,OjR7MEC4N\|A9N2F-
NCI-H1975	NX\4[2tES3m2b4TvfIlkcXS7IHHzd4F6		MlnYOFghcHK\|	MUjDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDOR2kuUDF7N{WgZ4VtdHNiYX\0[ZIhPDhiaILzJIJ6KE2WVDDhd5NigSxiSVO1NEA:KDdwNEm4JO69VS5?	NEjiToo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEmwNFg{OCd-MkS5NFA5OzB:L3G+
Sf9	M3;MZWZ2dmO2aX;uJIF{e2G7			NWD0fmVIUW6qaXLpeIlwdiCxZjDobZN1cWSrbnWteIFo\2WmIILlZ49u[mmwYX70JGVITlJiY4n0c5Bt[XOvaXOg[I9u[WmwIDjhcYlvdyCjY3nkd{A3PDVvMUG4OkkhMHWwa37ve44hd3KrZ3nuLUBmgHC{ZYPz[YQhcW5iU3[5JINmdGy\|IHHzd4V{e2WmIHHzJJJm\HWldHnvckBqdiCnbor5cYUh[XW2b4Doc5NxcG:{eXzheIlwdiCkeTDESWxHUUFxdHnt[U1z\XOxbI\l[EBndHWxcn;t[ZRzgSxiSVO1NEA:KDBwMEOg{txONg>?	MofpQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjVzN{K0NlEoRjJ3MUeyOFIyRC:jPh?=
A549	MmX3RY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		MUO0PEBpenN?	MWLBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEF3NEmgZ4VtdHNiYX\0[ZIhPDhiaILzJIJ6KE2WVDDhd5NigSxiSVO1NEA:KDBwMTFOwG0v	NYHpPZV{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWxO\|I1OjFpPkK1NVczPDJzPD;hQi=>
HepG2	MXrBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		NFG1NHc1QCCqcoO=	NVXycHEzSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDI[ZBIOiClZXzsd{Bi\nSncjC0PEBpenNiYomgUXRVKGG\|c3H5MEBKSzVyIE2gNE4yKM7:TT6=	M{DKTFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MUeyOFIyLz5{NUG3NlQzOTxxYU6=
Sf9	MX7GeY5kfGmxbjDhd5NigQ>?			NYL1W3ZLUW6qaXLpeIlwdiCxZjDobZN1cWSrbnWteIFo\2WmIILlZ49u[mmwYX70JGhGWjJiKIXub45wf25ib4Lp[4lvMSCneIDy[ZN{\WRiaX6gV4Y6KGOnbHzzJIF{e2W\|c3XkJIF{KHKnZIXjeIlwdiCrbjDlcpp6dWViYYX0c5Bpd3OyaH;yfYxifGmxbjDifUBFTUyISVGveIlu\S2{ZYPvcJZm\CCobIXvdo9u\XS{eTygTWM2OCB;IECuNkDPxE1w	NULiOXVLRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWxO\|I1OjFpPkK1NVczPDJzPD;hQi=>
NCI-H292	M2j0O2N6fG:2b4jpZ4l1gSCjc4PhfS=>		MUm3NkBpenN?	NIPlbHREgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBPS0lvSEK5NkBk\WyuczDh[pRmeiB5MjDodpMh[nliU2LCJIF{e2G7LDDJR\|UxKD1iMTFOwG0v	NWPifXlURGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWyNVU5PTZpPkK1NlE2QDV4PD;hQi=>
H460	MYjDfZRwfG:6aXPpeJkh[XO\|YYm=		NHThcFI4OiCqcoO=	MljaR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gTFQ3OCClZXzsd{Bi\nSncjC3NkBpenNiYomgV3JDKGG\|c3H5MEBKSzVyIE2gPU42KM7:TT6=	MWS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTJzNUi1Okc,OjV{MUW4OVY9N2F-
H460/Vbl	MmnXR5l1d3SxeHnjbZR6KGG\|c3H5		Mn6wO\|IhcHK\|	NHLPbJpEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBJPDZyL2\icEBk\WyuczDh[pRmeiB5MjDodpMh[nliU2LCJIF{e2G7LDDJR\|UxKD1iMkGuOUDPxE1w	MonGQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV{MUW4OVYoRjJ3MkG1PFU3RC:jPh?=
HT-29	NX76SXI4SW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		M{HpdFczKGi{cx?=	M{LBfGFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iSGStNlkh[2WubIOgZZN{\XO\|ZXSgZZMhcW6qaXLpeIlwdiCxZjDj[YxtKHC{b3zp[oVz[XSrb36geY5l\XJibn;ycY95cWFiY3;u[Il1cW:wczDh[pRmeiB5MjDodpMh[nliU2LCJIF{e2G7LDDJR\|UxKD1iMj65PEDPxE1w	NETuZno9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUS2PFA1PCd-MkW0OlgxPDR:L3G+
HT-29	MlviRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		MWG3NkBpenN?	MlvrRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCKVD2yPUBk\WyuczDhd5Nme3OnZDDhd{BqdmirYnn0bY9vKG:oIHPlcIwheHKxbHnm[ZJifGmxbjD1coRmeiCqeYDvfIliKGOxbnTpeIlwdnNiYX\0[ZIhPzJiaILzJIJ6KFOUQjDhd5NigSxiSVO1NEA:KDRwM{eg{txONg>?	MnnRQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV2NkiwOFQoRjJ3NE[4NFQ1RC:jPh?=
A549	M2jrZmFvfGmycn;sbYZmemG2aY\lJIF{e2G7		MlLxO\|IhcHK\|	NEfzVZRCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFG1OFkh[2WubIOgZZN{\XO\|ZXSgZZMhcW6qaXLpeIlwdiCxZjDj[YxtKHC{b3zp[oVz[XSrb36geY5l\XJibn;ycY95cWFiY3;u[Il1cW:wczDh[pRmeiB5MjDodpMh[nliU2LCJIF{e2G7LDDJR\|UxKD1iNz61PUDPxE1w	MV[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTR4OEC0OEc,OjV2NkiwOFQ9N2F-
A549	MVHBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		NIPZOpk4OiCqcoO=	M3fDbmFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iQUW0PUBk\WyuczDhd5Nme3OnZDDhd{BqdmirYnn0bY9vKG:oIHPlcIwheHKxbHnm[ZJifGmxbjD1coRmeiCqeYDvfIliKGOxbnTpeIlwdnNiYX\0[ZIhPzJiaILzJIJ6KFOUQjDhd5NigSxiSVO1NEA:KDlwMTFOwG0v	Mn\2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV2NkiwOFQoRjJ3NE[4NFQ1RC:jPh?=
A431	MVzGeY5kfGmxbjDhd5NigQ>?		M2WxS\|YxKG2rbh?=	MULJcohq[mm2aX;uJI9nKEWJRmKgbY4hcHWvYX6gRVQ{OSClZXzsd{Bkd22yb4Xu[EBxemW2cnXheIVlKG[xcjC2NEBucW5iYnXmc5JmKEWJRjDzeIlufWyjdHnvckBnd3JiMUCgcYlveyCkeTDwbI9{eGixdInyc5NqdmViRVzJV2Eh[3m2b3Lsc5QhdWW2aH;kMEBKSzVyIE2gNE4xODF{IN88UU4>	NXPJd\|hJRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW4PFI2OTlpPkK1PFgzPTF7PD;hQi=>
U251	NEHvNo9HfW6ldHnvckBie3OjeR?=		M{Pqe\|YxKG2rbh?=	MVPJcohq[mm2aX;uJI9nKF[HR1\SNkBqdiCqdX3hckBWOjVzIHPlcIx{KGOxbYDveY5lKHC{ZYTy[YF1\WRiZn;yJFYxKG2rbjDi[YZwemViVlXHSkB{fGmvdXzheIlwdiCob4KgNVAhdWmwczDifUBxcG:\|cHjveJlzd3OrbnWgSWxKW0FiY4n0c4Jtd3RibXX0bI9lNCCLQ{WwJF0hOC5zMkS3JO69VS5?	MlPSQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV6OEK1NVkoRjJ3OEiyOVE6RC:jPh?=
KB	NFryfW5CdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		NXHGSm1lPDhiaILz	MVzBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEuEIHPlcIx{KGW6cILld5NqdmdiRVfGVkBidmRiU4LjJIFnfGW{IES4JIhzeyCkeTDTVmIh[XO\|YYmsJGlEPTBiPTC1JO69VS5?	MX68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjF6OE[yNEc,OjZzOEi2NlA9N2F-
A498	MWjBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		NEW1SIc1QCCqcoO=	NHHHeIdCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFG0PVgh[2WubIOg[ZhxemW\|c3nu[{BGT0[UIHHu[EBUemNiYX\0[ZIhPDhiaILzJIJ6KFOUQjDhd5NigSxiSVO1NEA:KDJ3Lk[g{txONg>?	NFzRd\|g9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkG4PFYzOCd-Mk[xPFg3OjB:L3G+
NCI-H292	NXnGNJB[TnWwY4Tpc44h[XO\|YYm=		MVKxJIhz	NXPQRoNoUW6qaXLpeIlwdiCxZjDFS2ZTKHCqb4PwbI9zgWyjdHnvckBqdiCqdX3hckBPS0lvSEK5NkBk\WyuczDwdoVqdmO3YnH0[YQh\m:{IEGgbJIh\m:ubH;3[YQh[nlic4TpcZVt[XSrb36ge4l1cCCHR1[g[o9zKDhibXnud{BjgSCnbHXjeJJw[2inbXnseY1qdmW\|Y3XueEBqdW23bn;hd5NigSxiSVO1NEA:KDBwMEC2N{DPxE1w	MWq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjR3NUmxPUc,OjZ2NUW5NVk9N2F-
HCC827	NVLBTINSSW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		MnrWO\|IhcHK\|	MlPPRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCKQ1O4Nlch[2WubIOgZYZ1\XJiN{KgbJJ{KGK7IFPDT{05KGG\|c3H5MEBKSzVyIE2gNE4xOjlizszNMi=>	NGjRT5Q9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkS4O\|kyPyd-Mk[0PFc6OTd:L3G+
A431	MW\BcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		NF3HR\|c4OiCqcoO=	MmHIRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCDNEOxJINmdGy\|IHHmeIVzKDd{IHjyd{BjgSCFQ1utPEBie3OjeTygTWM2OCB;IECuPFQ1KM7:TT6=	NILKe2g9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkS4O\|kyPyd-Mk[0PFc6OTd:L3G+
PANC1	M{frUmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		Ml3MO\|IhcHK\|	MXXHdo94fGhiaX7obYJqfGmxbjDv[kBpfW2jbjDQRW5EOSClZXzsd{Bi\nSncjC3NkBpenNiYomgR2NMNThiYYPzZZktKEmFNUCgQUA{NjFizszNMi=>	MUW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjV2N{[5NEc,OjZ3NEe2PVA9N2F-
L3.6PL	MXvHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		NEO4SIg4OiCqcoO=	NVjZRnI6T3Kxd4ToJIlvcGmkaYTpc44hd2ZiaIXtZY4hVDNwNmDMJINmdGy\|IHHmeIVzKDd{IHjyd{BjgSCFQ1utPEBie3OjeTygTWM2OCB;IESg{txONg>?	NGTBTII9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkW0O\|Y6OCd-Mk[1OFc3QTB:L3G+
PCI35	NF\5RW1Iem:5dHigbY5pcWKrdHnvckBie3OjeR?=		M4fPc\|czKGi{cx?=	M13NZmdzd3e2aDDpcohq[mm2aX;uJI9nKGi3bXHuJHBEUTN3IHPlcIx{KGGodHXyJFczKGi{czDifUBES0tvODDhd5NigSxiSVO1NEA:KDdwNzFOwG0v	NUj2PGw1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[1OFc3QTBpPkK2OVQ4PjlyPD;hQi=>
PC9	MWjBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		M{L0b\|k3KGi{cx?=	MXLBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKFCFOTDj[YxteyCjZoTldkA6PiCqcoOgZpkhW3m2b4ig[5Jm\W5ibXHyb4VzKGKjc3XkJIZtfW:{ZYPj[Y5k\SCjbnHsfZNqeyxiSVO1NEA:KDBwMEeg{txONg>?	M{\MbVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4NUm5OVMzLz5{NkW5PVU{OjxxYU6=
H9	NV3uZmlYSW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		M1r4e\|czKGi{cx?=	NHXlUolCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFi5JINmdGy\|IHHmeIVzKDd{IHjyd{BjgSCFZXzsWIl1\XJvR3zvJIF{e2G7LDDJR\|UxKD1iMT6zJO69VS5?	NFLDN2s9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkW5PVU{Oid-Mk[1PVk2OzJ:L3G+
OVCAR3	MV7BcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		MlLZO\|IhcHK\|	NVvkeYI5SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDPWmNCWjNiY3XscJMh[W[2ZYKgO\|IhcHK\|IHL5JGNmdGyWaYTldk1IdG9iYYPzZZktKEmFNUCgQUA1NjZizszNMi=>	M{G5W\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4NUm5OVMzLz5{NkW5PVU{OjxxYU6=
Calu3	MoftRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		M3PYNlczKGi{cx?=	MVrBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEOjbIWzJINmdGy\|IHHmeIVzKDd{IHjyd{BjgSCFZXzsWIl1\XJiYnz1[UBie3OjeTygTWM2OCB;IESuO{DPxE1w	M3\EcFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4NUm5OVMzLz5{NkW5PVU{OjxxYU6=
MRC5	M1zuUWFvfGmycn;sbYZmemG2aY\lJIF{e2G7		NYPmRnpmPzJiaILz	MkTmRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCPUlO1JINmdGy\|IHHmeIVzKDd{IHjyd{BjgSCFZXzsWIl1\XJvR3zvJIF{e2G7LDDJR\|UxKD1iNT64JO69VS5?	MojpQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ3OUm1N\|IoRjJ4NUm5OVMzRC:jPh?=
U937	MXvBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		MVq3NkBpenN?	NHqzcGZCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIGW5N\|ch[2WubIOgZYZ1\XJiN{KgbJJ{KGK7IFPlcIxVcXSncjDicJVmKGG\|c3H5MEBKSzVyIE2gPU46KM7:TT6=	NGjndWk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkW5PVU{Oid-Mk[1PVk2OzJ:L3G+
BT474	NUjTNld2SW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		NHv5RZk4OiCqcoO=	NFnoT\|NCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFLUOFc1KGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDD[YxtXGm2ZYKgZox2\SCjc4PhfUwhUUN3MDC9JFE{KM7:TT6=	NIezSXI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkW5PVU{Oid-Mk[1PVk2OzJ:L3G+
FADU	NYDSWlV2SW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=			MlzVRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCIQVTVJINmdGy\|LDDJR\|UxKD1iMUig{txONg>?	MXS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjV7OUWzNkc,OjZ3OUm1N\|I9N2F-
MCF7	M2LaSGFvfGmycn;sbYZmemG2aY\lJIF{e2G7		Ml2zNVIhcHK\|	NEDLfFZCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIF3DSlch[2WubIOgZYZ1\XJiMUKgbJJ{KGK7IF3UWEBie3OjeTygTWM2OCB;IECuNUDPxE1w	NGXuXYk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{Nk[1NlQ5Oid-Mk[2OVI1QDJ:L3G+
HepG2	MnjJRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		MUCxNkBpenN?	NHHX[G9CdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFjldGczKGOnbHzzJIFnfGW{IEGyJIhzeyCkeTDNWHQh[XO\|YYmsJGlEPTBiPTCwMlEzKM7:TT6=	NFHXcnE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{Nk[1NlQ5Oid-Mk[2OVI1QDJ:L3G+
B16F10	Mkj6RY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		NYHJcpRbOTJiaILz	M3[ycGFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgcY92e2ViQkG2SlExKGOnbHzzJIFnfGW{IEGyJIhzeyCkeTDNWHQh[XO\|YYmsJGlEPTBiPTCwMlE4KM7:TT6=	MWW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjZ3MkS4Nkc,OjZ4NUK0PFI9N2F-
HeLa	MXLBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		NU\kUpM5OTJiaILz	NVHLeHE1SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDI[WxiKGOnbHzzJIFnfGW{IEGyJIhzeyCkeTDNWHQh[XO\|YYmsJGlEPTBiPTCwMlIh\|ryPLh?=	MluyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ4NUK0PFIoRjJ4NkWyOFgzRC:jPh?=
HCC827	M1e5c2Z2dmO2aX;uJIF{e2G7		M1ixNFIhcHK\|	MWHJcohq[mm2aX;uJI9nKEWJRmKg[IVt\XSrb36gcZV1[W62IHH1eI9xcG:\|cHjvdplt[XSrb36gbY4hcHWvYX6gTGNEQDJ5IHPlcIx{KGGodHXyJFIhcHK\|IHL5JJNidmS5aXPoJGVNUVODLDDJR\|UxKD1iMD6wNFgh\|ryPLh?=	MX:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjd3NkKyNkc,OjZ5NU[yNlI9N2F-
H3255	M{TFe2Z2dmO2aX;uJIF{e2G7		M1jJdFIhcHK\|	Mo[3TY5pcWKrdHnvckBw\iCHR1\SJGw5PTiUIH31eIFvfCCjdYTvdIhwe3Cqb4L5cIF1cW:wIHnuJIh2dWGwIFizNlU2KGOnbHzzJIFnfGW{IEKgbJJ{KGK7IIPhcoR4cWOqIFXMTXNCNCCLQ{WwJF0hOC5yMTFOwG0v	NXHxd2Z5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[3OVYzOjJpPkK2O\|U3OjJ{PD;hQi=>
PC9	NV7XdZI5TnWwY4Tpc44h[XO\|YYm=		MmfyNkBpenN?	Ml\KTY5pcWKrdHnvckBw\iCHR1\SJIRmdGW2aX;uJI12fGGwdDDheZRweGixc4Doc5J6dGG2aX;uJIlvKGi3bXHuJHBEQSClZXzsd{Bi\nSncjCyJIhzeyCkeTDzZY5lf2mlaDDFUGlUSSxiSVO1NEA:KDBwMEGxJO69VS5?	MYe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjd3NkKyNkc,OjZ5NU[yNlI9N2F-
A549	NWDP[2dKTnWwY4Tpc44h[XO\|YYm=			NVWyfXlJUW6qaXLpeIlwdiCxZjDFS2Yue3SrbYXsZZRm\CC5aXzkJJR6eGViRVfGVkBifXSxcHjvd5Bpd3K7bHH0bY9vKGW6cILld5Nm\CCrbjDoeY1idiCDNUS5JINmdGy\|IHL5JJNidmS5aXPoJGVNUVODLDDJR\|UxKD1iMD6wNVEh\|ryPLh?=	M2fZXFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4N{W2NlIzLz5{Nke1OlIzOjxxYU6=
NCI-H1975	MXHGeY5kfGmxbjDhd5NigQ>?		NW\qb2NqOiCqcoO=	NHLzRoRKdmirYnn0bY9vKG:oIFXHSnIhVDh3OGKvWFc6OE1iZH;1ZoxmKG23dHHueEBifXSxcHjvd5Bpd3K7bHH0bY9vKGmwIHj1cYFvKE6FST3INVk4PSClZXzsd{Bi\nSncjCyJIhzeyCkeTDzZY5lf2mlaDDFUGlUSSxiSVO1NEA:KDlizszNMi=>	NXHhbVNpRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[3OVYzOjJpPkK2O\|U3OjJ{PD;hQi=>
PC9-DRH	M3\vPWZ2dmO2aX;uJIF{e2G7		NU\JRmMzOiCqcoO=	M4XUVWlvcGmkaYTpc44hd2ZiRVfGVkBl\WyndHnvck9VPzlyTTDteZRidnRiYYX0c5Bpd3OyaH;yfYxifGmxbjDpckBpfW2jbjDQR\|kuTFKKIHPlcIx{KGGodHXyJFIhcHK\|IHL5JJNidmS5aXPoJGVNUVODLDDJR\|UxKD1iOT63JO69VS5?	NG\OV2o9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{Nke1OlIzOid-Mk[3OVYzOjJ:L3G+
A549	NGHHUYJCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		MojXOFghcHK\|	M{f0UWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iQUW0PUBk\WyuczDhd5Nme3OnZDDhd{B3cWGkbHWgZ4VtdHNiYX\0[ZIhPDhiaILzJIJ6KEOFS{igZZN{[XluIFnDOVAhRSB4LkK2JO69VS5?	NF7mcHk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{Nki3PVMyPCd-Mk[4O\|k{OTR:L3G+
NCI-H358	NVW3UY1pSW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		Mn6zOFghcHK\|	NITtb\|BCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIF7DTU1JOzV6IHPlcIx{KGG\|c3Xzd4VlKGG\|II\pZYJt\SClZXzsd{Bi\nSncjC0PEBpenNiYomgR2NMQCCjc4PhfUwhUUN3MDC9JFYvQDVizszNMi=>	MV:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjh5OUOxOEc,OjZ6N{mzNVQ9N2F-
HepG2	NV\yUoJ3SW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		M3ewfVQ5KGi{cx?=	MnXzRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCKZYDHNkBk\WyuczDh[pRmeiB2ODDodpMh[nliTWTUJIF{e2G7LDDJR\|UxKD1iNT64JO69VS5?	MlTtQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ6OU[3NFgoRjJ4OEm2O\|A5RC:jPh?=
LO2	MnHhR5l1d3SxeHnjbZR6KGG\|c3H5		NUXST5FWPDhiaILz	Mlz4R5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gUG8zKGOnbHzzJIFnfGW{IES4JIhzeyCkeTDNWHQh[XO\|YYmsJGlEPTBiPTCxPE42KM7:TT6=	MlzNQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ6OU[3NFgoRjJ4OEm2O\|A5RC:jPh?=
NCI-H358	Ml30RY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		MV:0PEBpenN?	MVzBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKE6FST3IN\|U5KGOnbHzzJIF{e2W\|c3XkJIF{KHKnZIXjeIlwdiCrbjDj[YxtKH[rYXLpcIl1gSCjZoTldkA1QCCqcoOgZpkh[2OtODDhd5NigSxiSVO1NEA:KDNwOUGg{txONg>?	NVO5XI91RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkeyN\|Q5QDdpPkK3NlM1QDh5PD;hQi=>
A549	NHH0OmpCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		NGTVWVg1QCCqcoO=	NEDzdG1CdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFG1OFkh[2WubIOgZZN{\XO\|ZXSgZZMhemWmdXP0bY9vKGmwIHPlcIwhfmmjYnnsbZR6KGGodHXyJFQ5KGi{czDifUBk[2t6IHHzd4F6NCCLQ{WwJF0hPy5\|NTFOwG0v	NXvFXWJ6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkeyN\|Q5QDdpPkK3NlM1QDh5PD;hQi=>
BA/F3	MVfGeY5kfGmxbjDhd5NigQ>?		NFGxW3A1QCCqcoO=	NETST\|NKdmirYnn0bY9vKG:oIFXHSnIhVDh3OGKgcZV1[W62IDj1cotvd3ewIH;ybYdqdiliZYjwdoV{e2WmIHnuJI1wfXOnIFLBM2Y{KGOnbHzzJIF{e2W\|c3XkJIF{KHKnZIXjeIlwdiCrbjDj[YxtKH[rYXLpcIl1gSCjZoTldkA1QCCqcoOgZpkhYFSWIHHzd4F6NCCLQ{WwJF0hOC5yOEeg{txONg>?	NVLBV2NmRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkeyN\|U5PDFpPkK3NlM2QDRzPD;hQi=>
A431	M{PHdWZ2dmO2aX;uJIF{e2G7		NGThflg3OCCvaX7z	NXq3[lNUUW6qaXLpeIlwdiCxZjDFS2ZTKGmwIHj1cYFvKEF2M{GgZ4VtdHNiYYPz[ZN{\WRiYYOgdoVlfWO2aX;uJIlvKEWJRjDpcoR2[2WmIIDoc5NxcG:{eXzheIlwdiCycnXpcoN2[mG2ZXSg[o9zKDZyIH3pcpMh\m:ubH;3[YQh[nliRVfGJIFl\Gm2aX;uJI1m[XO3cnXkJIFnfGW{IEGwJI1qdnNiYomgSWxKW0FibXX0bI9lNCCLQ{WwJF0hOC5yMEGyJO69VS5?	MUS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzh7NEW4PUc,Ojd6OUS1PFk9N2F-
HEK293	MnHrSpVv[3Srb36gZZN{[Xl?		MVyyJI1qdnN?	MXXJcohq[mm2aX;uJI9nKGi3bXHuJG9EXDFiZYjwdoV{e2WmIHnuJGhGUzJ7MzDj[YxteyCjc4Pld5Nm\CCjczDk[YNz\WG\|ZTDpckB2eHSja3Wgc4YhSVOSKzDh[pRmeiB{IH3pcpMh[nliZnz1c5Jme2OnbnPlJIF{e2G7LDDJR\|UxKD1iMU[uNkDPxE1w	MlLNQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh{M{C5PFUoRjJ6MkOwPVg2RC:jPh?=
H3255	NIrYVZNHfW6ldHnvckBie3OjeR?=		NELZXFYzKGi{cx?=	NYHF[FBzUW6qaXLpeIlwdiCxZjDFS2ZTKEx6NUjSJI12fGGwdDDwbI9{eGixconsZZRqd25iaX6gbJVu[W5iSEOyOVUh[2WubIOgdJJmcW6ldXLheIVlKG[xcjCyJIhzeyCob3zsc5dm\CCkeTDFS2Yhe3SrbYXsZZRqd25iZn;yJFExKG2rboOgZpkhe2GwZIfpZ4ghTUyLU1GsJGlEPTBiPTCwMlAyKM7:TT6=	NFzxWnk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEK4O\|c{OCd-MkiyPFc4OzB:L3G+
A549	MlXqSpVv[3Srb36gZZN{[Xl?		NVTzO3o2OiCqcoO=	MVnJcohq[mm2aX;uJI9nKEWJRj3zeIlufWyjdHXkJJdqdGRvdInw[UBGT0[UIIDoc5NxcG:{eXzheIlwdiCrbjDoeY1idiCDNUS5JINmdGy\|IIDy[Ylv[3WkYYTl[EBnd3JiMjDodpMh\m:ubH;3[YQh[nliRVfGJJN1cW23bHH0bY9vKG[xcjCxNEBucW6\|IHL5JJNidmS5aXPoJGVNUVODLDDJR\|UxKD1iMD6wNVEh\|ryPLh?=	M2PIRVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6Mki3O\|MxLz5{OEK4O\|c{ODxxYU6=
PC9	NVjPWIg1TnWwY4Tpc44h[XO\|YYm=		Mly3NkBpenN?	NF\MeY5KdmirYnn0bY9vKG:oIFXHSnIh\XixbjCxPUBl\WyndHnvckBufXSjboSgdIhwe3Cqb4L5cIF1cW:wIHnuJIh2dWGwIGDDPUBk\WyuczDwdoVqdmO3YnH0[YQh\m:{IEKgbJJ{KG[xbHzve4VlKGK7IFXHSkB{fGmvdXzheIlwdiCob4KgNVAhdWmwczDifUB{[W6md3njbEBGVEmVQTygTWM2OCB;IECuNFEyKM7:TT6=	M3TpU\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6Mki3O\|MxLz5{OEK4O\|c{ODxxYU6=
H1975	Mnz5SpVv[3Srb36gZZN{[Xl?		M4TrdVIhcHK\|	M4juWGlvcGmkaYTpc44hd2ZiRVfGVkBVPzlyTT;MPFU5WiCmb4XicIUhdXW2YX70JJBpd3OyaH;yfYxifGmxbjDpckBpfW2jbjDINVk4PSClZXzsd{BxemWrbnP1ZoF1\WRiZn;yJFIhcHK\|IH\vcIxwf2WmIHL5JGVITiC\|dHnteYxifGmxbjDmc5IhOTBibXnud{BjgSC\|YX7ke4lkcCCHTFnTRUwhUUN3MDC9JFkvODB\|IN88UU4>	MXq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDJ6N{ezNEc,Ojh{OEe3N\|A9N2F-
PC9-DRH	MnT1SpVv[3Srb36gZZN{[Xl?		MUKyJIhzew>?	M2PlcWlvcGmkaYTpc44hd2ZiRVfGVkBVPzlyTT;lfI9vKDF7IHTlcIV1cW:wIH31eIFvfCCyaH;zdIhwenmuYYTpc44hcW5iaIXtZY4hWEN7LVTSTEBk\WyuczDwdoVqdmO3YnH0[YQh\m:{IEKgbJJ{KG[xbHzve4VlKGK7IFXHSkB{fGmvdXzheIlwdiCob4KgNVAhdWmwczDifUB{[W6md3njbEBGVEmVQTygTWM2OCB;IEmuO\|M3KM7:TT6=	MlHYQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh{OEe3N\|AoRjJ6Mki3O\|MxRC:jPh?=
Sf9	NVz4VXJsTnWwY4Tpc44h[XO\|YYm=		MnnPNVAhdWmwcx?=	MXPJcohq[mm2aX;uJI9nKEirc{[teIFo\2WmIILlZ49u[mmwYX70JGVITlJiY4n0c5Bt[XOvaXOg[I9u[WmwIDj1cotvd3ewIH;ybYdqdiliKE[0OUB1dyBzMUi2JJJme2mmdXXzLUBmgHC{ZYPz[YQhcW5iYnHjeYxwfmm{dYOgbY5n\WO2ZXSgV4YuQSClZXzsd{BxemWrbnP1ZoF1\WRiZn;yJFExKG2rboOg[o9tdG:5ZXSgZpkhSVSSIHHk[Il1cW:wIH3lZZN2emWmIHHmeIVzKDFiaIKgZpkhTEWORlnBM3RqdWVvUnXzc4x3\WRiZnz1c5JwdWW2comsJGlEPTBiPTCwMlA3KM7:TT6=	NVzB[JJDRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki0N\|E{PTNpPkK4OFMyOzV\|PD;hQi=>
HepG2	M4f2PWN6fG:2b4jpZ4l1gSCjc4PhfS=>		M1zJelI1KGi{cx?=	NXLmOYR{S3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hUGWyR{KgZ4VtdHNiYYPz[ZN{\WRiYYOg[IVkemWjc3WgbY4h[2WubDD2bYFjcWyrdImgZYZ1\XJiMkSgbJJ{KGK7IIPw[YN1em:yaH;0c41mfHK7LDDJR\|UxKD1iMkWg{txONg>?	Mmf4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh2OEexNlcoRjJ6NEi3NVI4RC:jPh?=
A549	MoPmRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		MYm3NkBpenN?	M4jVOmFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iQUW0PUBk\WyuczDh[pRmeiB5MjDodpMh[nliTWTUJIF{e2G7LDDJR\|UxKD1iMkGuN{DPxE1w	NXzXWGNDRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki4PFY2ODlpPkK4PFg3PTB7PD;hQi=>
MDA-MB-231	MkS2RY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		NHG0T2k4OiCqcoO=	M{P4c2FvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iTVTBMW1DNTJ\|MTDj[YxteyCrbnP1ZoF1\WRiZn;yJFczKGi{czDifUBOXFRiYYPzZZktKEmFNUCgQUA{OC5zMjFOwG0v	Mn2xQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh7MkOzPFMoRjJ6OUKzN\|g{RC:jPh?=
MDA-MB-231	M3L3UmFvfGmycn;sbYZmemG2aY\lJIF{e2G7		MWO0PEBpenN?	MWXBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKE2GQT3NRk0zOzFiY3XscJMhcW6ldXLheIVlKG[xcjC0PEBpenNiYomgUXRVKGG\|c3H5MEBKSzVyIE2gN\|MvPDZizszNMi=>	Mkm3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh7MkOzPFMoRjJ6OUKzN\|g{RC:jPh?=
MCF7	MnjORY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		MXy0PEBpenN?	MmrGRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCPQ1[3JINmdGy\|IHHmeIVzKDR6IHjyd{BjgSCPVGSgZZN{[XluIFnDOVAhRSByLkC4JO69VS5?	MUW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDl6OE[yOEc,Ojh7OEi2NlQ9N2F-
B16F10	NUTNPIt{SW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		M4Hsb\|Q5KGi{cx?=	NV7WfGxqSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBud3W\|ZTDCNVZHOTBiY3XscJMh[W[2ZYKgOFghcHK\|IHL5JG1VXCCjc4PhfUwhUUN3MDC9JFAvOTJizszNMi=>	MonhQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh7OEi2NlQoRjJ6OUi4OlI1RC:jPh?=
A549	NHThT\|dEgXSxdH;4bYNqfHliYYPzZZk>		NGT4bXIzPCCqcoO=	MlvwR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gRVU1QSClZXzsd{Bi\nSncjCyOEBpenNiYomgUXRVKGG\|c3H5MEBKSzVyIE2gNE44OyEQvF2u	NIjwWHc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUCyPFU{PCd-MkmwNlg2OzR:L3G+
A498	NUDhcYI6SW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		NGWy[nU1QCCqcoO=	NXqwXYpISW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDBOFk5KGOnbHzzJIFnfGW{IES4JIhzeyCkeTDNWHQh[XO\|YYmsJGlEPTBiPTCxNk42KM7:TT6=	NV;NTWg2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkmwOVcxPDJpPkK5NFU4ODR{PD;hQi=>
HuH7	M{Xu[GFvfGmycn;sbYZmemG2aY\lJIF{e2G7		NYC2WFBoPDhiaILz	NWD3[YhDSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDIeWg4KGOnbHzzJIFnfGW{IES4JIhzeyCkeTDNWHQh[XO\|YYmsJGlEPTBiPTCyOUDPxE1w	NHny[nk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUC1O\|A1Oid-MkmwOVcxPDJ:L3G+
NCI-H23	MXvDfZRwfG:6aXPpeJkh[XO\|YYm=		MlPFOFYhcHK\|	MnnVR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gUmNKNUh{MzDj[YxteyCjc4Pld5Nm\CCjczDy[YR2[3Srb36gbY4h[2WubDD2bYFjcWyrdImgZYZ1\XJiNE[gbJJ{KGK7IF3UWEBie3OjeTygTWM2OCB;IES5MlMh\|ryPLh?=	M2XIdVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7MUO4NFI4Lz5{OUGzPFAzPzxxYU6=
HT-29	MmD5RY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		MoPnOFghcHK\|	MVzBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDoeY1idiCKVD2yPUBk\WyuczDh[pRmeiB2ODDodpMh[nlicILvdIllcXWvIHnv[Ill\SC\|dHHpcolv\y2kYYPl[EBndHWxcnXzZ4Vv[2ViYYPzZZktKEmFNUCgQUAxNjB{IN88UU4>	NGnPV\|Q9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSwO\|k2Pid-Mkm0NFc6PTZ:L3G+
MIAPaCa2	NFj0[21CdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		NH:zZVk1QCCqcoO=	NYDMfmNGSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkhcHWvYX6gUWlCWGGFYUKgZ4VtdHNiYX\0[ZIhPDhiaILzJIJ6KHC{b4Dp[Il2dSCrb3Tp[IUhe3SjaX7pcocu[mG\|ZXSg[ox2d3Knc3PlcoNmKGG\|c3H5MEBKSzVyIE2gNE4xOyEQvF2u	NXXMVphFRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0NFc6PTZpPkK5OFA4QTV4PD;hQi=>
MCF7	NUG4[o92SW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		MoO5OFghcHK\|	M37Le2FvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIh2dWGwIF3DSlch[2WubIOgZYZ1\XJiNEigbJJ{KGK7IIDyc5Bq\Gm3bTDpc4Rq\GVic4ThbY5qdmdvYnHz[YQh\my3b4Lld4NmdmOnIHHzd4F6NCCLQ{WwJF0hOC5yMzFOwG0v	MXK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTRyN{m1Okc,Ojl2MEe5OVY9N2F-
PC3	Mn;VRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		NWC4O25YPDhiaILz	MUTBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDoeY1idiCSQ{OgZ4VtdHNiYX\0[ZIhPDhiaILzJIJ6KHC{b4Dp[Il2dSCrb3Tp[IUhe3SjaX7pcocu[mG\|ZXSg[ox2d3Knc3PlcoNmKGG\|c3H5MEBKSzVyIE2gNE4xOyEQvF2u	M1L2flxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEC3PVU3Lz5{OUSwO\|k2PjxxYU6=
A549	NUDjWXJ[SW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		Mo[2OFghcHK\|	NXfBW3k6SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkhcHWvYX6gRVU1QSClZXzsd{Bi\nSncjC0PEBpenNiYomgdJJweGmmaYXtJIlw\GmmZTDzeIFqdmmwZz3iZZNm\CCobIXvdoV{[2WwY3WgZZN{[XluIFnDOVAhRSByLkC0JO69VS5?	NEnMTlU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSwO\|k2Pid-Mkm0NFc6PTZ:L3G+
Sf9	MX7GeY5kfGmxbjDhd5NigQ>?		NF\KXFcyOCCvaX7z	M{PXUWlvcGmkaYTpc44hd2ZiSHnzOk11[WepZXSgSWdHWiBqdX7rco94diCxcnnnbY4qKGO7dH;wcIF{dWmlIHTvcYFqdiCneIDy[ZN{\WRiaX6gZoFkfWyxdnnyeZMhcW6oZXP0[YQhW2Z7IHnud4VkfCClZXzsd{Bi\nSncjCxNEBucW6\|IH\vcIxwf2WmIHL5JIFl\Gm2aX;uJI9nKEGWUD3N[2NtOiCjbnSgcYVie3W{ZXSgZYZ1\XJiMTDodkBjgSC2aX3lMZJme2:udnXkJIZtfW:{b33leJJq[yCjbnHsfZNqeyxiSVO1NEA:KDBwMEig{txONg>?	NHG0V2Y9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSwO\|k2Pid-Mkm0NFc6PTZ:L3G+
Sf9	MWnGeY5kfGmxbjDhd5NigQ>?			Ml3xTY5pcWKrdHnvckBw\iC{ZXPvcYJqdmGwdDDmeYxtNWynbnf0bEBIW1RvdHHn[4VlKGi3bXHuJGIuWkGIIG[2NFBGKG23dHHueEApPDF5IITvJFc3PiC{ZYPp[JVmeyliZYjwdoV{e2WmIHnuJGJi[3Wub4\pdpV{KGmwZnXjeIVlKFOoOTDj[YxteyC3c3nu[{BPNXSncn3pcoFtKEircz30ZYdo\WRiaIXtZY4hVUWNMTDhd{B{fWK\|dILheIUh[nliToWtdIFo\SCpZXytZoF{\WRicHjvd5Bpd3Jic3Py[YVvKGGwYXz5d4l{NCCLQ{WwJF0hOC5yNjFOwG0v	MUG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTV2OUi0NUc,Ojl3NEm4OFE9N2F-
Sf9	NXjyepk5TnWwY4Tpc44h[XO\|YYm=			Ml;sTY5pcWKrdHnvckBw\iCKaYOtOkB1[WepZXSgdoVkd22kaX7hcpQhTUeIUjDjfZRweGyjc33pZ{Bld22jaX6gLFY1PSC2bzCxNVg3KHKnc3nkeYV{MSBqdX7rco94diCxcnnnbY4qKGW6cILld5Nm\CCrbjDCZYN2dG:4aYL1d{Bqdm[nY4Tl[EBU\jliY3XscJMh[nliZHnzd49kcWG2aX;uMYVvcGGwY3XkJIxidnSqYX7p[IUh\my3b4Lld4NmdmOnIHntcZVvd2G\|c3H5M5RqdWVvcnXzc4x3\WRiZnz1c5JwdWW2cnnjJIFv[Wy7c3nzMEBKSzVyIE2gNE4xQCEQvF2u	MYK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTV2OUi0NUc,Ojl3NEm4OFE9N2F-
A549	Mlq3RY51cWOjbnPldkBie3OjeR?=		NX;FU5JmQTZiaILz	M{PnT2FvfGmlYX7j[ZIh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDBOVQ6KGOnbHzzJIF{e2W\|c3XkJIF{KHKnZIXjeIlwdiCrbjDj[YxtKH[rYXLpcIl1gSCjZoTldkA6PiCqcoOgZpkhVVSWIHHzd4F6NCCLQ{WwJF0hOTdwM{Kg{txONg>?	M{GycFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NUS5PFQyLz5{OUW0PVg1OTxxYU6=
MCF7	MljpRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		Mn\3OFghcHK\|	MXXBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKE2FRkegZ4VtdHNiYX\0[ZIhPDhiaILzJIJ6KE2WVDDhd5NigSxiSVO1NEA:KDJyIN88UU4>	M2LUXVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzNyMES3OFExLz5\|MEC0O\|QyODxxYU6=
HepG2	NU\VOZBSSW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		MX60PEBpenN?	NFnp[FFCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFjldGczKGOnbHzzJIFnfGW{IES4JIhzeyCkeTDNWHQh[XO\|YYmsJGlEPTBiPTCyOUDPxE1w	M4C0UFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzNyMES3OFExLz5\|MEC0O\|QyODxxYU6=
Sf9	MYPGeY5kfGmxbjDhd5NigQ>?		NEXB[I42KG2rboO=	NYf6[4QyUW6qaXLpeIlwdiCxZjDy[YNwdWKrbnHueEBpfW2jbjDHV3QufGGpZ3XkJGhGWjJiKE[3Ok1mdmRrIHX4dJJme3OnZDDpckBj[WO3bH;2bZJ2eyCrbn\lZ5Rm\CCVZkmgbY5{\WO2IHPlcIx{KHC{ZXnuZ5Vj[XSnZDDmc5IhPSCvaX7zJIZwdGyxd3XkJIJ6KEGWUDDh[IRqfGmxbjDhcoQhdWWjc4Xy[YQh[W[2ZYKgN\|AhdWmwczDifUBJXFKIIHHzd4F6NCCLQ{WwJF0hOC5yOUGg{txONg>?	MmLQQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzByOU[1PFAoRjNyMEm2OVgxRC:jPh?=
Sf9	M2f5RmZ2dmO2aX;uJIF{e2G7		MXG1JI1qdnN?	NYHifG9KUW6qaXLpeIlwdiCxZjDHV3QufGGpZ3XkJJJm[2:vYnnuZY51KGi3bXHuJHZGT0[UIDi3PFku\W6mKTDlfJBz\XO\|ZXSgbY4h[mGldXzveolzfXNiaX7m[YN1\WRiU3[5JIlve2WldDDj[YxteyCycnXpcoN2[mG2ZXSg[o9zKDVibXnud{Bnd2yub4fl[EBjgSCDVGCgZYRlcXSrb36gZY5lKG2nYYP1doVlKGGodHXyJFMxKG2rboOgZpkhUFSURjDhd5NigSxiSVO1NEA:KDBwMkWg{txONg>?	Mn\5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzByOU[1PFAoRjNyMEm2OVgxRC:jPh?=
A431	M2nheWZ2dmO2aX;uJIF{e2G7		MlHyOlAhdWmwcx?=	NFjQVpBKdmirYnn0bY9vKG:oIFXHSk1qdmS3Y3XkJGVITlJiYXP0bZZifGmxbjDpckBpfW2jbjDBOFMyKGOnbHzzJJBz\XS{ZXH0[YQh\m:{IE[wJI1qdnNiZn;scI94\WRiYomgSWdHKGGmZHn0bY9vKGGwZDDt[YF{fXKnZDDh[pRmeiBzMDDtbY5{KGK7IFXMTXNCNCCLQ{WwJF0hOC5yMEGyJO69VS5?	M2S5flxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzNyMEm4PFY6Lz5\|MEC5PFg3QTxxYU6=
U251	NFjBNXpHfW6ldHnvckBie3OjeR?=		MknYOlAhdWmwcx?=	NVfsRlQzUW6qaXLpeIlwdiCxZjDWSWdHNWmwZIXj[YQhXkWJRmKyJIFkfGm4YYTpc44hcW5iaIXtZY4hXTJ3MTDj[YxteyCycnX0doVifGWmIH\vdkA3OCCvaX7zJIZwdGyxd3XkJIJ6KF[HR1[gZYRlcXSrb36gZY5lKG2nYYP1doVlKGGodHXyJFExKG2rboOgZpkhTUyLU1GsJGlEPTBiPTCwMlEzPDdizszNMi=>	MYK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8{ODB7OEi2PUc,OzByOUi4Olk9N2F-
HEK293 Flp-In	NHO5TFJHfW6ldHnvckBie3OjeR?=		M{DyTVUhdWmwcx?=	M2[xV2lvcGmkaYTpc44hd2ZiaIXtZY4hdGm4ZYKgU2FVWDKEMTDlfJBz\XO\|ZXSgbY4hUEWNMkmzJGZteC2LbjDj[YxteyCjc4Pld5Nm\CCjczDy[YR2[3Srb36gbY4hYzOKXVWzV{B2eHSja3WgbY5kfWKjdHXkJIZweiB3IH3pcpMh[nlic3PpcpRqdGyjdHnvckBkd3WwdHnu[{whU2liPTCwMlU{KM7:TT6=	NYnqR4Q6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK1OFExPjhpPkKyOVQyODZ6PD;hQi=>
HEK293 Flp-In	MUjGeY5kfGmxbjDhd5NigQ>?			MlzpTY5pcWKrdHnvckBw\iCqdX3hckBtcX[ncjDPRXRROUJzIHX4dJJme3OnZDDpckBJTUt{OUOgSoxxNUmwIHPlcIx{KGG\|c3Xzd4VlKGG\|IILl[JVkfGmxbjDpckBGOTdvYnX0ZWchfXC2YXvlJIJ6KHOlaX70bYxt[XSrb36gZ492dnSrbnesJGtqKD1iMkGg{txONg>?	MXS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjV2MUC2PEc,OjJ3NEGwOlg9N2F-
HEK293 Flp-In	MVTGeY5kfGmxbjDhd5NigQ>?		MlXSOUBucW6\|	MlLHTY5pcWKrdHnvckBw\iCqdX3hckBtcX[ncjDPRXRROUJ\|IHX4dJJme3OnZDDpckBJTUt{OUOgSoxxNUmwIHPlcIx{KGG\|c3Xzd4VlKGG\|IILl[JVkfGmxbjDpckBcO0ifRUG3MYJmfGGJIIXweIFs\SCrbnP1ZoF1\WRiZn;yJFUhdWmwczDifUB{[2mwdHnscIF1cW:wIHPveY51cW6pLDDLbUA:KDRzIN88UU4>	MWC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjV2MUC2PEc,OjJ3NEGwOlg9N2F-
hematopoietic progenitor cells	M2\ZZ2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7	NF;wN5c2KHWP		M4nCT2dzd3e2aDDpcohq[mm2aX;uJI9nKEqDS{KgWlYyP0ZibYX0ZY51KGW6cILld5NqdmdiaIXtZY4heG:ueXP5eIhmdWmjII\ldoEhcGWvYYTvdI9q\XSrYzDwdo9o\W6rdH;yJINmdGy\|IHH0JFUhfU1iYomg[ZJ6fGi{b3nkJIJ2enO2LX\vdo1qdmdidX7peEBie3OjeR?=	MWG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPzF5OEeyNkc,OTdzN{i3NlI9N2F-
A431	MoTTSpVv[3Srb36gZZN{[Xl?		M{DDRlEhcHK\|	M1PqfmlvcGmkaYTpc44hd2ZiRVfGMYlv\HWlZXSgSWdHWiCyaH;zdIhwenmuYYTpc44hcW5iaIXtZY4hSTR\|MTDj[YxteyCycnX0doVifGWmIH\vdkAyKGi{czDmc4xtd3enZDDifUBGT0Zvc4TpcZVt[XSrb36gZpkhcW2vdX7vZoxwfCCjbnHsfZNqew>?	M4HxfFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7OU[5OFY2Lz5zOUm2PVQ3PTxxYU6=
PC9	M1HvOGN6fG:2b4jpZ4l1gSCjc4PhfS=>	M4jweVAvODBzIITvJFExKHWP		NFvTe\|JEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBRSzliY3XscJMh\XiycnXzd4lv\yB5NE[tO\|UxKHOncYXlcoNmKGSnbHX0[YQhTUeIUjDhd5Nme3OnZDDhd{Bk\WyuII\pZYJqdGm2eTDheEAxNjByMTD0c{AyOCC3TTDh[pRmeiB7NjDodpMh[nliY3XscEB1cXSncj3ncI8h[XO\|YYm=	M3HmO\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyMkKyO\|M{Lz5{MEKyNlc{OzxxYU6=
NCI-H1975	M{X6bGN6fG:2b4jpZ4l1gSCjc4PhfS=>	M{DiSVAvODBzIITvJFExKHWP		MoHIR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gUmNKNUhzOUe1JINmdGy\|IHX4dJJme3OrbnegSWdHWiCWN{mwUUBidmRiTEi1PHIhdXW2YX70JIF1KDBwMECxJJRwKDFyIIXNJIFnfGW{IEm2JIhzeyCkeTDj[YxtKHSrdHXyMYdtdyCjc4PhfS=>	MWe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zODJ{MkezN{c,OjB{MkK3N\|M9N2F-
HCC827	NWm0cZlVSXCxcITvd4l{KGG\|c3H5	NVe5THZXOSC3TR?=		NFWwPXZKdmS3Y4Tpc44hd2ZiYYDvdJRwe2m\|IHnuJIh2dWGwIFjDR\|gzPyClZXzsd{BifCBzIIXNJIFnfGW{IEK0JIhzeyC3c3nu[{Bxem:yaXTpeY0hcW:maXTlJIJ6KG[ub4egZ5l1d22ndIL5	MoHBQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR7MEC4N\|AoRjJ2OUCwPFMxRC:jPh?=
LLC	NGnENndCdnSrdIXtc5Ih[XO\|YYm=	MVixNFAhdWdxa3e=	NHLLO3UyPCCmYYnz	MVjBcpRqfHWvb4KgZYN1cX[rdImgZYdicW6\|dDDtc5V{\SCOTFOgZ4VtdHNiYXzsc4dz[W[2ZXSgbY4hW0OLRDDtc5V{\SCjc4Pld5Nm\CCjczDpcohq[mm2aX;uJI9nKHS3bX;yJIdzd3e2aDDheEAyODBibXevb4ctKHCxIIHkJIZweiBzNDDkZZl{	NGHodmo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkG4PFYzOCd-Mk[xPFg3OjB:L3G+
PC9	NXjIV5pjSW62aYT1cY9zKGG\|c3H5	Ml\nNVUhdWdxa3e=	NWX5VoNlPCC5ZXXrdy=>	M3\FeGFvfGm2dX3vdkBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIGDDPUBk\WyuczDlfJBz\XO\|aX7nJGVITlJiZYjvclE6KGSnbHX0bY9vKG23dHHueEB5\W6xZ4Lh[pRm\CCrbjDtc5V{\SCjc4Pld5Nm\CCjczD0eY1weiC{ZXfy[ZN{cW:wIHH0JFE2KG2pL3vnMEBy\CCvZXHzeZJm\CCjZoTldkA1KHenZXvz	M4e5dVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4M{GzNlUzLz5{NkOxN\|I2OjxxYU6=
PC9	M3\tU2FvfGm2dX3vdkBie3OjeR?=	NYixN4VXOTVibXevb4c>	MX[0JJdm\Wu\|	NUXRdWZHSW62aYT1cY9zKGGldHn2bZR6KGGpYXnud5QhcHWvYX6gVGM6KGOnbHzzJIV5eHKnc4PpcochTUeIUjDlfI9vOTliZHXs[ZRqd25ibYX0ZY51KHinbn;ndoFnfGWmIHnuJI1wfXOnIHH0JFE2KG2pL3vnMEBy\CCvZXHzeZJm\CCjZoTldkA1KHenZXvz	NHTVWFY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkOxN\|I2Oid-Mk[zNVMzPTJ:L3G+
A673	MWXxTHRUKGG\|c3H5			MUDxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhSTZ5MzDj[Yxtew>?	MonLQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
Saos-2	MofNdWhVWyCjc4PhfS=>			NXXncoJJeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IGPhc5MuOiClZXzsdy=>	NHThfHc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
BT-37	NV2yXpF7eUiWUzDhd5NigQ>?			MlX0dWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKEKWLUO3JINmdGy\|	MnjyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
BT-12	NHvVUIRyUFSVIHHzd4F6			MULxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhSlRvMUKgZ4VtdHN?	NHL1bVQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
NB1643	M3vJTZFJXFNiYYPzZZk>			NWq2cIpneUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IF7CNVY1OyClZXzsdy=>	Mnq3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
OHS-50	MU\xTHRUKGG\|c3H5			M2XoUZFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCRSGOtOVAh[2WubIO=	MWq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
Rh41	MmnOdWhVWyCjc4PhfS=>			NFGzd4dyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiUni0NUBk\Wyucx?=	NEfYTnQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
BT-37	MkPIdWhVWyCjc4PhfS=>			MnjldWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohS2:wZnnycYF1d3K7IIPjdoVmdiCob4KgRnQuOzdiY3XscJM>	NF;EcmU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
MG 63 (6-TG R)	NH;sV4xyUFSVIHHzd4F6			NHrnfGZyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCFb37mbZJu[XSxcomgd4Nz\WWwIH\vdkBOTyB4MzCoOk1VTyCUKTDj[Yxtew>?	M3XlSlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
Rh41	NEjzeZRyUFSVIHHzd4F6			MWfxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBEd26oaYLtZZRwenlic3Py[YVvKG[xcjDSbFQyKGOnbHzz	MVS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
SJ-GBM2	NVPXe5N2eUiWUzDhd5NigQ>?			M3G0dZFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCVSj3HRm0zKGOnbHzz	MX:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
SK-N-MC	NGDNOVFyUFSVIHHzd4F6			MoP5dWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKFONLV6tUWMh[2WubIO=	M17wTVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
NB-EBc1	NEC5O\|RyUFSVIHHzd4F6			Mn6zdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKE6ELVXCZ\|Eh[2WubIO=	MmLlQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
LAN-5	M3jrXpFJXFNiYYPzZZk>			Ml7HdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKEyDTj21JINmdGy\|	MU[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
Rh18	Mlm5dWhVWyCjc4PhfS=>			NGCzeHByUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiUnixPEBk\Wyucx?=	NVrve213RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
SK-N-MC	MkjIdWhVWyCjc4PhfS=>			NEHMNopyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCFb37mbZJu[XSxcomgd4Nz\WWwIH\vdkBUUy2QLV3DJINmdGy\|	MVi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
TC32	NI\kTHByUFSVIHHzd4F6			MWfxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBEd26oaYLtZZRwenlic3Py[YVvKG[xcjDUR\|MzKGOnbHzz	MWm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
NCI-H1648	MVfHdo94fGhiSX7obYJqfGmxbjDhd5NigQ>?			MnvUTY5pcWKrdHnvckBw\iCqdX3hckBPS0lvSEG2OFgh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NEA:KDBwMESwNFIh\|ryPLh?=	NUHvfpVmRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTV\|Lze+V2FPT0WUPD;hQi=>
TE-12	MX;Hdo94fGhiSX7obYJqfGmxbjDhd5NigQ>?			MkjaTY5pcWKrdHnvckBw\iCqdX3hckBVTS1zMjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyIE2gNE4xPTR2MTFOwG0v	NXvCOXkxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTV\|Lze+V2FPT0WUPD;hQi=>
ECC12	MlTIS5Jwf3SqIFnubIljcXSrb36gZZN{[Xl?			NHzxZ4ZKdmirYnn0bY9vKG:oIHj1cYFvKEWFQ{GyJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUAxNjB6MEWyJO69VS5?	NIHDb2Y9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2PTNxJ{7TRW5ITVJ:L3G+
BB30-HNC	MnzqS5Jwf3SqIFnubIljcXSrb36gZZN{[Xl?			M1;UR2lvcGmkaYTpc44hd2ZiaIXtZY4hSkJ\|MD3IUmMh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NEA:KDBwMUS3OlUh\|ryPLh?=	MljiQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVU{Nyd-U1HOS2VTRC:jPh?=
LB996-RCC	NXznXGZ3T3Kxd4ToJGlvcGmkaYTpc44h[XO\|YYm=			MU\Jcohq[mm2aX;uJI9nKGi3bXHuJGxDQTl4LWLDR{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwJF0hOC52MEG2NUDPxE1w	NUHlPGNnRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTV\|Lze+V2FPT0WUPD;hQi=>
EW-24	NI\FdYFIem:5dHigTY5pcWKrdHnvckBie3OjeR?=			NIf3PY1KdmirYnn0bY9vKG:oIHj1cYFvKEWZLUK0JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUAxNjV7NESzJO69VS5?	MnnXQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVU{Nyd-U1HOS2VTRC:jPh?=
LC-1F	NIPLbIJIem:5dHigTY5pcWKrdHnvckBie3OjeR?=			Mk\uTY5pcWKrdHnvckBw\iCqdX3hckBNSy1zRjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyIE2gNE43ODZ\|MjFOwG0v	MX28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1OVMwLz6VQV7HSXI9N2F-
TK10	M1X6[mdzd3e2aDDJcohq[mm2aX;uJIF{e2G7			M1TaWmlvcGmkaYTpc44hd2ZiaIXtZY4hXEtzMDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyIE2gNE45PTh5ODFOwG0v	NV[yZng6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTV\|Lze+V2FPT0WUPD;hQi=>
A388	NFz3TnVIem:5dHigTY5pcWKrdHnvckBie3OjeR?=			Ml\OTY5pcWKrdHnvckBw\iCqdX3hckBCOzh6IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTBiPTCxMlA6OzhizszNMi=>	M2Hn[FxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFU2Oy9pPmPBUmdGWjxxYU6=
EKVX	NEDvPHVIem:5dHigTY5pcWKrdHnvckBie3OjeR?=			MUfJcohq[mm2aX;uJI9nKGi3bXHuJGVMXlhiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OCB;IEGuNVI{PTRizszNMi=>	M3PhOVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFU2Oy9pPmPBUmdGWjxxYU6=
TE-9	NX;SNndzT3Kxd4ToJGlvcGmkaYTpc44h[XO\|YYm=			MUHJcohq[mm2aX;uJI9nKGi3bXHuJHRGNTliY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OCB;IEGuNlI2OTFizszNMi=>	M3rveVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFU2Oy9pPmPBUmdGWjxxYU6=
TE-1	M{Dvdmdzd3e2aDDJcohq[mm2aX;uJIF{e2G7			NHPhOHZKdmirYnn0bY9vKG:oIHj1cYFvKFSHLUGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3MDC9JFEvPDB2ODFOwG0v	M1q0SFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFU2Oy9pPmPBUmdGWjxxYU6=
MOLT-16	M{jXOmdzd3e2aDDJcohq[mm2aX;uJIF{e2G7			NGC3UZlKdmirYnn0bY9vKG:oIHj1cYFvKE2RTGStNVYh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NEA:KDFwOUK5NlUh\|ryPLh?=	NYqyd\|Q4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTV\|Lze+V2FPT0WUPD;hQi=>
TE-6	NV;6[JlTT3Kxd4ToJGlvcGmkaYTpc44h[XO\|YYm=			MlXoTY5pcWKrdHnvckBw\iCqdX3hckBVTS14IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTBiPTCyMlU3PzhizszNMi=>	MX[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1OVMwLz6VQV7HSXI9N2F-
697	MnfpS5Jwf3SqIFnubIljcXSrb36gZZN{[Xl?			M4r5W2lvcGmkaYTpc44hd2ZiaIXtZY4hPjl5IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTBiPTCyMlY2OzB3IN88UU4>	M{m3[lxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFU2Oy9pPmPBUmdGWjxxYU6=
A253	MYnHdo94fGhiSX7obYJqfGmxbjDhd5NigQ>?			MkThTY5pcWKrdHnvckBw\iCqdX3hckBCOjV\|IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTBiPTCyMlc2OTZizszNMi=>	M1i3TFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFU2Oy9pPmPBUmdGWjxxYU6=
OS-RC-2	M1P2Nmdzd3e2aDDJcohq[mm2aX;uJIF{e2G7			M3XFUWlvcGmkaYTpc44hd2ZiaIXtZY4hV1NvUlOtNkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwJF0hOi57NECyN{DPxE1w	NXL4bmU2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTV\|Lze+V2FPT0WUPD;hQi=>
KS-1	NGrhZ5hIem:5dHigTY5pcWKrdHnvckBie3OjeR?=			NYL1[\|RUUW6qaXLpeIlwdiCxZjDoeY1idiCNUz2xJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUAzNjl2NUSyJO69VS5?	MUe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1OVMwLz6VQV7HSXI9N2F-
MC116	NIfFdWpIem:5dHigTY5pcWKrdHnvckBie3OjeR?=			NF20VopKdmirYnn0bY9vKG:oIHj1cYFvKE2FMUG2JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUA{NjZ{MES5JO69VS5?	NV7qRVJKRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTV\|Lze+V2FPT0WUPD;hQi=>
LB2241-RCC	NYnlUHVtT3Kxd4ToJGlvcGmkaYTpc44h[XO\|YYm=			NYTrRWpjUW6qaXLpeIlwdiCxZjDoeY1idiCOQkKyOFEuWkOFIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTBiPTCzMlgyPzJ7IN88UU4>	NE\PR5E9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2PTNxJ{7TRW5ITVJ:L3G+
RL95-2	NFjUbWlIem:5dHigTY5pcWKrdHnvckBie3OjeR?=			M1;pfGlvcGmkaYTpc44hd2ZiaIXtZY4hWkx7NT2yJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUA1NjB\|M{Kg{txONg>?	M{DzblxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFU2Oy9pPmPBUmdGWjxxYU6=
HCE-T	NFHWNmRIem:5dHigTY5pcWKrdHnvckBie3OjeR?=			NFLHWopKdmirYnn0bY9vKG:oIHj1cYFvKEiFRT3UJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUA1NjFyMUi4JO69VS5?	NVryfppzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTV\|Lze+V2FPT0WUPD;hQi=>
NCCIT	NFntbYpIem:5dHigTY5pcWKrdHnvckBie3OjeR?=			M3TkNmlvcGmkaYTpc44hd2ZiaIXtZY4hVkOFSWSgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3MDC9JFQvOzh2OUeg{txONg>?	NXfaVpdjRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTV\|Lze+V2FPT0WUPD;hQi=>
GCIY	NEjkc45Iem:5dHigTY5pcWKrdHnvckBie3OjeR?=			MUHJcohq[mm2aX;uJI9nKGi3bXHuJGdEUVliY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OCB;IESuOlM2OzJizszNMi=>	MUm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1OVMwLz6VQV7HSXI9N2F-
LB1047-RCC	NFvmPWdIem:5dHigTY5pcWKrdHnvckBie3OjeR?=			NHq4[m1KdmirYnn0bY9vKG:oIHj1cYFvKEyEMUC0O{1TS0NiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OCB;IESuPVg{PzlizszNMi=>	NF\ITHo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2PTNxJ{7TRW5ITVJ:L3G+
A3-KAW	MorRS5Jwf3SqIFnubIljcXSrb36gZZN{[Xl?			MmftTY5pcWKrdHnvckBw\iCqdX3hckBCOy2NQWegZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3MDC9JFUvPDN7NE[g{txONg>?	MnrCQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVU{Nyd-U1HOS2VTRC:jPh?=
TE-15	NH\nOXlIem:5dHigTY5pcWKrdHnvckBie3OjeR?=			MmD2TY5pcWKrdHnvckBw\iCqdX3hckBVTS1zNTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyIE2gOU41PzJ5IN88UU4>	MWm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1OVMwLz6VQV7HSXI9N2F-
NOS-1	NFzzNoNIem:5dHigTY5pcWKrdHnvckBie3OjeR?=			M{\2SWlvcGmkaYTpc44hd2ZiaIXtZY4hVk:VLUGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3MDC9JFUvPDl\|OE[g{txONg>?	NVzTSY5vRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTV\|Lze+V2FPT0WUPD;hQi=>
EW-16	NULaeWU{T3Kxd4ToJGlvcGmkaYTpc44h[XO\|YYm=			NHrHVFFKdmirYnn0bY9vKG:oIHj1cYFvKEWZLUG2JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUA3NjJ3M{i3JO69VS5?	Mn7SQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVU{Nyd-U1HOS2VTRC:jPh?=
LAMA-84	MX\Hdo94fGhiSX7obYJqfGmxbjDhd5NigQ>?			M3KyPWlvcGmkaYTpc44hd2ZiaIXtZY4hVEGPQT24OEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwJF0hPy5yMEe3NkDPxE1w	NH3nNJc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2PTNxJ{7TRW5ITVJ:L3G+
TE-5	MVjHdo94fGhiSX7obYJqfGmxbjDhd5NigQ>?			NWi1UHE5UW6qaXLpeIlwdiCxZjDoeY1idiCWRT21JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUA4NjB2MkS3JO69VS5?	MXG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1OVMwLz6VQV7HSXI9N2F-
HEL	M{n0Wmdzd3e2aDDJcohq[mm2aX;uJIF{e2G7			MVvJcohq[mm2aX;uJI9nKGi3bXHuJGhGVCClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR\|UxKD1iNz6zN\|U3PCEQvF2u	MnHTQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVU{Nyd-U1HOS2VTRC:jPh?=
NCI-H209	NXTJSpRLT3Kxd4ToJGlvcGmkaYTpc44h[XO\|YYm=			M{j3OWlvcGmkaYTpc44hd2ZiaIXtZY4hVkOLLViyNFkh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NEA:KDhwMES0NVIh\|ryPLh?=	NX\kNXNyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTV\|Lze+V2FPT0WUPD;hQi=>
DJM-1	NWPCeJR2T3Kxd4ToJGlvcGmkaYTpc44h[XO\|YYm=			MV3Jcohq[mm2aX;uJI9nKGi3bXHuJGRLVS1zIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTBiPTC4MlUzQTZ2IN88UU4>	NIXBV4c9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2PTNxJ{7TRW5ITVJ:L3G+
OVCAR-4	Ml7zS5Jwf3SqIFnubIljcXSrb36gZZN{[Xl?			NETOVHFKdmirYnn0bY9vKG:oIHj1cYFvKE:YQ1HSMVQh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NEA:KDhwOESyNVkh\|ryPLh?=	NFrLR3E9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2PTNxJ{7TRW5ITVJ:L3G+
NB17	NF:yfmxIem:5dHigTY5pcWKrdHnvckBie3OjeR?=			NWjSZ5l5UW6qaXLpeIlwdiCxZjDoeY1idiCQQkG3JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUA6NjJ3OUmxJO69VS5?	Mof2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVU{Nyd-U1HOS2VTRC:jPh?=
SK-NEP-1	NFq4T\|FIem:5dHigTY5pcWKrdHnvckBie3OjeR?=			NX3te\|QyUW6qaXLpeIlwdiCxZjDoeY1idiCVSz3OSXAuOSClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR\|UxKD1iOT6zOVc4PiEQvF2u	NGLjbYk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2PTNxJ{7TRW5ITVJ:L3G+
NB5	MVTHdo94fGhiSX7obYJqfGmxbjDhd5NigQ>?			NWnH[JA{UW6qaXLpeIlwdiCxZjDoeY1idiCQQkWgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3MDC9JFExNjJ7IN88UU4>	Mo\FQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVU{Nyd-U1HOS2VTRC:jPh?=
BV-173	MV3Hdo94fGhiSX7obYJqfGmxbjDhd5NigQ>?			NUnEbYVuUW6qaXLpeIlwdiCxZjDoeY1idiCEVj2xO\|Mh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NEA:KDFyLkOyO\|Ih\|ryPLh?=	MYS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1OVMwLz6VQV7HSXI9N2F-
MPP-89	MUHHdo94fGhiSX7obYJqfGmxbjDhd5NigQ>?			MlHLTY5pcWKrdHnvckBw\iCqdX3hckBOWFBvOEmgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3MDC9JFExNjR2MjFOwG0v	NYnleo5wRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTV\|Lze+V2FPT0WUPD;hQi=>
RPMI-6666	M{\4[Wdzd3e2aDDJcohq[mm2aX;uJIF{e2G7			MnTGTY5pcWKrdHnvckBw\iCqdX3hckBTWE2LLU[2OlYh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NEA:KDFyLkS5Olkh\|ryPLh?=	NX3Td2ZpRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTV\|Lze+V2FPT0WUPD;hQi=>
MS-1	NESwUnVIem:5dHigTY5pcWKrdHnvckBie3OjeR?=			NFy5NmJKdmirYnn0bY9vKG:oIHj1cYFvKE2VLUGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3MDC9JFEyNjR4NUig{txONg>?	NV3OdWtwRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTV\|Lze+V2FPT0WUPD;hQi=>
ALL-PO	M3yzR2dzd3e2aDDJcohq[mm2aX;uJIF{e2G7			MnO4TY5pcWKrdHnvckBw\iCqdX3hckBCVExvUF:gZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3MDC9JFEyNjVzN{mg{txONg>?	NF3NU3g9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2PTNxJ{7TRW5ITVJ:L3G+
NB10	MXHHdo94fGhiSX7obYJqfGmxbjDhd5NigQ>?			MlvETY5pcWKrdHnvckBw\iCqdX3hckBPSjFyIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTBiPTCxNU44PTh5IN88UU4>	MYO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1OVMwLz6VQV7HSXI9N2F-
NB13	NIfWSXRIem:5dHigTY5pcWKrdHnvckBie3OjeR?=			MnTGTY5pcWKrdHnvckBw\iCqdX3hckBPSjF\|IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTBiPTCxNU46QTF2IN88UU4>	MWe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1OVMwLz6VQV7HSXI9N2F-
SCH	MnL6S5Jwf3SqIFnubIljcXSrb36gZZN{[Xl?			NWrvdINTUW6qaXLpeIlwdiCxZjDoeY1idiCVQ1igZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3MDC9JFEzNjF6OUGg{txONg>?	NYfaNpBtRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTV\|Lze+V2FPT0WUPD;hQi=>
ES6	Mk\yS5Jwf3SqIFnubIljcXSrb36gZZN{[Xl?			NX;KfWFCUW6qaXLpeIlwdiCxZjDoeY1idiCHU{[gZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3MDC9JFEzNjR5NTFOwG0v	NX3zT21nRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTV\|Lze+V2FPT0WUPD;hQi=>
ETK-1	NWnhcpAyT3Kxd4ToJGlvcGmkaYTpc44h[XO\|YYm=			M2i1UGlvcGmkaYTpc44hd2ZiaIXtZY4hTVSNLUGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3MDC9JFE1NjB6OEWg{txONg>?	NXG3UmMyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTV\|Lze+V2FPT0WUPD;hQi=>
ES4	Mo\OS5Jwf3SqIFnubIljcXSrb36gZZN{[Xl?			M3XJXmlvcGmkaYTpc44hd2ZiaIXtZY4hTVN2IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTBiPTCxOE45PDR3IN88UU4>	NXHuflRVRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTV\|Lze+V2FPT0WUPD;hQi=>
K-562	MX;Hdo94fGhiSX7obYJqfGmxbjDhd5NigQ>?			M1f0RWlvcGmkaYTpc44hd2ZiaIXtZY4hUy13NkKgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3MDC9JFE2NjhzNDFOwG0v	NX;PXmtxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTV\|Lze+V2FPT0WUPD;hQi=>
D-502MG	MkLyS5Jwf3SqIFnubIljcXSrb36gZZN{[Xl?			NGTETG9KdmirYnn0bY9vKG:oIHj1cYFvKERvNUCyUWch[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NEA:KDF5LkO0Olgh\|ryPLh?=	MVu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1OVMwLz6VQV7HSXI9N2F-
LB647-SCLC	NUe3VWhET3Kxd4ToJGlvcGmkaYTpc44h[XO\|YYm=			M1zER2lvcGmkaYTpc44hd2ZiaIXtZY4hVEJ4NEetV2NNSyClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR\|UxKD1iMUeuO\|czPiEQvF2u	NFTSc5E9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2PTNxJ{7TRW5ITVJ:L3G+
TE-10	M37QWGdzd3e2aDDJcohq[mm2aX;uJIF{e2G7			MlzYTY5pcWKrdHnvckBw\iCqdX3hckBVTS1zMDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyIE2gNVgvOTF\|ODFOwG0v	MoHRQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVU{Nyd-U1HOS2VTRC:jPh?=
MZ1-PC	M3ztWmdzd3e2aDDJcohq[mm2aX;uJIF{e2G7			MV7Jcohq[mm2aX;uJI9nKGi3bXHuJG1bOS2SQzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyIE2gNVgvOzd5NDFOwG0v	M4nTXlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFU2Oy9pPmPBUmdGWjxxYU6=
CTB-1	MkHXS5Jwf3SqIFnubIljcXSrb36gZZN{[Xl?			MkLITY5pcWKrdHnvckBw\iCqdX3hckBEXEJvMTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyIE2gNVgvPTB5NTFOwG0v	M2i1TVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFU2Oy9pPmPBUmdGWjxxYU6=
NMC-G1	MlH2S5Jwf3SqIFnubIljcXSrb36gZZN{[Xl?			M3XBTGlvcGmkaYTpc44hd2ZiaIXtZY4hVk2FLVexJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUAyQC56MEK5JO69VS5?	NWnVSFJDRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTV\|Lze+V2FPT0WUPD;hQi=>
C2BBe1	M1HiPGdzd3e2aDDJcohq[mm2aX;uJIF{e2G7			M1PwdmlvcGmkaYTpc44hd2ZiaIXtZY4hSzKEQnWxJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUAyQC56Nk[0JO69VS5?	MW[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1OVMwLz6VQV7HSXI9N2F-
SK-PN-DW	MmXiS5Jwf3SqIFnubIljcXSrb36gZZN{[Xl?			MoTBTY5pcWKrdHnvckBw\iCqdX3hckBUUy2STj3EW{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwJF0hOTlwNUS4NkDPxE1w	Mo\IQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVU{Nyd-U1HOS2VTRC:jPh?=
HCC2157	M1TvT2dzd3e2aDDJcohq[mm2aX;uJIF{e2G7			MX\Jcohq[mm2aX;uJI9nKGi3bXHuJGhESzJzNUegZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3MDC9JFIxNjN\|NkGg{txONg>?	MVK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1OVMwLz6VQV7HSXI9N2F-
Becker	NYGwVY9iT3Kxd4ToJGlvcGmkaYTpc44h[XO\|YYm=			MmLuTY5pcWKrdHnvckBw\iCqdX3hckBD\WOtZYKgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3MDC9JFIxNjN3NEGg{txONg>?	NGC1d4Y9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2PTNxJ{7TRW5ITVJ:L3G+
ST486	NV;6RotvT3Kxd4ToJGlvcGmkaYTpc44h[XO\|YYm=			M1LsbWlvcGmkaYTpc44hd2ZiaIXtZY4hW1R2OE[gZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3MDC9JFIxNjRyOUOg{txONg>?	M{H1RVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFU2Oy9pPmPBUmdGWjxxYU6=
LC-2-ad	NI\xUZFIem:5dHigTY5pcWKrdHnvckBie3OjeR?=			NITWTmRKdmirYnn0bY9vKG:oIHj1cYFvKEyFLUKtZYQh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NEA:KDJyLkm2N\|ch\|ryPLh?=	NV\adZg2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTV\|Lze+V2FPT0WUPD;hQi=>
NCI-H747	NV61fHo5T3Kxd4ToJGlvcGmkaYTpc44h[XO\|YYm=			NFLxSZBKdmirYnn0bY9vKG:oIHj1cYFvKE6FST3IO\|Q4KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVAhRSB{MT61NVM6KM7:TT6=	M{flTlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFU2Oy9pPmPBUmdGWjxxYU6=
BE-13	M4H5OGdzd3e2aDDJcohq[mm2aX;uJIF{e2G7			Mn7DTY5pcWKrdHnvckBw\iCqdX3hckBDTS1zMzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyIE2gNlEvQDF3ODFOwG0v	NWLhNFE6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTV\|Lze+V2FPT0WUPD;hQi=>
no-11	NUf5T5ozT3Kxd4ToJGlvcGmkaYTpc44h[XO\|YYm=			NIS5b2dKdmirYnn0bY9vKG:oIHj1cYFvKG6xLUGxJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUAzOS57MUC2JO69VS5?	MWm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1OVMwLz6VQV7HSXI9N2F-
TE-8	M2PQbWdzd3e2aDDJcohq[mm2aX;uJIF{e2G7			MWLJcohq[mm2aX;uJI9nKGi3bXHuJHRGNThiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OCB;IEKyMlY{OThizszNMi=>	MkfSQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVU{Nyd-U1HOS2VTRC:jPh?=
NB6	Mnu2S5Jwf3SqIFnubIljcXSrb36gZZN{[Xl?			M4rXS2lvcGmkaYTpc44hd2ZiaIXtZY4hVkJ4IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTBiPTCyNk45OzB\|IN88UU4>	Mn\iQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVU{Nyd-U1HOS2VTRC:jPh?=
BB65-RCC	MoTkS5Jwf3SqIFnubIljcXSrb36gZZN{[Xl?			MX3Jcohq[mm2aX;uJI9nKGi3bXHuJGJDPjVvUlPDJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUAzOi57NkKzJO69VS5?	NXTFcnNURGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTV\|Lze+V2FPT0WUPD;hQi=>
SK-UT-1	MoX1S5Jwf3SqIFnubIljcXSrb36gZZN{[Xl?			NFvMPIhKdmirYnn0bY9vKG:oIHj1cYFvKFONLWXUMVEh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NEA:KDJ\|LkG0PVch\|ryPLh?=	NFm2[3Q9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2PTNxJ{7TRW5ITVJ:L3G+
D-392MG	NGLrcZdIem:5dHigTY5pcWKrdHnvckBie3OjeR?=			MVPJcohq[mm2aX;uJI9nKGi3bXHuJGQuOzl{TVegZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3MDC9JFI1NjJ7M{Sg{txONg>?	MmL0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVU{Nyd-U1HOS2VTRC:jPh?=
JVM-2	MU\Hdo94fGhiSX7obYJqfGmxbjDhd5NigQ>?			M1\OTmlvcGmkaYTpc44hd2ZiaIXtZY4hUl[PLUKgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3MDC9JFI1NjV\|M{Og{txONg>?	MV:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1OVMwLz6VQV7HSXI9N2F-
SW954	MnrBS5Jwf3SqIFnubIljcXSrb36gZZN{[Xl?			MWTJcohq[mm2aX;uJI9nKGi3bXHuJHNYQTV2IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTBiPTCyOE42QTF4IN88UU4>	M33hclxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFU2Oy9pPmPBUmdGWjxxYU6=
QIMR-WIL	NYiyXpc2T3Kxd4ToJGlvcGmkaYTpc44h[XO\|YYm=			NHTnNZdKdmirYnn0bY9vKG:oIHj1cYFvKFGLTWKtW2lNKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVAhRSB{NT6xPVc{KM7:TT6=	MkjKQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVU{Nyd-U1HOS2VTRC:jPh?=
MEG-01	MX3Hdo94fGhiSX7obYJqfGmxbjDhd5NigQ>?			NVPxdId3UW6qaXLpeIlwdiCxZjDoeY1idiCPRVetNFEh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NEA:KDJ3LkmwNVYh\|ryPLh?=	M3;QUFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFU2Oy9pPmPBUmdGWjxxYU6=
A101D	NIrMW2lIem:5dHigTY5pcWKrdHnvckBie3OjeR?=			MlWyTY5pcWKrdHnvckBw\iCqdX3hckBCOTBzRDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyIE2gNlgvPzF\|OTFOwG0v	M1OybFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFU2Oy9pPmPBUmdGWjxxYU6=
LB831-BLC	M4S5VGdzd3e2aDDJcohq[mm2aX;uJIF{e2G7			NWfPelJTUW6qaXLpeIlwdiCxZjDoeY1idiCOQkizNU1DVENiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OCB;IEOwMlQxODRizszNMi=>	MoSxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVU{Nyd-U1HOS2VTRC:jPh?=
KGN	NGHlZnhIem:5dHigTY5pcWKrdHnvckBie3OjeR?=			M2XPPWlvcGmkaYTpc44hd2ZiaIXtZY4hU0eQIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTBiPTCzNE45PjZzIN88UU4>	MVG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1OVMwLz6VQV7HSXI9N2F-
HC-1	MlnyS5Jwf3SqIFnubIljcXSrb36gZZN{[Xl?			MWfJcohq[mm2aX;uJI9nKGi3bXHuJGhENTFiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OCB;IEOxMlM2ODhizszNMi=>	MlL0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVU{Nyd-U1HOS2VTRC:jPh?=
CP66-MEL	MnHtS5Jwf3SqIFnubIljcXSrb36gZZN{[Xl?			M4SwfmlvcGmkaYTpc44hd2ZiaIXtZY4hS1B4Nj3NSWwh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NEA:KDNzLkizOlYh\|ryPLh?=	NFq4dIo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2PTNxJ{7TRW5ITVJ:L3G+
D-542MG	MVrHdo94fGhiSX7obYJqfGmxbjDhd5NigQ>?			MVXJcohq[mm2aX;uJI9nKGi3bXHuJGQuPTR{TVegZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3MDC9JFMzNjR\|M{eg{txONg>?	M{D6c\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFU2Oy9pPmPBUmdGWjxxYU6=
LS-513	NUG5OJVST3Kxd4ToJGlvcGmkaYTpc44h[XO\|YYm=			NHjUS2hKdmirYnn0bY9vKG:oIHj1cYFvKEyVLUWxN{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwJF0hOzNwNEi0OEDPxE1w	MVe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1OVMwLz6VQV7HSXI9N2F-
DOHH-2	NYTwNFRbT3Kxd4ToJGlvcGmkaYTpc44h[XO\|YYm=			MlTxTY5pcWKrdHnvckBw\iCqdX3hckBFV0iKLUKgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3MDC9JFM{NjZ3OEmg{txONg>?	MofaQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVU{Nyd-U1HOS2VTRC:jPh?=
NB69	MkLwS5Jwf3SqIFnubIljcXSrb36gZZN{[Xl?			M2TGPWlvcGmkaYTpc44hd2ZiaIXtZY4hVkJ4OTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyIE2gN\|MvQTJyNjFOwG0v	NVHVUodYRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTV\|Lze+V2FPT0WUPD;hQi=>
SW962	NHj1T3ZIem:5dHigTY5pcWKrdHnvckBie3OjeR?=			NVrDPWRpUW6qaXLpeIlwdiCxZjDoeY1idiCVV{m2NkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwJF0hOzVwN{KxO{DPxE1w	MXG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1OVMwLz6VQV7HSXI9N2F-
J-RT3-T3-5	MVHHdo94fGhiSX7obYJqfGmxbjDhd5NigQ>?			NIHWXlZKdmirYnn0bY9vKG:oIHj1cYFvKEpvUmSzMXQ{NTViY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OCB;IEO2MlA4OjRizszNMi=>	MXq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1OVMwLz6VQV7HSXI9N2F-
MONO-MAC-6	MVjHdo94fGhiSX7obYJqfGmxbjDhd5NigQ>?			MUjJcohq[mm2aX;uJI9nKGi3bXHuJG1QVk9vTVHDMVYh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NEA:KDN4LkWzOVkh\|ryPLh?=	MlvrQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVU{Nyd-U1HOS2VTRC:jPh?=
MLMA	NI\I[JRIem:5dHigTY5pcWKrdHnvckBie3OjeR?=			NFXhTnBKdmirYnn0bY9vKG:oIHj1cYFvKE2OTVGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3MDC9JFM5NjZ3MjFOwG0v	NF;MRmI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2PTNxJ{7TRW5ITVJ:L3G+
HOP-62	NFLJV\|JIem:5dHigTY5pcWKrdHnvckBie3OjeR?=			NHLTUYpKdmirYnn0bY9vKG:oIHj1cYFvKEiRUD22NkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwJF0hOzlwMUe2OUDPxE1w	MmS4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVU{Nyd-U1HOS2VTRC:jPh?=
LP-1	M4LlPWdzd3e2aDDJcohq[mm2aX;uJIF{e2G7			MWjJcohq[mm2aX;uJI9nKGi3bXHuJGxRNTFiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OCB;IEO5MlQ1OTVizszNMi=>	NYf4dI13RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTV\|Lze+V2FPT0WUPD;hQi=>
ONS-76	MYLHdo94fGhiSX7obYJqfGmxbjDhd5NigQ>?			MULJcohq[mm2aX;uJI9nKGi3bXHuJG9PWy15NjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyIE2gN\|kvQTF3MjFOwG0v	NVLTNFZ[RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTV\|Lze+V2FPT0WUPD;hQi=>
KNS-42	NEnqfYlIem:5dHigTY5pcWKrdHnvckBie3OjeR?=			NXHXTZc6UW6qaXLpeIlwdiCxZjDoeY1idiCNTmOtOFIh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NEA:KDRyLkC1N\|Eh\|ryPLh?=	NEW4TIg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2PTNxJ{7TRW5ITVJ:L3G+
NCI-H1581	MmG1S5Jwf3SqIFnubIljcXSrb36gZZN{[Xl?			M3LKVGlvcGmkaYTpc44hd2ZiaIXtZY4hVkOLLVixOVgyKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVAhRSB2MT6xPFQzKM7:TT6=	NWDyV2FmRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTV\|Lze+V2FPT0WUPD;hQi=>
DSH1	NHnKc2dIem:5dHigTY5pcWKrdHnvckBie3OjeR?=			MmfsTY5pcWKrdHnvckBw\iCqdX3hckBFW0hzIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTBiPTC0Nk41ODdizszNMi=>	MWW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1OVMwLz6VQV7HSXI9N2F-
NCI-H1355	NEDmOW5Iem:5dHigTY5pcWKrdHnvckBie3OjeR?=			NU\xSo1jUW6qaXLpeIlwdiCxZjDoeY1idiCQQ1mtTFE{PTViY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OCB;IESyMlg{QSEQvF2u	M4joUVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFU2Oy9pPmPBUmdGWjxxYU6=
D-247MG	MULHdo94fGhiSX7obYJqfGmxbjDhd5NigQ>?			MU\Jcohq[mm2aX;uJI9nKGi3bXHuJGQuOjR5TVegZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3MDC9JFQ2NjdzOTFOwG0v	NUj2bppmRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTV\|Lze+V2FPT0WUPD;hQi=>
MC-CAR	MmnZS5Jwf3SqIFnubIljcXSrb36gZZN{[Xl?			NF;ITJNKdmirYnn0bY9vKG:oIHj1cYFvKE2FLVPBVkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwJF0hPDVwOU[5NUDPxE1w	MmS1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVU{Nyd-U1HOS2VTRC:jPh?=
EW-1	NEToOm5Iem:5dHigTY5pcWKrdHnvckBie3OjeR?=			NUT4UXpqUW6qaXLpeIlwdiCxZjDoeY1idiCHVz2xJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUA1Py53NkK0JO69VS5?	MnzNQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVU{Nyd-U1HOS2VTRC:jPh?=
GI-ME-N	MUfHdo94fGhiSX7obYJqfGmxbjDhd5NigQ>?			NX3LeJZjUW6qaXLpeIlwdiCxZjDoeY1idiCJST3NSU1PKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVAhRSB2OD6xN\|g1KM7:TT6=	NFGydnA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2PTNxJ{7TRW5ITVJ:L3G+
BT-474	NULLcXd2T3Kxd4ToJGlvcGmkaYTpc44h[XO\|YYm=			NVm0XJRCUW6qaXLpeIlwdiCxZjDoeY1idiCEVD20O\|Qh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NEA:KDR6LkG3N\|gh\|ryPLh?=	MlfsQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVU{Nyd-U1HOS2VTRC:jPh?=
LB373-MEL-D	M1rFT2dzd3e2aDDJcohq[mm2aX;uJIF{e2G7			M4LDbWlvcGmkaYTpc44hd2ZiaIXtZY4hVEJ\|N{OtUWVNNURiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OCB;IES4Mlc2PjNizszNMi=>	MY[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1OVMwLz6VQV7HSXI9N2F-
BHT-101	MV\Hdo94fGhiSX7obYJqfGmxbjDhd5NigQ>?			MVLJcohq[mm2aX;uJI9nKGi3bXHuJGJJXC1zMEGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3MDC9JFIzNjB4Mkmg{txONg>?	MV68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1OVMwLz6VQV7HSXI9N2F-
OVCAR-4	NFXQfVVIem:5dHigTY5pcWKrdHnvckBie3OjeR?=			NFK0Sm5KdmirYnn0bY9vKG:oIHj1cYFvKE:YQ1HSMVQh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NEA:KDJ{LkS3JO69VS5?	NEHXbJQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2PTNxJ{7TRW5ITVJ:L3G+
SW1573	M{LZPGdzd3e2aDDJcohq[mm2aX;uJIF{e2G7			NGO0eGFKdmirYnn0bY9vKG:oIHj1cYFvKFOZMUW3N{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwJF0hOjJwN{mzOEDPxE1w	NI\t[Zo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2PTNxJ{7TRW5ITVJ:L3G+
CHL-1	MkD1S5Jwf3SqIFnubIljcXSrb36gZZN{[Xl?			Mmn3TY5pcWKrdHnvckBw\iCqdX3hckBEUExvMTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyIE2gNlMvOjh\|MzFOwG0v	NYO0e45kRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTV\|Lze+V2FPT0WUPD;hQi=>
BFTC-905	NXP1NmdKT3Kxd4ToJGlvcGmkaYTpc44h[XO\|YYm=			NWnveJFNUW6qaXLpeIlwdiCxZjDoeY1idiCERmTDMVkxPSClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR\|UxKD1iMkOuNlg6OiEQvF2u	M1m5e\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFU2Oy9pPmPBUmdGWjxxYU6=
TE-12	NIHBOIJIem:5dHigTY5pcWKrdHnvckBie3OjeR?=			M3nvUGlvcGmkaYTpc44hd2ZiaIXtZY4hXEVvMUKgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3MDC9JFI{NjV5OEKg{txONg>?	NUfq[4VrRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTV\|Lze+V2FPT0WUPD;hQi=>
NCI-H358	MYHHdo94fGhiSX7obYJqfGmxbjDhd5NigQ>?			NILROFhKdmirYnn0bY9vKG:oIHj1cYFvKE6FST3IN\|U5KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVAhRSB{Mz62OFc4KM7:TT6=	MVO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1OVMwLz6VQV7HSXI9N2F-
OVCAR-5	MVHHdo94fGhiSX7obYJqfGmxbjDhd5NigQ>?			MXjJcohq[mm2aX;uJI9nKGi3bXHuJG9XS0GULUWgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3MDC9JFI1NjFyNDFOwG0v	NYjzUZI2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTV\|Lze+V2FPT0WUPD;hQi=>
CGTH-W-1	NGfaXGdIem:5dHigTY5pcWKrdHnvckBie3OjeR?=			NHrJUIRKdmirYnn0bY9vKG:oIHj1cYFvKEOJVFitW{0yKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVAhRSB{NT6wPFA1KM7:TT6=	NELEdYI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2PTNxJ{7TRW5ITVJ:L3G+
SNU-423	NH6xZnNIem:5dHigTY5pcWKrdHnvckBie3OjeR?=			MorWTY5pcWKrdHnvckBw\iCqdX3hckBUVlVvNEKzJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUAzPS5\|Nk[g{txONg>?	NE\IdFU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2PTNxJ{7TRW5ITVJ:L3G+
CP50-MEL-B	M1WxR2dzd3e2aDDJcohq[mm2aX;uJIF{e2G7			NWD0TVVIUW6qaXLpeIlwdiCxZjDoeY1idiCFUEWwMW1GVC2EIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTBiPTCyOU44Ozl7IN88UU4>	MonWQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVU{Nyd-U1HOS2VTRC:jPh?=
NCI-H2087	NIPJ[pZIem:5dHigTY5pcWKrdHnvckBie3OjeR?=			NWXabm1tUW6qaXLpeIlwdiCxZjDoeY1idiCQQ1mtTFIxQDdiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OCB;IEK1Mlg3PTVizszNMi=>	NWPsboJIRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTV\|Lze+V2FPT0WUPD;hQi=>
RMG-I	Mnn6S5Jwf3SqIFnubIljcXSrb36gZZN{[Xl?			NYnRVHJTUW6qaXLpeIlwdiCxZjDoeY1idiCUTVetTUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwJF0hOjVwOUKxPUDPxE1w	NH3LbZQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2PTNxJ{7TRW5ITVJ:L3G+
KP-N-YS	MVXHdo94fGhiSX7obYJqfGmxbjDhd5NigQ>?			M{fpbGlvcGmkaYTpc44hd2ZiaIXtZY4hU1BvTj3ZV{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwJF0hOjZwMkCyJO69VS5?	M2PpXVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFU2Oy9pPmPBUmdGWjxxYU6=
OMC-1	M3W2ZWdzd3e2aDDJcohq[mm2aX;uJIF{e2G7			MYPJcohq[mm2aX;uJI9nKGi3bXHuJG9OSy1zIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTBiPTCyOk42ODhizszNMi=>	MVm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1OVMwLz6VQV7HSXI9N2F-
DMS-114	NU\0RnBET3Kxd4ToJGlvcGmkaYTpc44h[XO\|YYm=			M3T3fmlvcGmkaYTpc44hd2ZiaIXtZY4hTE2VLUGxOEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwJF0hOjdwM{m2OkDPxE1w	M{LCZ\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFU2Oy9pPmPBUmdGWjxxYU6=
SHP-77	MUPHdo94fGhiSX7obYJqfGmxbjDhd5NigQ>?			MXHJcohq[mm2aX;uJI9nKGi3bXHuJHNJWC15NzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyIE2gNlcvPDh6IN88UU4>	NWrlO415RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTV\|Lze+V2FPT0WUPD;hQi=>
MPP-89	NHP6TmhIem:5dHigTY5pcWKrdHnvckBie3OjeR?=			M3u2WmlvcGmkaYTpc44hd2ZiaIXtZY4hVVCSLUi5JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUAzPy57NEO4JO69VS5?	MnnlQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVU{Nyd-U1HOS2VTRC:jPh?=
NCI-H1581	M33tV2dzd3e2aDDJcohq[mm2aX;uJIF{e2G7			M{jEeGlvcGmkaYTpc44hd2ZiaIXtZY4hVkOLLVixOVgyKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVAhRSB{OD60OVM2KM7:TT6=	NGLJZ5M9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2PTNxJ{7TRW5ITVJ:L3G+
D-283MED	NIHSc5BIem:5dHigTY5pcWKrdHnvckBie3OjeR?=			NVHpRWpjUW6qaXLpeIlwdiCxZjDoeY1idiCGLUK4N21GTCClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR\|UxKD1iMkiuOFY4PCEQvF2u	MUK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1OVMwLz6VQV7HSXI9N2F-
MOLT-4	NV\Pe3ZwT3Kxd4ToJGlvcGmkaYTpc44h[XO\|YYm=			NIDJZZVKdmirYnn0bY9vKG:oIHj1cYFvKE2RTGStOEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwJF0hOjhwOUC3NkDPxE1w	NWLvOZlRRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTV\|Lze+V2FPT0WUPD;hQi=>
ES6	MVvHdo94fGhiSX7obYJqfGmxbjDhd5NigQ>?			MVLJcohq[mm2aX;uJI9nKGi3bXHuJGVUPiClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR\|UxKD1iMkmuOlQ{PiEQvF2u	NV;XOHRCRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTV\|Lze+V2FPT0WUPD;hQi=>
NB6	MlnKS5Jwf3SqIFnubIljcXSrb36gZZN{[Xl?			NEf6[m1KdmirYnn0bY9vKG:oIHj1cYFvKE6ENjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyIE2gNlkvQDZ\|ODFOwG0v	NWrqWZA1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTV\|Lze+V2FPT0WUPD;hQi=>
SW954	MoTlS5Jwf3SqIFnubIljcXSrb36gZZN{[Xl?			MVfJcohq[mm2aX;uJI9nKGi3bXHuJHNYQTV2IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTBiPTCyPU46PDB5IN88UU4>	M4P3WFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFU2Oy9pPmPBUmdGWjxxYU6=
A388	NGntUodIem:5dHigTY5pcWKrdHnvckBie3OjeR?=			M1q0U2lvcGmkaYTpc44hd2ZiaIXtZY4hSTN6ODDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyIE2gNlkvQTR{MjFOwG0v	NIn2PGs9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2PTNxJ{7TRW5ITVJ:L3G+
OAW-28	NFP5eWhIem:5dHigTY5pcWKrdHnvckBie3OjeR?=			NHTYe3BKdmirYnn0bY9vKG:oIHj1cYFvKE:DVz2yPEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwJF0hOzBwMkK3PEDPxE1w	MYG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1OVMwLz6VQV7HSXI9N2F-
SK-MES-1	MmG4S5Jwf3SqIFnubIljcXSrb36gZZN{[Xl?			MmjITY5pcWKrdHnvckBw\iCqdX3hckBUUy2PRWOtNUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwJF0hOzFwMkKwPEDPxE1w	MkLTQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVU{Nyd-U1HOS2VTRC:jPh?=
NCI-H441	MWfHdo94fGhiSX7obYJqfGmxbjDhd5NigQ>?			MnniTY5pcWKrdHnvckBw\iCqdX3hckBPS0lvSES0NUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwJF0hOzFwOUi2PEDPxE1w	NUPETXBLRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTV\|Lze+V2FPT0WUPD;hQi=>
HOP-92	M2PnR2dzd3e2aDDJcohq[mm2aX;uJIF{e2G7			NWPkXVlnUW6qaXLpeIlwdiCxZjDoeY1idiCKT2CtPVIh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NEA:KDN{LkKzOVYh\|ryPLh?=	NIqxU5I9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2PTNxJ{7TRW5ITVJ:L3G+
NB14	NWrycpR2T3Kxd4ToJGlvcGmkaYTpc44h[XO\|YYm=			Ml3oTY5pcWKrdHnvckBw\iCqdX3hckBPSjF2IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTBiPTCzNk44OjVzIN88UU4>	NX3lZZRERGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTV\|Lze+V2FPT0WUPD;hQi=>
MS-1	NIrYd\|JIem:5dHigTY5pcWKrdHnvckBie3OjeR?=			MnnwTY5pcWKrdHnvckBw\iCqdX3hckBOWy1zIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTBiPTCzNk44PjB2IN88UU4>	NGXNbow9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2PTNxJ{7TRW5ITVJ:L3G+
YKG-1	MVjHdo94fGhiSX7obYJqfGmxbjDhd5NigQ>?			MoPwTY5pcWKrdHnvckBw\iCqdX3hckB[U0dvMTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyIE2gN\|IvQDN\|NjFOwG0v	M2T6[\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFU2Oy9pPmPBUmdGWjxxYU6=
SiHa	NHfRbm1Iem:5dHigTY5pcWKrdHnvckBie3OjeR?=			NFzYTplKdmirYnn0bY9vKG:oIHj1cYFvKFOrSHGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3MDC9JFM{NjN6Mkmg{txONg>?	Mlv4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVU{Nyd-U1HOS2VTRC:jPh?=
HAL-01	MWHHdo94fGhiSX7obYJqfGmxbjDhd5NigQ>?			NVfGSWN{UW6qaXLpeIlwdiCxZjDoeY1idiCKQVytNFEh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NEA:KDN2LkKzO\|Yh\|ryPLh?=	NFnTfI49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2PTNxJ{7TRW5ITVJ:L3G+
Ca-Ski	NWfkO5hiT3Kxd4ToJGlvcGmkaYTpc44h[XO\|YYm=			MkC3TY5pcWKrdHnvckBw\iCqdX3hckBE[S2Va3mgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3MDC9JFM1Njd4Nkmg{txONg>?	NXP5bYVJRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTV\|Lze+V2FPT0WUPD;hQi=>
NCI-H747	MWDHdo94fGhiSX7obYJqfGmxbjDhd5NigQ>?			NFXFSoVKdmirYnn0bY9vKG:oIHj1cYFvKE6FST3IO\|Q4KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVAhRSB\|ND65PFc2KM7:TT6=	M2XFe\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFU2Oy9pPmPBUmdGWjxxYU6=
KYSE-510	MWrHdo94fGhiSX7obYJqfGmxbjDhd5NigQ>?			NXfJUFN1UW6qaXLpeIlwdiCxZjDoeY1idiCNWWPFMVUyOCClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR\|UxKD1iM{WuOlQ5PSEQvF2u	M{jwVVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFU2Oy9pPmPBUmdGWjxxYU6=
A204	MW\Hdo94fGhiSX7obYJqfGmxbjDhd5NigQ>?			M{GzSmlvcGmkaYTpc44hd2ZiaIXtZY4hSTJyNDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyIE2gN\|UvPzJyOTFOwG0v	M{\TR\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFU2Oy9pPmPBUmdGWjxxYU6=
HSC-3	M3;PWWdzd3e2aDDJcohq[mm2aX;uJIF{e2G7			NWLCTnhzUW6qaXLpeIlwdiCxZjDoeY1idiCKU1OtN{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwJF0hOzZwMEC4OkDPxE1w	M1nkW\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFU2Oy9pPmPBUmdGWjxxYU6=
HuP-T3	NGTvOXpIem:5dHigTY5pcWKrdHnvckBie3OjeR?=			M1zndGlvcGmkaYTpc44hd2ZiaIXtZY4hUHWSLWSzJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUA{Pi52OEOyJO69VS5?	NHnnSHc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2PTNxJ{7TRW5ITVJ:L3G+
RPMI-8226	MoXoS5Jwf3SqIFnubIljcXSrb36gZZN{[Xl?			NETkOnNKdmirYnn0bY9vKG:oIHj1cYFvKFKSTVmtPFIzPiClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR\|UxKD1iM{[uOlIxQCEQvF2u	Ml3WQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVU{Nyd-U1HOS2VTRC:jPh?=
QIMR-WIL	MoLLS5Jwf3SqIFnubIljcXSrb36gZZN{[Xl?			NUj6[mFYUW6qaXLpeIlwdiCxZjDoeY1idiCTSV3SMXdKVCClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR\|UxKD1iM{[uOlQ1KM7:TT6=	MmDvQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVU{Nyd-U1HOS2VTRC:jPh?=
HuH-7	NXXkSIQ{T3Kxd4ToJGlvcGmkaYTpc44h[XO\|YYm=			MnXpTY5pcWKrdHnvckBw\iCqdX3hckBJfUhvNzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyIE2gN\|gvPjF6NDFOwG0v	MnmxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVU{Nyd-U1HOS2VTRC:jPh?=
CAL-12T	MYLHdo94fGhiSX7obYJqfGmxbjDhd5NigQ>?			M4G5fmlvcGmkaYTpc44hd2ZiaIXtZY4hS0GOLUGyWEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwJF0hOzhwOUSxOkDPxE1w	NYD1SmNvRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTV\|Lze+V2FPT0WUPD;hQi=>
GT3TKB	NEPrdlVIem:5dHigTY5pcWKrdHnvckBie3OjeR?=			NXj4d4RzUW6qaXLpeIlwdiCxZjDoeY1idiCJVEPUT2Ih[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NEA:KDN7LkG5NlEh\|ryPLh?=	MmXHQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVU{Nyd-U1HOS2VTRC:jPh?=
OC-314	NUnVdXN{T3Kxd4ToJGlvcGmkaYTpc44h[XO\|YYm=			M17GTmlvcGmkaYTpc44hd2ZiaIXtZY4hV0NvM{G0JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUA{QS55MUK1JO69VS5?	NF3me209[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2PTNxJ{7TRW5ITVJ:L3G+
NCI-H2228	MVrHdo94fGhiSX7obYJqfGmxbjDhd5NigQ>?			MVLJcohq[mm2aX;uJI9nKGi3bXHuJG5EUS2KMkKyPEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwJF0hPDBwMUSwN{DPxE1w	MkHIQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVU{Nyd-U1HOS2VTRC:jPh?=
NCI-H727	NWPYVmhTT3Kxd4ToJGlvcGmkaYTpc44h[XO\|YYm=			MXTJcohq[mm2aX;uJI9nKGi3bXHuJG5EUS2KN{K3JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUA1OC5{NUOxJO69VS5?	NYfTe4ZMRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTV\|Lze+V2FPT0WUPD;hQi=>
NTERA-S-cl-D1	Mk\1S5Jwf3SqIFnubIljcXSrb36gZZN{[Xl?			MWfJcohq[mm2aX;uJI9nKGi3bXHuJG5VTVKDLWOtZ4wuTDFiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OCB;IESwMlQ4ODZizszNMi=>	M3zCW\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFU2Oy9pPmPBUmdGWjxxYU6=
MMAC-SF	NFTGe4JIem:5dHigTY5pcWKrdHnvckBie3OjeR?=			MVzJcohq[mm2aX;uJI9nKGi3bXHuJG1OSUNvU1[gZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3MDC9JFQxNjl{M{Wg{txONg>?	NXTUZ2NtRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTV\|Lze+V2FPT0WUPD;hQi=>
HTC-C3	M1L2eWdzd3e2aDDJcohq[mm2aX;uJIF{e2G7			M3T4e2lvcGmkaYTpc44hd2ZiaIXtZY4hUFSFLVOzJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUA1OS52MU[5JO69VS5?	M2i3eVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFU2Oy9pPmPBUmdGWjxxYU6=
SF295	M3\5SGdzd3e2aDDJcohq[mm2aX;uJIF{e2G7			MXnJcohq[mm2aX;uJI9nKGi3bXHuJHNHOjl3IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTBiPTC0NU42Ozd7IN88UU4>	NHSxb4s9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2PTNxJ{7TRW5ITVJ:L3G+
U-2-OS	MWPHdo94fGhiSX7obYJqfGmxbjDhd5NigQ>?			M1nqS2lvcGmkaYTpc44hd2ZiaIXtZY4hXS1{LV;TJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUA1OS56NU[3JO69VS5?	NV7pZmJQRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTV\|Lze+V2FPT0WUPD;hQi=>
HPAF-II	MVLHdo94fGhiSX7obYJqfGmxbjDhd5NigQ>?			M{n0SGlvcGmkaYTpc44hd2ZiaIXtZY4hUFCDRj3JTUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwJF0hPDFwOUO4NkDPxE1w	NUm3UZpnRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTV\|Lze+V2FPT0WUPD;hQi=>
KYSE-450	MYTHdo94fGhiSX7obYJqfGmxbjDhd5NigQ>?			NHjWUHRKdmirYnn0bY9vKG:oIHj1cYFvKEu\U1WtOFUxKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVAhRSB2Mj60O\|A4KM7:TT6=	MYi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1OVMwLz6VQV7HSXI9N2F-
DMS-273	MkPVS5Jwf3SqIFnubIljcXSrb36gZZN{[Xl?			MVLJcohq[mm2aX;uJI9nKGi3bXHuJGROWy1{N{OgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3MDC9JFQ{NjJ6M{[g{txONg>?	NWD1SGxqRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTV\|Lze+V2FPT0WUPD;hQi=>
HT-1376	MkXDS5Jwf3SqIFnubIljcXSrb36gZZN{[Xl?			Mlv0TY5pcWKrdHnvckBw\iCqdX3hckBJXC1zM{e2JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUA1Oy5\|MUW2JO69VS5?	NXLyWVBMRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTV\|Lze+V2FPT0WUPD;hQi=>
786-0	Mm[1S5Jwf3SqIFnubIljcXSrb36gZZN{[Xl?			MVrJcohq[mm2aX;uJI9nKGi3bXHuJFc5Pi1yIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTBiPTC0N{43OjZzIN88UU4>	MlSyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVU{Nyd-U1HOS2VTRC:jPh?=
NCI-H810	NYDpdopqT3Kxd4ToJGlvcGmkaYTpc44h[XO\|YYm=			MlrSTY5pcWKrdHnvckBw\iCqdX3hckBPS0lvSEixNEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwJF0hPDRwMEGzOkDPxE1w	MVu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1OVMwLz6VQV7HSXI9N2F-
8305C	NGXJOlZIem:5dHigTY5pcWKrdHnvckBie3OjeR?=			MUHJcohq[mm2aX;uJI9nKGi3bXHuJFg{ODWFIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTBiPTC0OE43PDVizszNMi=>	MX28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1OVMwLz6VQV7HSXI9N2F-
DSH1	M2jWZmdzd3e2aDDJcohq[mm2aX;uJIF{e2G7			NWKzOW5OUW6qaXLpeIlwdiCxZjDoeY1idiCGU1ixJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUA1PS55MESyJO69VS5?	M{HKO\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFU2Oy9pPmPBUmdGWjxxYU6=
KYSE-520	MUjHdo94fGhiSX7obYJqfGmxbjDhd5NigQ>?			NH75dYpKdmirYnn0bY9vKG:oIHj1cYFvKEu\U1WtOVIxKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVAhRSB2Nj61O\|IyKM7:TT6=	MmPSQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVU{Nyd-U1HOS2VTRC:jPh?=
TYK-nu	NYTNfXZCT3Kxd4ToJGlvcGmkaYTpc44h[XO\|YYm=			NVPIW4l7UW6qaXLpeIlwdiCxZjDoeY1idiCWWVutcpUh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NEA:KDR4LkewPVIh\|ryPLh?=	M1zqO\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFU2Oy9pPmPBUmdGWjxxYU6=
EPLC-272H	M1zIPGdzd3e2aDDJcohq[mm2aX;uJIF{e2G7			M3n2V2lvcGmkaYTpc44hd2ZiaIXtZY4hTVCOQz2yO\|JJKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVAhRSB2Nj63Nlg{KM7:TT6=	Mn:zQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVU{Nyd-U1HOS2VTRC:jPh?=
T-24	NFrLWnFIem:5dHigTY5pcWKrdHnvckBie3OjeR?=			MoW2TY5pcWKrdHnvckBw\iCqdX3hckBVNTJ2IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTBiPTC0O{46Ojl{IN88UU4>	MmHYQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVU{Nyd-U1HOS2VTRC:jPh?=
BHY	MW\Hdo94fGhiSX7obYJqfGmxbjDhd5NigQ>?			NGP6VGtKdmirYnn0bY9vKG:oIHj1cYFvKEKKWTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyIE2gOFcvQTl7IN88UU4>	Mn;LQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVU{Nyd-U1HOS2VTRC:jPh?=
NCI-H82	M4fWW2dzd3e2aDDJcohq[mm2aX;uJIF{e2G7			MYDJcohq[mm2aX;uJI9nKGi3bXHuJG5EUS2KOEKgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3MDC9JFQ5NjJzNzFOwG0v	NISzSm09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2PTNxJ{7TRW5ITVJ:L3G+
SF268	NH7HVGFIem:5dHigTY5pcWKrdHnvckBie3OjeR?=			MWLJcohq[mm2aX;uJI9nKGi3bXHuJHNHOjZ6IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTBiPTC0PE43OTh7IN88UU4>	MXG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1OVMwLz6VQV7HSXI9N2F-
C-33-A	Mk[xS5Jwf3SqIFnubIljcXSrb36gZZN{[Xl?			NVXsTVVYUW6qaXLpeIlwdiCxZjDoeY1idiCFLUOzMWEh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NEA:KDR6Lke1OVQh\|ryPLh?=	M4TUXVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFU2Oy9pPmPBUmdGWjxxYU6=
MIA-PaCa-2	NW\BXldIT3Kxd4ToJGlvcGmkaYTpc44h[XO\|YYm=			NHTRc5pKdmirYnn0bY9vKG:oIHj1cYFvKE2LQT3QZWNiNTJiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OCB;IES4Mlg{QDhizszNMi=>	NGP0em09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2PTNxJ{7TRW5ITVJ:L3G+
HCC1954	MlfGS5Jwf3SqIFnubIljcXSrb36gZZN{[Xl?			MoP1TY5pcWKrdHnvckBw\iCqdX3hckBJS0NzOUW0JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUA1QS5yOEexJO69VS5?	MlzMQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVU{Nyd-U1HOS2VTRC:jPh?=
NCI-H1666	MkDxS5Jwf3SqIFnubIljcXSrb36gZZN{[Xl?			NFjyVVNKdmirYnn0bY9vKG:oIHj1cYFvKE6FST3INVY3PiClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR\|UxKD1iNEmuN\|Y1OiEQvF2u	M{WzbVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFU2Oy9pPmPBUmdGWjxxYU6=
GR-ST	MonZS5Jwf3SqIFnubIljcXSrb36gZZN{[Xl?			NGrINZhKdmirYnn0bY9vKG:oIHj1cYFvKEeULWPUJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUA1QS5\|Nkm1JO69VS5?	NGTWeXM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2PTNxJ{7TRW5ITVJ:L3G+
Ca9-22	M37WZmdzd3e2aDDJcohq[mm2aX;uJIF{e2G7			NXmwZm5rUW6qaXLpeIlwdiCxZjDoeY1idiCFYUmtNlIh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NEA:KDR7LkSwNVMh\|ryPLh?=	NWTFWJZmRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTV\|Lze+V2FPT0WUPD;hQi=>
D-502MG	NVLCdY15T3Kxd4ToJGlvcGmkaYTpc44h[XO\|YYm=			NFPJXY5KdmirYnn0bY9vKG:oIHj1cYFvKERvNUCyUWch[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NEA:KDR7LkSxO{DPxE1w	MnG1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVU{Nyd-U1HOS2VTRC:jPh?=
SCC-4	MoPuS5Jwf3SqIFnubIljcXSrb36gZZN{[Xl?			M3rVbGlvcGmkaYTpc44hd2ZiaIXtZY4hW0OFLUSgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3MDC9JFQ6NjV4MEKg{txONg>?	MoPoQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVU{Nyd-U1HOS2VTRC:jPh?=
RKO	MoHsS5Jwf3SqIFnubIljcXSrb36gZZN{[Xl?			M{GwOmlvcGmkaYTpc44hd2ZiaIXtZY4hWkuRIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTBiPTC0PU45OzV4IN88UU4>	M4rTOVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFU2Oy9pPmPBUmdGWjxxYU6=

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	Cleaved PARP / PARP ; PubMed: 27508092 Am J Cancer Res HCC827 or H1650 cells were treated with DMSO, celecoxib, erlotinib alone, or in combination for 48 h. Western blot analysis showed that cleaved PARP was higher in cells after combination treatment. P-Raf-1 / t-Raf-1 / p-MEK / t-MEK / p-ERK / t-ERK / p-PI3K / t-PI3K / p-AKT / AKT; PubMed: 27508092 Am J Cancer Res Cells from both ER and ECR groups were treated with 3 μM erlotinib for 72 h. Cell lysates were used for Western blotting with indicated antibodies. p-STAT3 / STAT3 / PTPMeg2 / p-EGFR / EGFR / pJAK2 / JAK2 / Bcl2 / Bcl-xl / Survivin; PubMed: 24019973 PLoS One Tu212 and Tu686 cells were treated with erlotinib (0.1µM) for various times. Levels of various proteins (pSTAT3, PTPMeg2, pEGFR, Bcl2, Bcl-XL, etc.) were analyzed by Western blot.	27508092 24019973
Immunofluorescence	β-catenin; PubMed: 25209444 Cancer Distribution of β-catenin by immunofluorescence staining after erlotinib treatment for 48h. These experiments were repeated in triplicate. E-cadherin / Vimentin ; PubMed: 19825949 Clin Cancer Res SUM149 cells were plated in 3D culture without or with erlotinib for 4 days. Immunofluorescence analysis was performed to detect E-cadherin, β-catenin, and vimentin. Nuclei were visualized with DAPI. D, SUM149 cells were transfected with control or ERK si䲧疝Ỵ疞㧀疜膉痘 瘿�෋ᾰƌ෋à 㺣痖帉痖Ѐ瑖堘𢡄빢᎒෋à鑸᎒彿堙奋堙巫堙᎒ﻺ᎒彿堙ﻮ᎒塚堙ﻺ᎒ꍈ堞빢᎒學堙漸堞圔堙빢᎒圞堙圭堙𢡄玚Wᾰƌ	25209444 19825949
Growth inhibition assay	Cell viability ; PubMed: 30377412 Cancer Cell Int a The MTT assay for PANC-1 viability. Different doses of erlotinib were added to the medium of PANC-1 cells. c The MTT assay for PaCa-2 cells in the presence of erlotinib treatment. IC50; PubMed: 17671085 Mol Cancer Ther dose-response curves of A-431 cells and 10 breast cancer cell lines after treatment with erlotinib at final concentrations of 0.03, 0.06, 0.1, 0.2, 0.3, 0.6, 1, 2, 3, 6, 10, or 20 μmol/L for 72 h. The surviving fractions were determined by MTT assay. Poin䲧疝Ỵ疞㧀疜膉痘 瘿�෋ᾰƌ෋à 㺣痖帉痖Ѐ	30377412 17671085

In vivo

At doses of 100 mg/kg, Erlotinib HCl completely prevents EGF-induced autophosphorylation of EGFR in human HN5 tumors growing as xenografts in athymic mice and of the hepatic EGFR of the treated mice. ^[1] Erlotinib HCl (100 mg/Kg) inhibits H460a and A549 tumor models with 71 and 93% inhibition rate. ^[5]

Protocol

Kinase Assay: ^[1]	- Collapse Kinase assays: 96-well plates are coated by incubation overnight at 37 °C with 100 μL per well of 0.25 mg/mL PGT in PBS. Excess PGT is removed by aspiration, and the plate is washed 3 times with washing buffer (0.1% Tween 20 in PBS). The kinase reaction is performed in 50 μL of 50 mM HEPES (pH 7.3), containing 125 mM sodium chloride, 24 mM magnesium chloride, 0.1 mM sodium orthovanadate, 20 μM ATP, 1.6 μg/mL EGF, and 15 ng of EGFR, affinity purified from A431 cell membranes. Erlotinib HCl in DMSO is added to give a final DMSO concentration of 2.5%. Phosphorylation is initiated by addition of ATP and proceeded for 8 minutes at room temperature, with constant shaking. The kinase reaction is terminated by aspiration of the reaction mixture and is washed 4 times with washing buffer. Phosphorylated PGT is measured by 25 minutes of incubation with 50 μL per well HRP-conjugated PY54 antiphosphotyrosine antibody, diluted to 0.2 μg/mL in blocking buffer (3% BSA and 0.05% Tween 20 in PBS). Antibody is removed by aspiration, and the plate is washed 4 times with washing buffer. The colorimetric signal is developed by addition of TMB Microwell Peroxidase Substrate, 50μL per well, and stopped by the addition of 0.09 M sulfuric acid, 50 μL per well. Phosphotyrosine is estimated by measurement of absorbance at 450 nm. The signal for controls is typically 0.6-1.2 absorbance units, with essentially no back ground in wells without AlP, EGFR, or PGT and is proportional to the time of incubation for 10 minutes.
Cell Research: ^[2]	- Collapse Cell lines: A549, H322, H3255, H358 H661, H1650, H1975, H1299, H596 cells Concentrations: 30 nM-20 μM Incubation Time: 72 hours Method: Exponentially growing cells are seeded in 96-well plastic plates and exposed to serial dilutions of erlotinib, pemetrexed, or the combination at a constant concentration ratio of 4:1 in triplicates for 72 h. Cell viability is assayed by cell count and the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay. Growth inhibition is expressed as the percentage of surviving cells in drug-treated versus PBS-treated control cells (which is considered as 100% viability). The IC50 value is the concentration resulting in 50% cell growth inhibition by a 72-h exposure to drug(s) compared with untreated control cells and is calculated by the CalcuSyn software. (Only for Reference)
Animal Research: ^[6]	- Collapse Animal Models: Male 5-week-old BALB-nu/nu mice with HPAC cells Dosages: 50 mg/kg Administration: Oral administration (Only for Reference)

References

- Collapse

Solubility (25°C)

In vitro	DMSO	78 mg/mL (198.25 mM)
	Water	Insoluble
	Ethanol	''''15 mg/mL warmed
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 5% DMSO+30% PEG 300+5% Tween 80+ddH2O For best results, use promptly after mixing.	3mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Erlotinib (OSI-774) SDF

Molecular Weight	393.44
Formula	C₂₂H₂₃N₃O₄
CAS No.	183321-74-6
Storage	3 years-20°C powder 2 years-80°C in solvent
Synonyms	CP358774, NSC 718781, Tarceva
Smiles	COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage

mg/kg

Average weight of animals

Dosing volume per animal

Number of animals

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO+ % + % Tween 80+ % ddH₂O

Calculate Reset

Calculation results:

Working concentration： mg/ml；

Method for preparing DMSO master liquid: ： mg drug pre-dissolved in μL DMSO (Master liquid concentration mg/mL， Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation：Take μL DMSO master liquid, next addμL PEG300， mix and clarify, next addμL Tween 80，mix and clarify, next add μL ddH₂O，mix and clarify.

Note：1.Please make sure the liquid is clear before adding the next solvent.
2.Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2021-05-17)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT03460678	Terminated	Drug: Pemetrexed\|Drug: Erlotinib	Carcinoma Non-Small-Cell Lung	Hikma Pharmaceuticals LLC	February 28 2018	Phase 4
NCT02942095	Active not recruiting	Drug: Ixazomib\|Drug: Erlotinib	Solid Tumors	M.D. Anderson Cancer Center\|Millennium: The Takeda Oncology Company	March 6 2017	Phase 1
NCT02080078	Terminated	Drug: Theophylline\|Drug: Erlotinib	Non-small Cell Lung Cancer\|Advanced Solid Malignancies	AHS Cancer Control Alberta\|Cross Cancer Institute	September 2014	Phase 1
NCT01835938	Unknown status	Drug: 1- Erlotinib\|Drug: placebo	Chronic Hepatitis C Infection\|HCV Genotype 1b	University Hospital Strasbourg France	May 2013	Phase 1\|Phase 2
NCT01085838	Completed	Drug: Erlotinib	Myelodysplastic Syndrome	Groupe Francophone des Myelodysplasies\|Roche Pharma AG	July 2010	Phase 1\|Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
Can you please give me some advice for which solvent we should use to dissolve it for animal studies?
Answer:
For in vivo application, we recommend to use 5% DMSO+45% PEG 300+ddH2O up to 6mg/ml.

EGFR Signaling Pathway Map

Related EGFR Products

Afatinib (BIBW2992) Dimaleate ^New

Afatinib (BIBW2992) Dimaleate irreversibly inhibits EGFR/HER2 including EGFR(wt), EGFR(L858R), EGFR(L858R/T790M) and HER2 with IC50 of 0.5 nM, 0.4 nM, 10 nM and 14 nM, respectively; 100-fold more active against Gefitinib-resistant L858R-T790M EGFR mutant. Afatinib (BIBW2992) Dimaleate induces autophagy.
Poziotinib (HM781-36B) ^New

Poziotinib (HM781-36B, NOV120101) is an irreversible pan-HER inhibitor with IC50 of 3.2 nM, 5.3 nM and 23.5 nM for HER1, HER2, and HER4, respectively. Poziotinib also induces apoptosis and G1 cell cycle arrest. Phase 2.
AZ5104 ^New

AZ5104, the demethylated metabolite of AZD-9291, is a potent EGFR inhibitor with IC50 of <1 nM, 6 nM, 1 nM, and 25 nM for EGFR (L858R/T790M), EGFR (L858R), EGFR (L861Q), and EGFR (wildtype), respectively. Phase 1.
Gefitinib (ZD1839)

Gefitinib (ZD-1839, Iressa) is an EGFR inhibitor for Tyr1173, Tyr992, Tyr1173 and Tyr992 in the NR6wtEGFR and NR6W cells with IC50 of 37 nM, 37nM, 26 nM and 57 nM, respectively. Gefitinib promotes autophagy and apoptosis of lung cancer cells via blockade of the PI3K/AKT/mTOR pathway.

Features:A potent EGFR tyrosine kinase inhibitor.
Erlotinib HCl (OSI-744)

Erlotinib HCl (OSI-744, CP358774, NSC 718781) is an EGFR inhibitor with IC50 of 2 nM in cell-free assays, >1000-fold more sensitive for EGFR than human c-Src or v-Abl.
Afatinib (BIBW2992)

Afatinib (BIBW2992) inhibits EGFR/ErbB irreversibly in vitro with IC50 of 0.5, 0.4, 10, 14, 1 nM for EGFR^wt, EGFR^L858R, EGFR^L858R/T790M ErbB2 (HER2) and ErbB4 (HER4), respectively. Afatinib induces autophagy.
Osimertinib (AZD9291)

Osimertinib (AZD9291) is an oral, irreversible, and mutant-selective EGFR inhibitor with IC50 of 12.92, 11.44 and 493.8 nM for Exon 19 deletion EGFR, L858R/T790M EGFR, and WT EGFR in LoVo cells, respectively. Phase 3.
Lapatinib (GW-572016)

Lapatinib (GW-572016, GSK572016, GW2016), used in the form of Lapatinib Ditosylate, is a potent EGFR and ErbB2 inhibitor with IC50 of 10.8 and 9.2 nM in cell-free assays, respectively. Lapatinib induces ferroptosis and autophagic cell death.
AG-490 (Tyrphostin B42)

AG-490 (Tyrphostin B42, Zinc02557947) is an inhibitor of EGFR with IC50 of 0.1 μM in cell-free assays, 135-fold more selective for EGFR versus ErbB2, also inhibits JAK2 with no activity to Lck, Lyn, Btk, Syk and Src.
Rociletinib (CO-1686)

Rociletinib (CO-1686, AVL-301) is an irreversible, mutant-selective EGFR inhibitor with K_i of 21.5 nM and 303.3 nM for EGFR^L858R/T790M and EGFR^WT in cell-free assays, respectively. Phase 2.

Choose Your Country or Region

By Signaling Pathways

By product type

Erlotinib (OSI-774)